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Abstract 
 
The aim of this thesis was to study two objective methods of osteoarthritis (OA) diagnosis in 
horses and use them on the assessment of new intra-articular treatments. The studied methods were 
a new inertial-sensor based system of lameness detection and cartilage biomarkers in serum. It was 
found that distal limb flexion is significantly correlated to the presence of metacarpo-phalangeal OA in 
hind limbs and that inertial-sensors are sensitive in detecting asymmetry in these cases. A positive 
and significant correlation was observed between Coll2-1 concentration in serum and the presence of 
joint disease in males and young horses. Fib3-2 measurement has good potential to be used since it 
is not influenced by sex or age. Using an experimental model of OA, adipose stem cells pre-activated 
with interferon-gamma decreased joint inflammation and radiographic lesions. In clinical cases, a 
single injection of high-concentrated and high-molecular weight hyaluronic-acid decreased joint 
inflammation and biomarkers’ concentration. 
 
Key words: equine; osteoartrithis; objective diagnosis; intra-articular treatment 
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OSTEOARTRITE DO MEMBRO DISTAL NO CAVALO 
 
Resumo 
 
A finalidade desta tese foi estudar dois métodos de diagnóstico objetivo de osteoartrite (OA) em 
equinos e aplicá-los na avaliação de novas terapias intra-articulares. Utilizou-se um sistema de 
sensores de movimento e foi avaliada a concentração de biomarcadores de cartilagem no soro. 
Concluiu-se que a flexão distal positiva está correlacionada com OA na articulação metacarpo-
falângica nos membros posteriores e que os sensores são sensíveis na detecção de assimetria 
nestes casos. Existe uma correlação positiva e significativa entre as concentrações de Coll2-1 e a 
presença de doença articular, sobretudo em machos e jovens. A dosagem de Fib3-2 tem utilidade 
por não ser influenciada pelo sexo nem idade. Num modelo experimental da doença, a terapia à 
base de células estaminais reduziu a inflamação articular e as lesões radiográficas. Em casos 
clínicos, o tratamento com ácido-hialurónico de alta concentração e peso molecular provoca uma 
diminuição da inflamação articular e dos biomarcadores no soro. 
 
Palavras-chave: equino; osteoartrite, diagnóstico objetivo; tratamento intra-articular 
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INTRODUCTION 
 
Lameness, and particularly osteoarthritis (OA), is still one of the main reasons for early retirement 
of horses and economic losses in the equine industry. Articular cartilage is the main component of 
a joint and is responsible, together with synovial fluid (SF), for the frictionless movement. OA is 
characterized by degeneration and loss of cartilage,  w h ich  occurs when catabolic pathway 
overcomes  the anabolic  process (Frisbie, 2012). The general objective of this thesis was to 
advance further the diagnosis of OA and at treatment knowledge in horses. We used two objective 
diagnostic methodologies of OA: lameness detection with intertial sensors technology and analysis of 
serum cartilage biomarkers in combination with traditional subjective lameness assessment and 
radiographic examination. We used these methods to assess two novel intra-articular (IA) treatments: 
adipose tissue-derived allogeneic mesenchymal stem cells (ASCs) pre-activated with interferon-
gamma (IFN-γ) on experimental induced OA and a high concentrated and high molecular weight 
(HMW) hyaluronic acid (HA) on naturally occurring disease.  
Osteoarticular pain is the key of OA disease assessment but it is difficult to quantify in horses. A 
recent method appeared in order to objectively determine the amount of asymmetry of the four limbs. 
This system uses wireless transmission of data from small inertial sensors attached to the horse’s 
body. Keegan et al. first introduced this technology in 2002 and its repeatability and sensitivity has 
been demonstrated (Keegan et al., 2011; McCracken et al., 2012). In this research we have 
objectively evaluated lameness and response to IA treatments using this technology, owned by the 
VetAgro Sup – Veterinary Campus of Lyon. The PhD student spent 3 months in this institution, 
learning how to use this technology while testing pre-activated ASCs with IFN-γ (ASCs-γ) IA 
treatment.  
Mesenchymal stem cells (MSCs) have reparative effects, due to their differentiation properties and 
to paracrine actions, but they need to be activated by inflammatory mediators released from immune 
cells. Pre-activation with IFN-γ enhances the therapeutic activity of MSCs in animal models of colitis 
and graft versus host disease (Polchert et al., 2008; Duijvestein et al., 2011). Therefore, pre-activation 
of MSCs could lead to a more efficient therapeutic activity than unstimulated cells, initiating 
regeneration and repair of hyaline cartilage. Murine collagenase induced OA models showed that a 
single injection of autologous ASCs reduced synovitis, enthesophyte formation and decreased score 
of cartilage lesions (ter Huurne et al., 2012). Furthermore, ASCs have recently shown a protective 
effect in human cartilage in vitro by preventing chondrocyte apoptosis and fibrosis (Maumus et al., 
2013). Our objective was to study the effects of INF-γ pre-activated or “primed” allogeneic ASCs in an 
experimental OA model in horses. The preliminary results of this experiment were orally presented at 
the I congresso da Associação Portuguesa de Médicos Veterinários de Equinos (APMVE), Lisboa 
2014, in the 24th Annual Meeting of the European College of Veterinary Surgeons (ECVS), Berlin 2015 
(Appendix A: abstract) and at the 1rst European Stem Cell Symposium for vets, Maastricht 2015.  
To achieve early recognition of disease, equine research, as a valid model for human OA, has 
focused on biomarker analysis. Verwilghen et al. (2011) correlated higher OA advanced degenerative 
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lesions with increased type II collagen 108HRGYPGLDG116 peptide (Coll2-1) in SF and severity of 
radiological lesions with increased Coll2-1 nitrated form (Coll2-1NO2) in horse blood (Verwilghen et al., 
2009). In humans, Fibulin 3 peptide fragment 1 (Fib3-1) and fragment 2 (Fib3-2) have recently shown 
to be elevated in serum of OA patients and differentiate between OA and normal populations (Henrotin 
et al., 2012) but have never been studied in horses. In this project we have studied Coll2-1, Coll2-
1NO2 and Fib3-2 in naturally occuring OA in 51 Lusitano horses. The abstract have been accepted at 
the poster session of the 25th Annual Meeting of the ECVS (Lisboa): Susana Monteiro, Olivier M 
Lepage, Luís Antunes, Liliane Damásio, Sandra Branco, Manuela Oliveira, Elisa Bettencourt. 
Relationship between biomarkers of cartilage in serum and degenerative joint disease in Lusitano 
horses. Using the same Lusitano horse population, subjective lameness assessment was compared to 
objective lameness detection and related to radiographic distal limb OA findings. The results have 
been presented at the V Congreso Annual de La Asociación de Veterinarios Especialistas en Équidos 
de España (AVEE), WEVA Intermadiate meeting España-Portugal (Madrid): Cómo están relacionados 
los hallazgos radiográficos de la extremidad distal con la evaluación objectiva de cojera. 
Finally, a group of eight horses presenting clinical OA were treated with a single injection of HMW-
HA and objectively assessed for lameness and serum biomarkers’ concentration. Hyluronic acid is 
injected due to viscosupplementation, light anti-infllammatory properties (Takahashi et al., 1999) and 
disease-modifying effects (Marshall et al., 2000). On the other hand, Coll2-1 and Coll2-1NO2 
biomarker have been shown to be significantly decreased in serum of OA human patients after HA 
treatment (Henrotin et al., 2013). High molecular weight HA is reported to have superior cartilage-
sparing properties in OA models (Asari et al., 1998), to enhance in vitro lubricant function (Antonacci 
et al. 2012) as well as to induce better clinical improvement (Philips, 1989) when compared to the 
lower molecular weight.  
This thesis is divided in seven chapters. Chapter I contains a brief review on distal limb OA 
pathogenesis, diagnosis and conventional OA treatment. An extensive review of IA biologic therapies 
was published: Monteiro SO, Bettencourt EV, Lepage OM. Biologic strategies for intra-articular 
treatment and cartilage repair. J Eq Vet Sci 2015; 35:175-190 (Appendix B). Chapter II includes the 
comprehensive research work, which presents the results of a survey to Portuguese equine 
veterinarians about OA (Appendix C: questionnaire) and the preliminary results of the effects of equine 
allogeneic ASCs-γ in vitro (a collaborative study). The fundamental research work is presented in the 
following four chapters and consisted in testing ASCs-γ treatment on experimental OA in vivo (Chapter 
III), evaluating cartilage biomarkers in serum (Chapter IV) and studying lameness detection (Chapter 
V) in a Lusitano horse population and finally assessing the effect of a single injection of HA treatment 
on clinical cases of OA using both objective methodologies (Chapter VI). A general conclusion is 
presented at the end of the thesis. 
We believe that veterinarian researchers should focus their work on objective methodologies and 
that biologic strategies will play an important role in equine OA therapy. This PhD thesis is just a piece 
of the puzzle. 
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CHAPTER I – Review of literature 
 
 
1. Articular biology of equine distal limb joints 
 
Joint health is of major importance for horses’ performance and survival. The equine distal limb is 
made up of diarthrodial joints that allow smooth articulation of 2 bone ends. The joint capsule supports 
the synovial structures and is made up of a fibrous tissue surrounded by tendons and colateral 
ligaments. Below the capsule there is a thin synovial membrane with 3 types of cells: synovial type A 
cells that have a phagocytic function; type B cells that produce hyaluronic acid (HA) and an 
intermediate celular type (C cells). The gaps between synoviocytes, the absence of a basal membrane 
and the presence of subsynovial blood vessels allow exchange of molecules under 10 kilodalton (kDa) 
between plasma and sinovyal fluid (SF) (Todhunter, 1996b). Synoviocytes are also able to produce 
inflammatory mediators, making the synovial membrane an important structure during joint 
inflammation (Briston et al., 2010). 
Hyaline cartilage covers the bone extremities and is made up of a small population of chondrocytes 
distributed in the extracelular matrix (ECM). This avascular connective tissue is especially developed 
for shock absorption and weight bearing (Palmer & Bertone, 1996), being highly dependent on the 
macromolecular arrangement (Kempson, 1980). The collagen molecules make a cross-linked network 
together with HA molecules. HA is connected by link proteins to proteoglycan aggrecans, which are 
negatively charged by their polyanionic glycosaminoglycan (GAG) sidechains: keratan and chondrotin 
sulphate (Ogston, 1970). This allows an osmotic swelling pressure, attracting water and expanding the 
collagen network, which results in a highly stiff but resilient tissue (Ogston, 1970; Eyre & Wu, 1995; 
van Weeren & Brama, 2001). The articular cartilage has a non-calcified section, which is divided in a 
superfitial tagential zone, where chondrocytes and collagen fibrils are horizontally oriented, an 
intermediate and deep zone, where they are vertically oriented and consequently less resistant. The 
underlying calcified section is separated by a tidemark from the subchondral bone (SCB) that consists 
of a dense cortical bone plate followed by a trabecular bone. SCB provides a structural support to the 
joint and vascular supply to the immature cartilage. 
Viscosity of SF is due to high HA concentration, acting like a lubricant that reduces friction, 
improves joint motion and plays a role in joint homeostasis. This joint component is excellent for joint 
health assessment both in clinical and research settings; moreover, the correlation between 
concentration of small molecules in SF and plasma encourages research based on the evaluation of 
these molecules in the blood (van Weeren & Firth, 2008). 
Equine distal limb has 3 synovial joints, 2 high-motion: metacarpo/tarsal-phalangeal (fetlock) and 
distal interphalangeal (DIP) joint and 1 low-motion: proximal interphalangeal (PIP) joint (Sisson, 1986). 
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2. Pathogenesis of equine OA  
 
OA is the most frequently used term for joint disease and is specifically defined as degeneration 
and loss of articular cartilage, it is also known as osteoarthrosis or degenerative joint disease. The 
terminology debate is present because an inflammatory feature is not always present. However, 
inflammation is considered to be the key of OA pathogeny and the term osteoarthritis will be 
consistently used in this text. Equine degenerative arthritis was first reported in 1938, after comparing 
human and equine cartilage (Callender & Kelser, 1938). Although not life-threatening, OA is a 
disabling disease representing a very important economic burden.  
The joint is a complex organ and there are several ways in which traumatic damage can occur, 
eventually resulting in cartilage degradation. Nowadays, it is recognised that OA can be the 
consequence of numerous disorders affecting not only the cartilage (Brandt et al., 2006) but other 
joint-associated tissues, like synovial membrane and subchondral bone (SCB). OA can also be 
defined as a “failed repair of damage that has been caused by excessive mechanical stress (defined 
as force/unit area) on joint tissue” (Brandt et al., 2009). This disease can be triggered by several 
factors, including genetics, molecular and biochemical changes of cells and ECM, or be secondary to 
conditions like osteochondritis dissecans (OCD), synovitis/capsulitis, desmitis and subchondral bone 
disease. Cartilage can also be disrupted by intra-articular (IA) fractures. Direct trauma can cause 
ulcerative lesions and cyclic fatigue damage can be responsible for collagen network injury. It is 
currently accepted that synovitis and capsulitis contribute to the degenerative process through the 
release of enzymes, inflammatory mediators and cytokines (Mcllwraith & Van Sickle, 1981; Briston et 
al., 2010). Subchondral bone disease can also lead to secondary cartilage damage due to the loss of 
support and the release of cytokines or the decrease of shock absorption, in case of bone sclerosis 
(Lories & Luyten, 2011; Pan et al., 2012). 
OA is primarly trigerred by interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNFα), 
identified as the major pro-inflammatory cytokines in joints (Smith et al., 1997; Kappor et al., 2011). 
Secretion of inflammatory mediators like substance P and prostaglandin E2 (PGE2) will induce further 
release of other pro-inflammatory cytokines (IL-6, IL-17, IL-18), chemokines and other inflammatory 
mediators such as nitric oxide, oncostatin-M (OSM) and leukemia inhibitory factor (Goldring, 2000). 
Trauma can, in fact, initiate the degradation process or cause a direct physical defect. This will initiate 
both IL-1β and (TNFα) release, up-regulating metaloproteinase (MMP) production by synoviocytes. 
MMP1 interstitial collagenase, MMP3 stromelysin and MMP13 (collagenase 3), disintegrin-like and 
metalloproteinase with thombospondin type 1 motifs 4 and 5 (ADAMTS 4 and 5) are the most 
important catabolic MMPs that are responsible for ECM degradation (Lefebvre et al., 1990; Mengshol 
et al., 2000; Tortorella et al., 2001). Together with down-regulation of synthesis, articular cartilage 
matrix components, like collagen II, aggregan and small proteoglycan are destroyed (Chadjichristos et 
al., 2003; Seguin & Bernier, 2003).  
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3. Diagnosis of equine OA 
 
Cartilage lesions can be characterized by local splitting and fragmentation (fibrillation) of cartilage 
and are usually accompanied by synovitis and joint effusion (Jaffe, 1972). Degenerative lesions were 
at first not well correlated with the evidence of pain but cartilage wear lines were commonly seen 
(Nilsson, 1973). In horses, any joint can be affected, but, OA is more commonly found in distal limb 
joints (interphalangeal joints and metacarpo/tarsophalangeal joints), carpus, tarsus and stifle. A single 
joint can be affected but frequently several joints are affected at the same time (Kidd et al., 2001).  
As previously mentioned, the equine distal limb has three synovial joints and there are differences 
between high and low-motion joints. High-motion joints frequently exhibit synovitis, cartilage erosion, 
subchondral sclerosis and capsular fibrosis. Low-motion joints usually show little evidence of synovitis 
but frequently present full thickness cartilage necrosis with little erosion but subchondral lysis, due to 
resorption of the subchondral bone by osteoclasts, generally progreding towards ankylosis (Pool, 
1996).  
Despite OA affecting most prominently the cartilage, clinical signs are essentially related to joint 
inflammation and pain. The inflammation role is controversial but it is accepted to be present at least 
in the initial stages of the disease. The most commonly complaints presented by the owner are slowly 
progressive lameness, often bilateral, and poor performance. Besides clinical history, it is essential to 
perform a thorough physical examination. It is common to find variable joint effusion and, at advanced 
stages of the disease, bone remodelling is sometimes associated to limited range of joint motion (Kidd 
et al., 2001). To confirm the origin of pain veterinarians should perform a complete lameness 
examination. The following section briefly describes some of the limitations of subjective assessment 
and introduces a new objective technology for lameness detection in horses. 
 
3.1 Lameness evaluation 
Lameness scales have been developed in order to improve communication among veterinarians, 
with their clients and to better assess and quantify the clinical improvement (Ross, 2003). Despite the 
routine application of these scales by equine practitioners, several confounding factors can influence 
their application in practice, namely the horse temperament and the veterinarians’ experience 
(Keegan, 2007). In recent years, subjective evaluations have been assessed and compared to new 
objective techniques. It has been found that subjective agreement for mild lameness is low, so, 
detection and evaluation of the most lame limb should not be performed by more than one evaluator, 
when doing clinical trials or when studying other lameness evaluation methods. Moreover, agreement 
is not improved by lungeing and flexion test compared to straight line alone, nor by videotaped 
recordings compared to real time evaluation (Keegan et al., 2004).  
For an objective detection of lameness, we can use two different approaches: the kinematics, that 
describes motion using a treadmill, stationary cameras and passive markers and the kinetics, that 
studies the action of forces using stationary force plates or force-measuring treadmills (Keegan, 2007). 
The wireless, inertial sensor-based system device was first described as a method of continuous 
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lameness quantification, that could be used in the field (Keegan et al., 2002).  This device consists of 
2 single-axis acceleration sensors, one attached to the head and another between the tubera sacrale, 
and 1 single-axis piezoelectric, gyroscopic sensor, attached to the right front pastern (Figure 1). 
Lameness is detected and quantified by analysing the patterns of vertical head (Figure 2A) and pelvic 
(Figure 2B) movement during trot movement (Keegan, 2004). Data is then transmitted wirelessly and 
analysed using commercially available software (Lameness Locator®, Equinosis). 
 
 
 
Figure 1: Horse instrumented with 3 inertial sensors during a lameness exam. There is a uni-axial accelerometer 
attached to the head bumper; one uni-axial accelerometer placed between the tubera sacrale on the midline of 
the most dorsal aspect of the pelvis with tape and a third uni-axial gyroscope wrapped to the dorsal aspect of the 
right forelimb pastern (VetAgro Sup - Veterinary Campus of Lyon). 
 
 
Figure 2: Illustration of data used for detection and quantification of lameness in horses using inertial sensor 
system (Keegan 2004). A: There is less downward movement of the head during the stance phase of the right 
forelimb (righ forelimb lameness) and B: more downward movement of the pelvis during the stance phase of the 
right hind limb (left hind limb lameness). 
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Its repeatability was assessed (Keegan et al., 2011), compared to a stationary force plate (Keegan 
et al., 2012) and sensitivity compared to subjective evaluations (McCracken et al., 2012). In the latter 
study the inertial sensors detected lameness sooner than the consensus of 3 experienced evaluators, 
regardless the induced pain location or fore/hind limb lameness in the straight line. Furthermore, this 
device has been evaluated for proximal hind limb response to flexion (Marshall et al., 2012). It was 
found that subjective positive response to flexion resulted in significant changes in objective 
measurements of pelvic asymmetry. However, this was never studied for distal limb flexion in 
forelimbs and hind limbs. 
 
3.2 Imaging techniques 
Several imaging techniques, like scintigraphy, can be useful particularly if there is multiple limb 
lameness or no response to local analgesia. Standing magnetic resonance imaging (MRI) is available 
for horses and may be an option for distal limb problems particularly if soft tissue structures are a 
concern (Schramme, 2015). However, both exams are expensive and not available in every country 
nor every equine hospital. Eventually, ultrasound can detect different degrees of synovitis and 
periarticular fibrosis, however it is not frequently used for OA diagnosis. The gold standard method to 
detect OA is the radiographic examination. This method, noninvasive, portable and cost-effective, is 
very useful when lameness examination is performed thoroughly and regional analgesia is able to 
localise the source of pain. Despite being indispensable to evaluate joint status, there is, however, a 
poor correlation between radiographic changes and clinical signs (Widmer & Blevins, 1994). Baccarin 
et al. (2012) have more recently reported no correlation between radiographic scores and the 
presence or absence of lameness.  
Joint inflammation, arthritis, can be seen radiographically as evident capsule distension without 
apparent new bone formation. Osteoarthritis or osteoarthrosis are characterized by bone involvement 
with or without an inflammatory soft-tissue component, respectively. If a primary cause is known, such 
as in OCD or IA fracture, the term secondary joint disease can be used. Immune mediated joint 
disease should be considered if several joints are affected and infection can be excluded. 
Degenerative joint disease is used to refer to any condition that affects the joint and its supporting 
structures. It is more frequently encountered in adults but can be present in young horses sometimes 
due to poor conformation and/or hard use (Butler, 2008). Radiographic abnormalities associated to 
joint disease include several features that can be related to different pathogenic mechanisms (Table 
1). 
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Table 1: Radiographic features and pathogenic mechanism of OA (adapted from Frisbie, 2012). 
Radiographic feature Pathogenic Mechanism Research work images 
 
Periarticular ostophyte 
formation 
 
Endochondral ossification 
occurring at bony margins of 
unknown cause. Possible repair 
attempt modulated by altered 
cytokine milieu. 
 
 
Subchondral bone 
sclerosis 
 
Deposition of new bone as a 
response to changes in force 
transmission and from healing 
of trabecular microfractures. 
Corresponds to areas of 
maximum stress. Significant 
sclerosis often corresponds to 
full-thickness cartilage loss. 
 
 
Subchondral bone lysis 
 
Less-common change of 
uncertain pathogenesis. 
Possibly pressure necrosis from 
synovial fluid, gaining access to 
subchondral plate via fissures, 
or related to pressure necrosis 
from trauma to bone. 
 
 
 
Osteochondral bodies 
 
Disintegration of joint surfaces 
or fractured osteophytes. 
 
 
Joint space narrowing 
 
Cartilage degeneration and 
loss. Usually areas of weight 
bearing or high stress. May be 
absent when focal cartilage loss 
occurs. 
 
 
Advanced remodelling / 
ankylosis 
 
Articular response to advanced 
degeneration.  
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One or more features can be associated with joint disease. Periarticular osteophytes should be 
differentiated from entheseophyte formation (bone production at ligament insertion) and, as discussed 
before, are not necessarily synonymous of clinical signs. Conversely, absence of radiographic 
changes does not preclude the existence of cartilage degeneration. 
In order to quantify and compare radiographic evaluations semi-quantitative scales were developed 
allowing radiographic lesions’ classification. In humans, the Kellgren & Lawrence (1957) scale (0-4) is 
commonly used. In horses, metacarpophalangeal lesions may be classified from 0-4 depending on the 
severity of osteophytes, subchondral sclerosis and narrowing of the joint space (de Grauw et al., 
2006). 
 Radiographic lesions are frequently present bilaterally and may only be found in latter stages of 
OA. Therefore, in order to find a method for earlier recognition of the disease, other techniques have 
been studied like the measurement of cartilage biomarkers in SF and serum. 
 
3.3 Cartilage Biomarkers 
Intensive research has been developed on equine cartilage degradation and inflammation 
biomarkers, which are described as more dynamic and more suitable signal-to-noise ratio than 
imaging techniques (Ameye et al., 2007). Ideally, they should be able to predict disease, differentiate 
OA affected from non-affected joints, quantify the degree of cartilage degradation and evaluate 
response to therapy (Mcllwraith, 2005; de Grauw et al., 2006). Direct biomarkers from cartilage 
metabolism are breakdown products like type II collagen (e.g. Coll2-1, Coll2-1NO2) and proteoglycan 
fragments (e.g. GAG), interesting for clinical purposes. Indirect biomarkers can be produced 
secondarly to stress or damage, including inflammatory mediators (e.g. PGE2) proteolytic enzymes 
(e.g. MMPs); link proteins (e.g. cartilage oligomeric matrix protein) and pro-inflammatory cytokines 
(e.g. IL-1), being more interesting for research purposes. These molecules have their epitopes 
identified by specific immunoassays, that are commercially available for humans and increasingly 
present in the market for horses. 
There are additional factors that should be considered when choosing the type of sample to be 
analysed. Repeated SF samples can be difficult to obtain in equine athletes. Moreover they are 
considered responsible for the increase of GAG and PGE2 concentrations (Frisbie et al., 2008) and 
have associated infection risk. Blood samples are better tolerated and it has been described as having 
significant correlation with the concentration of the molecules in SF (Catteral et al., 2010). Several 
factors can influence biomarkers in serum and SF. Exercise alone can induce significant increase of 
collagen metabolism biomarkers in serum (Billinghurst et al., 2003) and GAG in SF (Frisbie et al., 
2008). This was not the case for PGE2, which was significantly increased in SF of experimental OA-
joints compared to exercise alone-joints. This difference was not evident in the serum (Frisbie et al., 
2008).  
Collagen type II molecules (Coll2-1 and Coll2-1NO2) were studied as potential biochemical markers 
for cartilage metabolism in humans (Deberg et al., 2005) and in mice (Ameye et al., 2007). Type II 
collagen peptide (Coll2-1) is located in the collagen triple helix, requiring 
CHAPTER I 
12 
 
of the collagen molecule. Coll2-1NO2 is the nitrated form of Coll2-1, requiring oxidative stress in 
articular cartilage and may indicate the level of inflammation in the synovium, being higher in 
rheumatoid human patients compared to OA patients (Deberg et al., 2005). Coll2-1 and Coll2-1NO2 
are expressed in the ECM around superficial lesions and in tendon insertion sites but absent from 
healthy and intact cartilage (Ameye et al., 2007). In this study mices were followed for 5 months, 
Coll2-1 was found to be constant but Coll2-1NO2 increased with age, suggesting different biologic 
processes and providing complementary information. In humans, type II collagen biomarkers are also 
expressed in superficial cartilage lesions and Coll2-1 decresases to reference values 3 months after 
hip replacement (Deberg et al., 2008). Moreover, Coll2-1 biomarker is significantly lower in patients 
responding to viscosuplementation (Henrontin et al., 2013) and has been shown to be significantly 
decreased in serum of OA human patients after systemic curcumin treatment (Henrotin et al., 2014). 
In horses, Verwilghen et al. (2009) studied these two molecules as diagnostic tools and reported a 
tendency towards an increase in severity of radiological class lesions with increased Coll2-1NO2. 
Significantly higher plasmatic levels of Coll2-1 were found in degenerative joint disease group 
(Verwilghen et al., 2009) and higher SF and plasmatic values were associated to more severe 
degenerative cartilage lesions of tarsocrural joints assessed by arthroscopy (Verwilghen et al. 2011).  
Fibulin 3 is a member of extracellular matrix proteins that has been found to be elevated in OA 
cartilage (Wu et al., 2007). More recently, fibulin 3 fragments (Fib3-1 and Fib3-2) were shown to be 
elevated in urine and serum of severe OA patients compared to healthy controls (Henrotin et al., 
2012). In particular, Fib3-2 was not modified by sex, aging or hormonal changes and has never been 
studied in horses. Also, there are no studies in equine medicine reporting the serum profile of these 
molecules after applying any type of treatment. 
 
4. Treatment of equine OA 
 
The articular cartilage is incapable of an adequate self-repair and full-thickness cartilage defects 
are replaced by less functional fibrocartilage, predominantly composed by type I instead of the original 
type II collagen. The depth, size and location of the defect and age of the patient affect endogenous 
repair (Frisbie et al., 2012). In OA treatment, the target is not only to abolish pain effectively, but also, 
to re-establish its function. The additional factor is the constant pressure on equine veterinarians to 
successfully treat performance-limiting joint problems, preferably with something inexpensive, effective 
and risk-free (Richardson & Loinaz, 2007).  
OA treatment has not yet a gold standard therapy and despite all efforts it is still accepted that 
established OA cannot be cured. Nevertheless, clinicians have several options between clinical signs 
or disease modyfing drugs available on the market, the latter drugs are supposed to decrease pain but 
also revert the disease evolution. Both groups have systemic and IA administration options. The most 
commonly used systemic drugs of the first group are the non-steroidal anti-inflammatory drugs 
(NSAIDs) like the non-selective cyclooxygenase (COX) inhibitors: phenylbutazone, suxibutazone, 
flunixin meglumine and ketoprofen. They are inexpensive but frequently associated to secondary 
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effects, like gastric ulcers and renal failure if long-term therapies are applied (Erkert et al., 2005; 
Goodrich & Nixon, 2006). More recently, selective COX-2 inhibitors, like meloxicam and firocoxib have 
been studied with encouraging results in equine synovitis and OA (de Grauw et al., 2009; Orsini et al., 
2012). Systemic disease-modyfing drugs are becoming increasingly common and consist of 
polisulphate glycosaminoglycan (PSGAG), HA and nutraceutical agents like glucosamine and 
chondroitin sulphate. These therapies have limited evidence of efficacy (Richardson & Loinaz, 2007; 
Vandeweerd et al., 2012) and were not under the scope of this thesis. We did a review on IA drugs 
used to manage lameness in the equine athlete and focused in the most recent biologic strategies 
(Monteiro et al., 2015).  
 
4.1 Intra-articular synthetic drugs 
Corticosteroids 
The most commonly used groups of drugs in IA treatment are corticosteroids, HA and PSGAG. 
Among these medications the corticosteroids have the most potent anti-inflammatory and pain relief 
effect, by inhibition of phospholipase A2 and COX-2 expressions (Masferrer & Seibert, 1994). They 
are also capable of supressing the most important cartilage degradation mediators, IL-1 and TNF-α  
(Laufer et al., 2002), and have cartilage-sparing effects at low-doses, without marked effects on 
chondrocyte health (Richardson & Dodge, 2003). A recent study showed that IA corticosteroid 
treatment, associated to systemic NSAIDs, have better owner-reported return to performance, in 
particularly in the fetlock joint and negative prognostic if DIP joint was involved (Brommer et al., 2012). 
Adverse effects may follow repeated injections of high doses of corticosteroids in vigorously exercised 
horses. Methylprednisolone acetate (MPA), particularly, inhibits proteoglycan synthesis and 
unfavorably influences the structural organization of collagens within cartilage in vitro model 
(Todhunter et al., 1996a) and in vivo model (Frisbie et al., 1998). Negative effects were not observed 
in subsequent in vitro and in vivo studies about MPA (Kawcak et al., 1998; Murphy et al., 2000; Murray 
et al., 2002; Raynauld et al., 2003). Neverthless, in a 2010 review made by Mcllwraith he described 
that betamethasone esters have no deleterious side effects, triamcinolone acetonide (TA) is 
chondroprotective and MPA has deleterious effects and therefore should be used juditiously. 
 
Hyaluronic acid (HA) 
Hyaluronic acid is also frequently used as an IA drug. This glycosaminoglycan is an important 
component of articular cartilage and SF. Antonacci et al. (2012) reported that equine SF from acutely 
inflamed joints presented significantly lower HA concentration, but, when concerning chronic 
inflammation cases, there was no difference compared to controls. The same authors reported poor 
boundary lubrication in acute post-injury, probably due to diminished concentration and molecular 
weight of HA. In clinical practice exogenous HA is injected due to viscosuplementation properties but 
also for the anti-infllammatory (Takahashi et al., 1999) and disease-modifying effects (Marshall et al., 
2000). High molecular weight (HMW) HA is reported to have superior cartilage-sparing properties in 
OA models (Asari et al., 1998), to restore in vitro lubricant function (Antonacci et al., 2012) as well as 
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better clinical improvement (Philips, 1989) when compared to the lower molecular weight. Also, higher 
concentrations (20mg and 40mg) have been described to better improve lameness after a single 
injection, when compared to lower doses (Richardson & Loinaz, 2007). In humans, clinical efficacy 
has been described to be higher in mild cases of OA (Wang et al., 2004). In horses, there is still a lack 
of scientific evidence on clinical efficacy. A study on experimental OA revealed that 3 injections of 
22mg HA together with 125mg amikacin, didn’t improve lameness but reduced cartilage fibrillation 
(Frisbie et al., 2009a). Some other studies also suggest that the natural time course of lubrication is 
important (Antonacci et al., 2012) and this could explain disappointing results in chronic cases. 
Corticosteroids are frequently combined with HA in order to combine potent anti-infllammatory with 
chondroprotective action (Mcllwraith, 2010). However, it has been found that a single IA injection of 
TA-HA association compared to the steroid alone, had worst clinical results 3 weeks post treatment 
and the same outcome 3 months post-injection (de Grauw et al., 2014). 
 
Polysulfated Glycosaminoglycan (PSGAG)  
PSGAG is a semisynthetic preparation, from bovine trachea, composed mainly of chondroitin 
sulphate, a glycosaminoglycan found in articular cartilage. Its intra articular efficacy has been reported 
in horses (Hamm & Jones, 1988). However, due to risk of joint infection (Gustafson et al., 1989), 
injections should be accompanied by an antibiotic administration (e.g. amikacin, 125 mg). HA together 
with sodium chondroitin sulphate and N-acetyl-D-glucosamine was compared to IA saline and 
amikacin alone (placebo). In this study, there was 16% improvement in lameness scores, slight 
improvement on radiographic bone proliferation and less cartilage erosion compared to placebo 
treated joints (Frisbie et al., 2013). 
In conclusion, controversy about efficacy and recommended doses and protocols for intra-articular 
HA and PSGAG still exist. Their application in OA prevention also needs further clarification. 
Conversely, these drugs do not present limitations in competing events and detection times, as 
doping, like for systemic NSAIDs and corticosteroids. Therefore, these therapies still play a role for the 
treatment of OA.  
In the last decades, a different category of disease modifying drugs has gained popularity both in 
human and equine medicine. These are based on biological and natural organism ability to repair and 
try to amplify their effects, the so-called regenerative or biologic therapies. 
 
4.2 Intra-articular biologic strategies  
These therapies may be classified into two main groups: the cell and the blood derived therapies 
(Appendix B: Biologic strategies for intra articular treatment and cartilage repair). Few studies on the 
effect of biologic therapies on equine cartilage regeneration have been published, most being in vitro 
or on disease-induced protocols, and scarce studies were done on natural occurring disease. Blood 
derived therapies are widely available because there are no restrictions and few legislation regulating 
their use. They are based on autologous products, so readily available from the patient, and supposed 
to be safe for the same reason. There are two main products being used in equine patients, 
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autologous conditioned serum and platelet rich plasma (PRP). The main interest associated with these 
products is based on their anti-catabolic and anabolic effects. As performance enhancement has not 
been demonstrated, these therapies are not included in the prohibited list of doping controls and, 
consequently, competing horses can benefit from their effects. They have been adapted from human 
medicine, with little supporting investigation. Nevertheless, they are being widely applied to equine 
patients. 
 
Mesenchymal stem cells 
Stem cells are unspecialized cells, which have the ability to renew themselves indefinitely and, 
under appropriate conditions, give rise to a variety of mature cell types (Caplan, 1991). Multipotency 
means they can differentiate into two or more cell lines (Spencer et al., 2011). Autologous multipotent 
cells are normally used because they have good differentiation capacity and require simple 
procedures to be collected from the patient. Mesenchymal line, containing undifferentiated cells from 
bone marrow and adipose adult tissues are the two populations most frequently used for cartilage 
repair (Caplan, 2007). Some studies report a significant higher chondrogenic potential of bone 
marrow-derived stem cells, synovial membrane and peri-articular fat (Mochizuki et al., 2006; Vidal et 
al., 2008; Vinardell et al., 2012). However, adipose subcutaneous tissue has gained popularity 
because it is more readily available and allows obtaining a high number of cells in the initial yield, 
which means little need of expansion and culture time (Vidal et al., 2008).  
In horses, two studies using a carpal osteochondral fragment model of osteoarthritis and focused 
on clinical assessment of pain besides radiographic lesions, SF and histologic evaluation, did not 
found significant improvement in pain score after MSCs therapy (Frisbie et al., 2009b; Mcllwraith et al., 
2011). These studies in experimental osteoarthritis models give little support to the use of MSCs at the 
acute phase. Even so, a prospective multicenter study was designed on naturally occurring OA. 
Treated joints were mostly stifles with advanced fibrillation and loss of soft tissue structures and 
received bone marrow MSCs and HA. In an average of 21 months follow-up, authors reported 76% 
return to work, from which 38% of horses returned to their primary intended use. Authors also found a 
superior long-term outcome, when treatment was performed in at least one month after diagnosis 
(Ferris et al., 2009). More recently, this has been published in 33 clinical cases of stifle lesions using 
autologous bone marrow derived MSCs (Ferris et al., 2014) and allogeneic peripheral blood-MSCs 
added with PRP, in 91 clinical cases of OA in different joints (Broeks et al., 2014). Both studies 
reported high rates of horses returning to work, 75% at 24 months and 78% at 6 months follow-up, 
respectively. Based on these reports, IA administration of stem cells seems an interesting and 
straightforward therapy. 
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CHAPTER II – Comprehensive research work 
 
This chapter consists of two sections. The first section presents the results of a survey to 
Portuguese equine veterinarians about diagnosis and treatment of OA, which helped understanding 
the Portuguese reality and the clinical practice needs. The subsequent section presents the in vitro 
work about the effects of different doses of equine allogeneic ASCs with or without IFN-γ pre-activation 
before application in an experimental model of the disease in vivo. 
 
1. Survey to Portuguese equine veterinarians 
 
A survey (Appendix C: Questionnaire) was prepared for equine veterinarians in order to understand 
the most common clinical features of OA and most common treatments used in equine field practice in 
Portugal. 
 
1.1  Materials & Methods 
Contact with 106 members of Associação Portuguesa de Médicos Veterinários de Equinos 
(APMVE) from April 2013 to April 2014 was attempted electronically, sending them a link for a web-
based survey (Google Drive form) via email. Moreover, a form was distributed at the I Congress of the 
Associação Portuguesa de Médicos Veterinários de Equinos (APMVE), on the 17th April 2014, about 
sport horse medicine and all answers were inserted online.  
 
1.2  Results 
Sample characterization 
A total of 24 surveys were analysed: 7 forms were submitted online and 17 written forms were 
completed. The majority of respondents (87.5%) indicated to have more than 75% of their activity in 
equine practice. There were 3 young veterinarians (less than 5 years of experience), 45.8% (11/24) 
between 6 and 10 years of experience and 41,7% (10/24) with more than 11 years of experience.  
Most of the veterinarians (37.5%) worked primarily with show jumping horses.  
 
Diagnostic responses 
Regardless of the veterinarians’ experience and the main equine sport discipline, OA was most 
commonly diagnosed in 10 to 14 year-old horses (58.3%), followed by 5-9 year-old (16.7%) and 15-19 
year-old (12.5%). Horses presenting OA were described to work at moderate level (more than 
5h/week) by 41.7% of the veterinarians. The majority (87.5%) of the answers reported to find OA 
clinical signs without radiographic lesions, which were most frequently seen in the fetlock and DIP 
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joints. Moreover, 87.5% of the answers reported to find radiographic lesions without OA clinical signs, 
which were most frequently seen in the PIP joints and distal intertarsal and tarso-metatarsal joints. 
 
Treatment responses 
The most common first choice treatment was IA injection (11/24, 45.8%) followed by corrective 
shoeing (6/24, 25%). The alternative approach to OA treatment was systemic NSAIDs (4/24, 16.7%) 
and food/work management (3/24, 12.5%). The less frequently recommended options, as the first 
choice, were other systemic drugs: oral supplements, intramuscular (IM) PSGAG followed by 
endovenous HA. Tetracyclines were rarely choosen. 
Considering the scope of this thesis we further asked which drugs and protocols were currently 
performed for the IA treatment at high motion joints. The first choice protocol was a single injection of 
TA alone (12/24, 50%) or together with HA (6/24, 25%). The doses of TA varied from 4 to 12mg per 
joint. Reported doses of HA, low molecular weight, were 20-25mg per joint, with 4,2% (2/24) of the 
practioners performing a second injection 2 weeks after. Betamethasone sulphate was the first choice 
for (5/24, 20.8%) of the veterinarians (6-12mg per joint) and MPA the first choice for (4/24, 16.7%) of 
the veterinarians (20-40mg per joint). Antibiotic injection together with other treatments was 
considered by 50% (12/24) of the respondents, most frequently in the less than 10 years of experience 
group (8/12) compared to the more than 10 years of experience group (4/12). Biologic therapies like 
IRAP, PRP and MSC were the least used therapies together with PSGAG. There were 37.5% (9/24) of 
the veterinarians considering to use at least one of the biologic products, most frequently in clinical 
cases not responding to other therapies. This was not correlated with years of experience (r = 0.430). 
 
1.3  Discussion 
The number of participating veterinarians was lower than expected but interesting answers were 
found. The results concerning presence of OA without radiographic changes in DIP and fetlock joints 
did not fit the previous findings of Baccarin et al. (2012), which found significantly lower scores in distal 
limb joints in sound horses compared to lame horses. However, the results about small tarsal joints 
are in agreement. In the same study there was a low correlation between radiographic scores and 
lameness. Therefore, it would be interesting to find if lameness and, eventually, flexion-test response 
assessed objectively would show higher correlation with distal radiographic findings, compared to 
subjective evaluation. 
 The second point that was supposed to be addressed was using IA injection as a first line 
treatment. Almost half of the enquired veterinarians treated OA this way. This is probably due to the 
pressure imposed by owners to return animals back to work as soon as possible. Neverthless, 
NSAIDs are still the second choice after corrective shoeing, commonly used as support the treatment. 
Systemic PSGAG, HA and nutraceuticals are not a common choice probably due to their low efficacy 
and associated high price. One should agree that in terms of price/efficacy corticosteroids are the gold 
standard but veterinarians should limit their doses (Richardson & Dodge, 2003). In fact, some 
veterinarians are using MPA and TA at doses under the recommended guidelines (Caron, 2005). On 
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the other hand, for the last decades MPA has shown detrimental effects in the cartilage of high-motion 
joints (Frisbie et al., 1998) and that is probably why it is the least frequently used steroid. An American 
equine veterinarian survey confirmed that TA is most frequently used in high motion joints but MPA is 
still used in low motion joints (Ferris et al., 2011). Similarly to this study, the most common 
combination with steroids was HA and the use of antimicrobials, regardless of the injected product. 
Finally, veterinarians are faced with particular OA cases in which they don’t recommend steroids. 
American practioners reported to apply HA products alone more frequently in acute disease affecting 
high motion joints, followed by chronic cases with radiographic indication of OA and chronic 
maintenance cases (Ferris et al., 2011) but they were not asked about injection protocols. In Portugal, 
veterinarians reported HA therapy use on a single injection protocol, which supported our interest in 
further exploring this protocol. Biologic therapies were not used but they were considered, most 
commonly, in cases not responding to steroids any more. 
In conclusion, alternative therapies to steroids are needed in particular cases. The problem is the 
lack of clinical and scientific evidence. Therefore, our goal was to objectively study the effects of new 
IA therapies. Before in vivo application, adipose stem cells activation with INF-γ was studied in vitro. A 
part of the results about the effects of this treatment on a model of osteoarthritis in equine cartilage 
explants are presented in the following section. 
 
2. Effects of allogeneic ASCs pre-activated by INF-γ  on experimental OA in 
vitro 
 
Abstract 
The objective of this part of the work was to study the dose-effect of allogeneic adipose 
mesenchymal stem cells (ASCs) and preactivation with interferon-γ (INF-γ), using an equine fetlock 
OA model in vitro. Equine fetlock cartilage explants were OA-induced with 1 ng/mL of interleukin-1β 
(IL-1β) and 10 ng/mL of oncostatin-M (OSM) and tested with or without a low (25 x103) and high dose 
(100 x103) of ASCs. OA induction increased cartilage degradation genes (n=2) and significantly 
increased GAG release (n=10) (P < 0.001), these effects being reverted by the high dose of ASCs. 
Subsequently we tested both concentrations with or without IFN-γ preactivation (100 ng/mL for 24h) 
for GAG release during 12 days. The high dose of ASCs decreased GAG release and preactivation 
shortened the onset and the necessary dose to reach the effect.   
 
2.1  Introduction 
The immunomodulatory capacity of MSCs has been the focus of allogeneic treatments and 
immuno-mediated diseases. The rationale would be to control host exacerbated response to the “non-
self” therapy (Polchert et al., 2008). IFN-γ was first reported to stimulate MSCs production of 
indoleamine 2,3-dioxygenase, which in turn inhibited the proliferation of activated T or natural killer 
cells (Krampera et al., 2006). In recent years the stimulation of MSCs has been studied and several 
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studies support better immunomodulatory properties after preconditioning of cells in inflammatory 
conditions (Crop et al., 2010; Carrade et al., 2012). This preactivation can affect ASCs morphology, 
proliferation and citokine expression but their differentiation capacity seems to be preserved (Crop et 
al., 2010). Therefore, IFN-γ preactivation of ASCs could improve clinical efficacy after IA treatment in 
horses with osteoarthritis, even if the immune features are less well understood than in human 
patients. 
 
2.2  Material & Methods 
 
Isolation, characterization and pre-activation of cells 
Adipose tissue was retrieved from the subcutaneous gluteal fat from a 4-year-old French 
Standardbred donor horse owned by Sanofi-Pasteur. The procedure was performed standing, under 
sedation and local anesthesia, using tail head standard technique (Frisbie et al., 2009). Tissues were 
kept at 4-10ºC in a dissection medium, Dulbeco’s phosphate buffer saline (PBS, Gibco, Life 
Technologies), during transportation and processed within 3 hours. Fat was digested with 0.25% 
collagenase 1 (Worthington Biochemical Corp.) under agitation at 37ºC during 1h30 and the 
homogenate was centrifuged during 10 min at 300 ga using routine laboratory techniques. The stromal 
vascular fraction was collected, cells were filtered successively through a large sterile filter, a 100 and 
a 70 µm porous membrane filters, in order to remove fat. To avoid red cells, a hemolysis step was 
done briefly by adding a lysis buffer for less than 5 min. Single cells were seeded in 10 cm Nunclon 
Petri dishes (passage 0) and amplified in a 5% CO2 incubator at 37ºC. After 2-3 days, cultures were 
washed with PBS before changing the medium. After one week, cells were trypsinized (passage 1) 
and split for another amplification step. Following cell growth and checking for colony formation cells 
were trypsinized (passage 2), counted and stocked at 3 to 15 million cells per mL in freezing buffer at -
80ºC or -160ºC. ASCs were characterized by their immunophenotype (positive for CD44, CD73, 
CD90, CD105 and negative for CD34 and CD45) and their trilineage potential.  
ASCs preparation for preactivation consisted in thawing cells at 37ºC, transferring to prewarmed 
culture medium and plated (passage 2) at 1 million cells for a 10 cm Nunclon petri dish. Medium was 
changed every 2-3 days for 10 days. At day 9, cells had an IFN-γ pretreatment (100ng/mL) during 24h. 
ASCs were then trypsinized (passage 3) counted and centrifuged during 5 min at 300 ga and 
resuspended in injection medium (vehicle) without IFN-γ (Stem Alpha 7900).  
 
Cartilage explant model and OA induction 
Equine joint specimens were retrieved from 4-8 year-old French trotters, euthanized for any other 
reason than osteoarthritis (n = 10). Macroscopically healthy fetlock joints were processed within 3 
hours and allowed retrieving five cartilage explants per well using 3 mm biopsy punch (Harris Uni-
core). Cartilage explants were cultured with 1mL buffered Dulbecco’s modified Eagle’s medium 
(DMEM), high Glucose-glutamax (Gibco, Life Technologies), Hepes 20 mM, ascorbic acid 5 µg/mL 
(Carlo Erba Reagents), 0.5 µg/mlL Insulin, 0.5 µg/mL Transferrin, 0.5 ng/mL Selenium (2.5 µL) ITS-
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Supplement (Sigma-Aldrich) and 50µg/mL Gentamycin for preliminary two days of stabulation. OA 
condition was induced by injection of two cytokines: 1 ng/mL IL-1β (R&D Systems) and 10 ng/mL 
OSM (Invitrogen, Life Technologies) to the culture medium (Pelletier & Martel-Pelletier, 1989; Barksby 
et al., 2006)   
 
Cell Coculture and GAG release 
Cartilage explants (n = 10) were cultured with DMEM (control), DMEM/ IL-1β /OSM (OA condition) 
alone and together with one of the 4 different ASCs treatments: 25 x103 or 100 x103 cells, both 
concentrations with or without IFN-γ. GAG release speed was assessed for each condition in order to 
test the dose and the preactivation effects. Culture medium was assessed in triplicate and changed 
every 2-3 days until day 12 after treatment. Microplate was read by spectrometry at 656 nanometers 
(Flexstation, Molecular devices) after quantitative dye-binding method, for analysis of sulfated 
proteoglycan and glycosaminoglycans (Blyscan®, Biocolor). The median value obtained from the 
triplicate measurements was divided by the number of days in order to obtain the GAG degradation 
speed. Each cartilage explant showed similar weight, 8 ± 0.19 mg (mean ± SEM) which precluded a 
normalization step. Mean GAG values for each condition were calculated at days 2, 5, 7, 9 and 12 and 
compared to OA condition baseline. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Additionally, cartilage explants from two horses (n = 2) were used in order to test the in vitro OA 
model (OA condition versus control) as well as the two ASCs concentration effects on culture explants 
(ASCs versus OA condition) by presenting the fold-change in gene concentration. After a 10 day-
treatment the explants were digested with collagenase II for subsequent RNA extraction. Total cellular 
RNA was isolated from 45mg of cartilage together with 1mL of TRIzol (Invitrogen). Each sample 
(0.06µg) was reverse transcribed using High capacity cDNA Reverse Transcription kit (Applied 
Biosystem). Quantitative real-time PCR (qRT-PCR) was carried out to determine the mRNA levels of 
cartilage matrix synthesis genes (collagen type 2 and 9 and aggrecan) and cartilage matrix 
degradation genes: ADAMTS-4, ADAMTS-5 (disintegrin and metalloproteinase with thrombospondin 
motifs 4 and 5), matrix metalloproteinase-1, 3 and 13 (MMP-1, MMP-3 and MMP-13) with miRNEasy 
Kit (Qiagen) according to manufacturer’s instructions. After amplification, target genes were 
normalized against the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The following probes (Applied Biosystem) were used: Collagen II (ref EC03467411); Collagen IX (ref 
EC03470076); Aggrecan (ref EC03469667); ADAMTS-4 (ref EC03469180) ADAMTS-5 (ref 
EC03470666); MMP1, MMP3, MMP13 (ref EC03468020, ref EC03468674 and EC03467796). 
 
Statistical Analysis 
Genetic study (qRT-PCR) was performed in cartilage explants from two horses precluding 
statistical analysis. The rest of the data were tested for normality and the homogeneity of variances by 
using the Shapiro–Wilk and the Levene tests, respectively. In vitro, GAG values were analyzed with 
two-way analysis of variance (ANOVA) with the Dunnett’s method for multiple comparisons. Statistical 
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analysis was performed using software package EverStat V6 under SAS v9.2. Significance was set at 
P ≤ 0.05. 
 
2.3  Results 
GAG release and gene expression on OA-induced cartilage explants  
OA induction by IL-1β and OSM treatment significantly increased the GAG release speed 
(µg/mL/day) at all times compared to culture medium controls (P < 0.001) (Figure 3).  
 
 
Figure 3: Mean (± SD) glycosaminoglycan release speed over 12 days of culture (n = 10). Explant model - culture 
medium controls compared to OA condition. Significantly different results are represented by *** P ˂ 0.001. 
 
The OA model was further validated by decreased expression of cartilage matrix synthesis genes 
and increased expression of cartilage degradation genes compared to medium control in both 
cartilage explants. Aggrecan was 87 and 100-fold less expressed after OA induction in cartilage 
explants 1 and 2, respectively. Collagen 2 was less expressed in both cartilage explants and collagen 
9 was not expressed after OA induction. Concerning degradation genes, ADAMTS-5 was 4.4 and 2.2-
fold more expressed in cartilage explant 1 and 2, respectively. ADAMTS-4 was not detected in 
controls but was expressed in both cartilage explants after OA induction. MMP1 was 63 and 56-fold 
more expressed; MMP-3 was 217 and 330-fold more expressed and MMP13 was 217 and 413-fold 
more expressed after OA induction, in cartilage explant 1 and 2, respectively. 
 
Effects of ASCs on cartilage OA-model 
Cartilage synthesis and degradation genes were assessed in cartilage explants of two horses for 
the low dose (25 x103) and high dose (100 x103) of ASCs and compared to OA condition. The most 
consistent results from cartilage synthesis genes were observed for collagen 2, more expressed with 
the high dose in the 2 horses (39 and 1.63-fold) and collagen 9, which was not detected in any 
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condition. Concerning the degradation genes, the first cartilage explant presented less expression of 
ADAMTS-4 with low (7-fold) and high dose (20-fold) and less expression of ADAMTS-5 with low (4.3-
fold) and high dose (14.3-fold) of ASCs. In the second cartilage explant, there was increased 
expression of ADAMTS-4 and ADAMTS-5 at low dose, 1.32 and 2.82-fold, respectively. However, 
decreased expression of both genes was observed with higher dose, 3.5 and 2.4-fold, respectively. A 
similar tendency was found in the first cartilage explant, presenting a better reduction on expression of 
MMP1 (2.6-fold), MMP3 (50-fold) and MMP13 (25-fold) with high, compared to low dose, of ASCs. In 
the second cartilage explant there was increased expression with both concentrations of MMP1 and 
with the low dose of MMP-3 and 13. There was decreased expression of MMP-3 (3.7-fold) and MMP-
13 (2.4-fold) with the high dose. These results show more collagen 2 expression and less degradation 
by MMP and aggrecanases in cultures using the highest dose of ASCs in both cartilage explants. 
 
Effects of INF-γ  pre-activated ASCs on GAG release  
Allogeneic ASCs treatments revealed significant differences in GAG release compared to OA 
condition (Figure 4), showing a transient increase in GAG mean values at day 2 and 5. Cartilage 
explants treated with 100 x103 ASCs significantly decreased GAG release at day 9 (P ˂ 0.001) and 
IFN-γ preactivation extended the significant period from day 7 (P ˂ 0.001) to day 12 (P ˂ 0.001). 
Treatment with 25 x103 ASCs alone didn’t show significant GAG reduction but with IFN-γ pre-
activation, induced significant reduction, presenting the lowest values at day 7, at day 9 and at day 12 
(P ˂ 0.001). These results show that high dose ASCs decreased GAG release and preactivation 
shorten the onset and the necessary dose to reach the effect. 
 
 
Figure 4: Mean (± SD) glycosaminoglycan release speed over 12 days culture (n = 10). Coculture - ASCs low 
(25x103) and high dose (100x103) ASCs, with or without IFN-γ pre-treatment, compared to OA condition alone. 
Significantly different results are represented by * P ˂ 0.05 ** P ˂ 0.01 and *** P ˂ 0.001. 
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2.4 Discussion 
The role of IFN-γ in the immunosuppressive function of MSCs has been reported (Krampera et al., 
2006) but it was never studied in equine experimental OA. The in vitro part of the study was performed 
in nearly safe cartilage explants and IL-1β and OSM treatment was effective in producing experimental 
OA. This was shown by significant increase of GAG release, which is similar to a human cartilage 
coculture model (Fearon et al., 2006). Moreover, qRT-PCR results further confirmed the cartilage 
degradation with increased expression of cartilage degradation genes (ADAMTS-4, ADAMTS-5, 
MMP1, MMP3 and MMP13). The OA-baseline for GAG release allowed the evaluation of the two 
ASCs concentrations but more importantly the INF-γ preactivation effect. All ASCs treatments induced 
transient increase followed by decreased GAG release into different culture conditions. The initial 
GAG release could be explained by transient cartilage degradation or ASCs production (Tapp et al., 
2008) and proteomics analysis could be interesting to clarify this question. Without preactivation, 
higher dose had decreased GAG release speed compared to lower dose, which is similar to a dose-
dependent study that reports better efficacy of higher concentration of autologous ASCs (Jo et al., 
2014). This was further supported in our study by the reduced expression of cartilage degradation 
genes with high dose of ASCs. With preactivation, both ASCs concentrations decreased GAG release 
during an extended period of time, which reflects an additional protective effect. However, this was 
more evident with lower dose (25 x 103) of ASCs. It is possible that at higher concentrations ASCs 
preactivation could induce cluster formation too quickly and subsequent cell death, stimulating 
cytokine production that would induce GAG release. This could also be due to an effect on the 
degradation/synthesis balance showing the importance of knowing the correct dose for optimal effect. 
In conclusion, high concentration of ASCs is important to reach an anti-catabolic effect of cartilage in 
vitro and IFN-γ preactivation allows reduction of the number of needed cells, extending the effective 
period of action. Further research in vivo is necessary to clarify these findings and better 
understanding the clinical potential of this therapy. 
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Abstract 
The aim of this work was to study the effects of allogeneic adipose mesenchymal stem/stromal 
cells activated with INF-γ (ASCs-γ) in equine experimental osteoarthritis (OA) in vivo. We used the 
metacarpophalangeal groove model in one forelimb while the contralateral joint was sham operated. 
The study involved ten Standardbred horses divided in two groups. Group A (n = 6) received an intra-
articular (IA) injection of 15 million ASCs-γ in 3 mL of vehicle and Group B (n = 4) received the vehicle 
alone (3 mL). After surgery and 2 weeks stall-rest, horses respected an exercise protocol for 8 weeks. 
Animals had objective lameness evaluation, SF biochemical analysis and radiographic examination. In 
the end, horses were euthanized for macroscopic and microscopic joint assessment. The groove 
model was validated by group B results. It was observed a significant increase in total proteins (TP) at 
week 1 and 2, significant increased in the radiographic score at week 6 and 10 as well as significant 
increased microscopic lesion score adjacent to groove in OA-joints compared to sham-joints. The 
allogeneic cell treatment effects were represented by results in group A: significant decrease in 
prostaglandin E2 (PGE2) values in OA-joints compared to sham-joints at week 10 was observed. One 
horse from group A presented a flare reaction and had a chondroid-like cell focus inside one of the 
grooves. Another cell-treated horse presented mesenchymal-like cell focus inside two grooves. The 
latter horse was not lame, had no radiographic increased score and presented normal TP in the OA-
joint throughout the study. There were no significant differences between OA-joints of both treatment 
groups but significant increased radiographic scores of OA-joints compared to sham-joints were 
present in group B but not in group A and could demonstrate an ASCs-γ effect. Our results confirmed 
the efficacy of the groove model. The IA allogeneic adipose-derived stem/stromal cell treatment 
showed possible modifying disease effects that should be further explored before application in clinical 
OA in horses. 
 
1. Introduction 
 
Mesenchymal stem/stromal cells (MSCs) have shown protective effects by preventing chondrocyte 
apoptosis and fibrosis due to their differentiation properties but also to paracrine actions (Maumus et 
al., 2013). In a murine collagenase induced OA model, a single intra-articular injection of autologous 
adipose derived-tissue mesenchymal stem cells (ASCs) reduced synovitis, osteophyte formation and 
decreased score of cartilage lesions (ter Huurne et al., 2012) and could depict a potential therapeutical 
effect in other species. MSCs need to be activated by local inflammatory mediators released from 
activated immune cells (Ghannam et al., 2010). However, while inflammatory conditions are required 
for the immunosuppressive function of MSCs, they do not enhance their capacity to survive in vivo 
(Toupet et al., 2015). IFN-γ was first reported to stimulate MSCs’ production of Indoleamine 2,3-
dioxygenase, which in turn inhibited the proliferation of activated T or natural killer cells (Krampera et 
al., 2006). More recently, human ASCs have been showed to increase immunosuppressive capacity 
under inflammatory conditions in vitro, which affected gene expression of cytokines as well as ASCs 
morphology and proliferation while their differentiation capacity was preserved (Crop et al., 2010). A 
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different study found that non-stimulated MSC did not change lymphocyte proliferation, but, when 
activated there was an increase in the secretion of PGE2 and Interleukin-6 as well as an inhibitory 
effect on T-cell proliferation and cytokine production (Carrade et al., 2012). Additionally, pre-treatment 
with IFN-γ enhances the therapeutic activity of MSCs (Duijvestein et al., 2011) and IFN-γ alone have 
shown protective effects on osteoarthritic animal models in vitro and in vivo (Page et al., 2010).  
Most equine studies use an autologous source of stem cells (Frisbie et al., 2009; Mcllwraith et al., 
2011). This is probably due to the fact that the use of allogeneic source increases the occurrence of 
rejection and induces faster elimination of cells (Zani et al., 2009). Moreover, the allogeneic source 
can induce a loss of activity and have associated risks of spontaneous tumor transformation or 
differentiation in other cell types (Sivanathan et al., 2014). Conversely, autologous source supposes a 
delay from harvesting cells to their production and the use of allogeneic stem cells would have the 
advantage of being readily available and allow to standardize protocols. In a murine model, allogeneic 
MSCs were able to suppress graft to host disease after donor T-cell recognition of antigen only after 
IFN-γ pre-activation. In this study, it was sustained that allogeneic MSCs required a minimal threshold 
of IFN-γ and that more exposure amplified MSCs suppression potential. Therefore, in vivo, cytokine 
levels and time of MSCs injection would be critical for effective anti-inflammatory effects (Polchert et 
al., 2008). IFN-γ pre-treatment could enhance an ASCs treatment and has never been tested in horses 
before. 
Equine OA diagnosis and the evaluation of treatment efficacy is performed mainly by radiographic 
examination and subjective lameness evaluation. In recent years, an inertial sensor methodology has 
been used for objective detection of pain. This technology measures head and pelvic asymmetry 
(Keegan et al., 2004) and its repeatability confirmed (Keegan et al. 2011), compared to a stationary 
force plate (Keegan et al., 2012) and proven to be more sensitive in mild cases of lameness when 
compared to subjective evaluation (McCracken et al., 2012). Therefore, it could be particularly 
interesting for therapy assessment both in natural as well as induced OA. An equine groove model of 
metacarpo-phalangeal (MCP) OA has been developped and under a controlled exercise regime 
displayed significant radiographic, macroscopic and microscopic degenerative changes, close to 
naturally ocurring OA and allowing assessement of therapy effects (Maninchedda et al., 2015). 
The purpose of this study was to evaluate the effects of allogeneic ASCs pre-activated with INF-γ 
(ASCs-γ) of the equine groove model of MCP OA previously described by Maninchedda et al. (2015) 
while validating the efficacy of this model. We hypothesized that, using the OA model in vivo, IA 
injection of allogeneic ASCs-γ would have protective effects demonstrated by reduced lameness, 
radiographic lesions, SF inflammation and cartilage degenerative features. 
 
2. Materials & Methods 
 
This study was carried out in strict accordance with the recommendations stated in the ARRIVE 
(Animal Research: Reporting In Vivo Experiments) guidelines. The Ethical Committee of VetAgro Sup-  
Veterinary Campus of Lyon approved the protocol (Permit Number: RECH-ETIC-P003-E01). All 
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procedures were performed under general anesthesia or sedation and all efforts were made to 
minimize suffering. 
 
2.1. Isolation and characterization of ASCs 
Adipose tissue was retrieved from the subcutaneous gluteal fat from a 4-year-old French 
Standardbred donor horse owned by Sanofi-Pasteur. The procedure was performed standing, under 
sedation and local anesthesia, using tail head standard technique (Frisbie et al., 2009). Tissues were 
kept at 4-10ºC in a dissection medium, Dulbeco’s phosphate buffer saline (PBS, Gibco, Life 
Technologies), during transportation and processed within 3 hours. Fat was digested with 0.25% 
collagenase 1 (Worthington Biochemical Corp.) under agitation at 37ºC during 1h30 and the 
homogenate was centrifuged during 10 min at 300 ga using routine laboratory techniques. The stromal 
vascular fraction was collected, cells were filtered successively through a large sterile filter, a 100 and 
a 70 µm porous membrane filters, in order to remove fat. To avoid red cells, a hemolysis step was 
done briefly by adding a lysis buffer for less than 5 min. Single cells were seeded in 10 cm Nunclon 
Petri dishes (passage 0) and amplified in a 5% CO2 incubator at 37ºC. After 2-3 days, cultures were 
washed with PBS before changing the medium. After one week, cells were trypsinized (passage 1) 
and split for another amplification step. Following cell growth and checking for colony formation cells 
were trypsinized (passage 2), counted and stocked at 3 to 15 million cells per mL in freezing buffer at -
80ºC or -160ºC. ASCs were characterized by their immunophenotype (positive for CD44, CD73, 
CD90, CD105 and negative for CD34 and CD45) and their trilineage potential. 
 
2.2. ASCs pre-activation with IFN-γ  
ASCs preparation for preactivation consisted in thawing cells at 37ºC, transferring them to 
prewarmed culture medium and plated (passage 2) at 1 million cells for a 10 cm Nunclon Petri dish. 
Medium was changed every 2-3 days for 10 days. At day 9, cells had an IFN-γ pretreatment 
(100ng/mL) during 24h. ASCs were then trypsinized (passage 3), counted and centrifuged during 5 
min at 300 ga and resuspended in injection medium (vehicle) without IFN-γ (Stem Alpha 7900).  
 
2.3. Groove model of metacarpophalangeal osteoarthritis 
Ten French Standardbreds owned by Sanofi-Pasteur were included. The group consisted in seven 
geldings and three mares without clinical musculoskeletal abnormalities. Animals were divided into 
two groups: group A (n = 6), mean age 6.9 ± 1.4 year-old, mean weight 535 ± 54 kg and group B (n = 
4), mean age 5.8 ± 0.7 year-old, mean weight 522 ± 38 kg. Animals were numerically identified and 
had complete MCP joint assessment. This included digital radiographic analysis and lameness 
evaluation of both front MCP joints.  
Before surgery, animals were attributed to 5 left side and 5 right side OA-joints, the contralateral 
joint being used for the sham procedure.  An adapted groove model described in a previous pilot study 
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was used to create experimental MCP OA (Maninchedda et al., 2015) by the same ECVS surgeon. 
The dorsal aspect of the joints was assessed for the presence of pre-existing degenerative lesions. 
Four vertical and horizontal grooves were then created, in a woven pattern on the weight-bearing area 
of both condyles, with an adapted arthroscopic 2mm hook probe. Grooving was performed under gas 
(CO2) distension followed by 3 min of lavage with lactated Ringer’s solution. Post–operatively, horses 
had stall rest for 2 weeks and then were turned out into paddocks while respecting an exercise 
program that consisted of trotting in a 10-m circle on a sand surface every other day for 15 min in each 
direction during 8 weeks.   
 
2.4. Intra-articular treatment 
One week after surgery viability of cells was evaluated to be above 96% for 24 hours with a Vi Cell 
Viability Analyzer (Beckmann Coulter Inc.). Up to 5 million ASCs-γ /mL were placed into 5 mL sterile 
syringes for the injection step. Syringes were kept refrigerated at 4-6ºC and brought to room 
temperature before treatment. Animals were randomly assigned to 6 ASCs-γ and 4 vehicle injections. 
IA injection consisted of 15 million allogeneic ASCs-γ in 3 mL of the vehicle (Stem Alpha 7900) in 
group A and 3 mL of the vehicle alone in group B. Horses were sedated with detomidine (Detogesic®, 
Fort Dodge Animal) and butorphanol (Turbogesic®, Fort Dodge Animal). The OA-joint was prepared 
under aseptic conditions, treatments were administered after SF sample collection on the proximo-
palmar-lateral synovial pouch and distal limb kept under a sterile bandage for 24h.  
 
2.5. Arthroscopic evaluation 
During arthroscopy images were recorded using high-resolution digital video (AIDA, Karl Storz). 
Arthroscopic exploration videos of OA and sham operated joints were blinded and scored (0-14) for 
general synovitis (0-1), dorso-distal third metacarpal bone (MC3) chondromalacia (0-1), fissure (0-1), 
fragment (0-1), wear lines (0-3) and erosion (0-3); and dorso-proximal first phalanx (P1) fragments (0-
1) and erosion (0-3). Wear lines were scored from none (0), 1-2 partial thickness wear lines (1), 3-5 
partial thickness wear lines or 1-2 full thickness wear lines (2) and more than 5 partial-thickness or 2 
full-thickness wear lines (3).  Erosions were scored from none (0), less than 5 mm partial-thickness 
erosion (1), more than 5 mm partial-thickness erosion (2) and full-thickness erosion (3). The other 
features were scored between absence (0) or presence (1) of the lesion.  
 
2.6. Lameness evaluation  
All horses had a clinical lameness examination including distal forelimb flexion tests before OA 
induction (week 0) and at weeks 6 and 10 post-operatively. The American Association of Equine 
Practitioners (AAEP) lameness scale was used (0= normal; 1= lameness difficult to observe and not 
consistently apparent regardless of circumstances; 2= lameness difficult to observe at a walk or 
trotting a straight line but consistently apparent under certain circumstances; 3= lameness consistently 
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observable at a trot under all circumstances; 4= obvious lameness at a walk; 5= minimal weight 
bearing) (Ross, 2003) for general exam and response to distal forelimb flexion classified as negative 
or positive. Simultaneously, objective lameness examinations were performed using an inertial sensor-
based system (Lameness Locator v2014.1.0, Equinosis). Results from Lameness locator were 
reported as head movement asymmetry (A1/A2 ratio), which reflect the amplitude of the vertical head 
movement due to lameness divided by the amplitude of the expected normal vertical movement of the 
head (McCracken et al., 2012; Mannincheda et al., 2015). These values were analyzed over concrete 
surface, for trotting sequences of minimum 25 strides in straight line and minimum 10 strides after 
front distal limb flexion (Marshall et al., 2012). One ECVS surgeon performed the clinical and objective 
evaluations at week 0, 6, and 10.  
 
2.7. Radiographic Examination 
Radiographic examination of both front MCP joints was performed under intravenous (IV) 
detomidine and butorphanol sedation at week 0, 6 and 10. Five radiographic projections (Fuji CR, 
Fujifilm medical system) including lateromedial, dorsopalmar, flexed dorsopalmar, 45-degree 
dorsolateral-palmaromedial and dorsomedial-palmarolateral obliques were taken. A blinded European 
College of Veterinary Diagnostic Imaging (ECVDI) radiologist analyzed all images using a diagnostic 
workstation (eFilm 3.0, Merge Healthcare). The radiographic changes were semi-quantitatively 
graded, from no finding (0) to marked finding (2), and median total radiographic score was recorded 
for each group. A total radiographic score (0-56) encompassed synovial effusion (0-2), joint space 
width (0-2) and osteophytes (0-24), subchondral bone sclerosis (0-14) subchondral bone lysis (0-14) 
at different locations (Maninchedda et al., 2015).  
 
2.8. Synovial fluid analysis 
SF samples, collected in EDTA tubes (Venoject, Terumo), from both MCP joints were assessed for 
TP concentration using a refractometer before OA induction (week 0), before treatment (week 1) and 
after treatment at week 2, 6 and 10. Tubes were centrifuged at 4°C, 1500 rpm for 10 min (Jouan XR4i 
Centrifuge, Thermo Electron Corporation). SF supernatants were stored at -20°C until being 
transferred to -80ºC for future analysis. Inflammatory PGE2 was analyzed using commercial ELISA 
kits (R&D Systems).  
 
2.9. Postmortem Examination 
At week 10 post-surgery, all horses were submitted to euthanasia with an IV injection of 1g 
embutramide 2.5g mebezonium and 250 mg tetracaine hydrochloride (T-61®, Intervet).   
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Macroscopic evaluation  
Digital macroscopic photographs of all cartilage surfaces were performed: distal MC3, proximal P1, 
and proximal sesamoid bones (PSB). One European College Veterinary Pathologist (ECVP) blindly 
evaluated all photographs. Cartilage findings were semi-quantitatively scored similarly to macroscopic 
guidelines of the Osteoarthritis Research Society International (OARSI) (Mcllwraith et al., 2010). A 
total macroscopic score (0-21) was obtained from the total MC3 (0-9), P1 (0-6) and PSB (0-6) 
(Maninchedda et al., 2015). The synovial membrane and grooved areas were only evaluated 
microscopically.  
 
Microscopic evaluation 
The distal end of MC3, proximal end of P1 and PSB were sampled with the attached synovial 
membrane and fixed with neutral buffered formalin (Carbo Erba Reagents). After fixation, latero-
medial transverse slices 3 to 4 mm thick of the dorsal and palmar aspect of the two MC3 condyles, of 
the two P1 articular surfaces and the two PSB were performed (Figure 5). The dorsal MC3 region 
slices were centered over the grooved areas to allow assessment of microscopic changes surrounding 
the grooves. All slices were decalcified and processed on histological slides as previously described 
(Maninchedda et al., 2015). One ECVP pathologist blinded assessed the microscopic slides. Each 
finding was evaluated using modified OARSI histological features and scored from 0 (no finding) to 4 
(marked finding). Medial and lateral bone surfaces scores were averaged for any type of finding.  
 
 
Figure 5: Macroscopic view of the articular surfaces of the metacarpo-phalangeal joint, (A) is the distal aspect of 
the third metacarpal bone, (B) is the proximal aspect of the first phalanx and (C) is dorsal aspect of lateral and 
medial proximal sesamoid bones. Black arrows represent the transverse section and grey arrows represent the 
articular capsule with synovial membrane used for microscopic analysis. Rectangular areas in grey were excluded 
from examination. L = lateral and M = medial. 
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Groove and non-groove areas were analyzed separately. Grooved areas consisted of cartilage of 
the dorsal MC3 and were scored for vertical grooves (0-4) and adjacent to groove cartilage for 
features of non-calcified cartilage (0-32): chondrocyte necrosis (0-4), chondrocyte clusters (0-4), 
fibrillation/fissuring (0-4), matrix softening (0-4), horizontal cracking (0-4) and focal ulcers (0-4) and 
subjacent calcified cartilage: chondrocyte necrosis (0-4) and fissuring (0-4) (Maninchedda et al., 
2015).  
Non-grooved areas consisted of cartilage away from grooves, not only in the distal MC3, dorsal 
and palmar as previsouly described (Maninchedda et al., 2015), but also in the proximal P1 and PSB. 
The four regions were assessed concerning articular cartilage, subchondral bone (SCB) and synovial 
membrane. Articular cartilage was scored according to chondrocyte necrosis (0-4), chondrocyte 
clusters (0-4), matrix softening (0-4) and fibrosis (0-4) adjacent to superficial swelled or depressed 
areas (0-4). The adjacent features (0-16) to swelled or depressed areas made a sub-total score of 20. 
The same features were assessed adjacent to superficial (0-4) or deep fissuring (0-4) which made a 
sub-total score of 24. Together they accomplished a 0-44 range for total non-grooved cartilage score.  
SCB was scored (0-20) for fissuring (0-4), osteoblastic margination (0-4), edema (0-4), congestion 
(0-4) and subacute inflammation (0-4) (Maninchedda et al., 2015). Finally, synovial membrane was 
scored (0-20) for intimal layer thickening (0-4) and associated inflammation (0-4); perivascular 
inflammation in the sub-intimal layer (0-4) and associated fibrosis (0-4); and for synovial folds (0-4) 
(Maninchedda et al., 2015). 
 
2.10. Statistical Analysis 
Data were tested for normality and the homogeneity of variances by using the Shapiro–Wilk’s and 
the Levene’s tests, respectively. Group A and B had a different number of observations, therefore, 
comparisons with non-parametric two-way analysis of variance (ANOVA) were performed for SF (post-
hoc using winner), for lameness and radiographic data with repeated measures on week and group. 
Arthroscopic, macroscopic and microscopic data were analyzed with one-way ANOVA within groups 
and Kruskal-Wallis test between treatment groups. Not normally distributed data were represented by 
median ± median absolute deviation (MAD) and normal distribution by mean ± standard deviation 
(SD). Statistical analysis was performed using software package EverStat V6 under SAS v9.2. 
Significance level was set at P ≤ 0.05. 
 
3. Results  
 
3.1. Arthroscopic evaluation 
At week 0, arthroscopic assessment of the dorsal MCP joint revealed pre-existing lesions (Table 2). 
The most common degenerative features of the dorsal aspect of the MCP joint were wear lines on the 
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dorsal MC3 and proximal P1 erosions. OA-joints from group A had significantly higher scores when 
compared to OA-joints from group B. However, total score differences were not significant between 
OA and sham-joints, which allowed comparisions within each group. 
 
Table 2: Mean arthroscopic scores (± SD) from dorsal MCP joint at week 0. 
 
Sham-joint OA-joint 
Group A (n=6) Group B (n=4) Group A (n=6) Group B (n=4) 
Arthroscopic scores 
MC3 (0-9) 1.33 (± 1.211) 1.00 (± 1.414) 1.17 (± 0.983) 0.00 (± 0.000) 
P1 (0-4) 0.83 (± 0.753) 0.25 (± 0.500) 1.00 (± 0.632) 0.25 (± 0.500) 
Synovitis (0-1) 0.50 (± 0.548) a*  0.75 (± 0,500) a* 0.00 (± 0.000) b 0.00 (± 0.000) b 
Total (0-14) 2.66 (± 2.066) 2.00 (± 2.160) 2.17 (± 1.472) ‡ 0.25 (± 0.500) 
Group A received ASCs-γ and Group B received the vehicle injection in OA-joints. 
Different letters represent significantly different results between sham and OA-joints within groups. * P ˂ 0.05 
Significantly different results between OA joint of the two groups are represented by ‡ P ˂ 0.05 
 
3.2. Lameness evaluation 
There were two horses of group A and one horse of group B with consistently grade 2 lameness 
and positive distal limb flexion test on the sham-joint. All other horses were consistently grade 2 
lameness on the OA-joints at week 6 and decreased to grade 1 at week 10, with positive distal limb 
flexion at all observations. One horse from group A had transient flare reaction one week after starting 
exercise, which was managed conservatively by stall rest and compressive bandages during one 
week. This horse presented lameness visible at walk (grade 4) at week 6, decreased to grade 3 at 
week 10 and had increased pain after flexion test at week 6. 
Objective lameness evaluation (median A1/A2 ratios) revealed increased asymmetry in OA-joints 
at week 6, decreasing by the end of the study (Table 3). OA-joints of group A had significantly lower 
asymmetry in straight-line compared to sham-joints at week 0. Significant differences were not 
observed in OA-joints of group A compared to group B for any circumstance at any time but 
asymmetry after flexion test in OA-joints at week 6 and 10 was less important in group A when 
compared to group B. 
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Table 3: Median A1/A2 ratio (± MAD) for asymmetry of front limbs trotting at straight line and after distal limb 
flexion. 
 
Sham-joint OA-joint  
Week 0  Week 6 Week 10 Week 0    Week 6 Week 10 
Straight-line       
A (n=6) 0.7052 
a** 
(± 0.1126)  
0.2198  
(± 0.1531) 
0.5978 
(± 0.2220) 
0.2261 b 
(± 0.0665)  
0.7273  
(± 0.2263) 
0.3944  
(± 0.2255) 
B (n=4) 
0.4287  
(± 0.2304) 
0.1093 
(± 0.0555)  
0.1648  
(± 0.0558) 
0.4193  
(± 0.2862) 
0.6269  
(± 0.2032) 
0.3482  
(± 0.2770) 
Flexion-test       
A (n=6) 
0.5977  
(± 0.0833) 
0.4182  
(± 0.0689) 
0.5795  
(± 0.2990) 
0.1589  
(± 0.0573) 
0.2873  
(± 0.2401) 
0.2039  
(± 0.1988) 
B (n=4) 
0.5607  
(± 0.3901) 
0.0730  
(± 0.0626) 
0.0631  
(± 0.0365) 
0.2558  
(± 0.2558) 
0.8468  
(± 0.0516) 
0.5382  
(± 0.2558) 
Group A received ASCs-γ and Group B received the vehicle injection in OA-joints. 
Different letters represent significantly different results between sham and OA-joints within groups. ** P ˂ 0.01 
There were no significant differences between OA-joints of the two groups. 
 
3.3. Radiographic examination 
Radiographic examination revealed increased median total scores at the end of the study 
compared to the exam before OA induction, for all groups. There was pre-existing SCB sclerosis in all 
groups and pre-existing osteophytes in group A. Significantly higher total median radiographic scores 
in OA-joints compared to sham-joints of group B were observed at week 6 and at week 10. Significant 
differences were not observed in OA-joints of group A compared to group B at any time (Figure 6). 
The most common features after OA induction was synovial effusion and increased osteophytes 
formation at week 10 (Figure 7).  
 
 
 
Figure 6: Radiographic scores at week 0, 6 and 10. Median radiographic total scores (0-56) of evaluated features 
in ASCs-γ treated group (Group A, n = 6), vehicle treated group (Group B, n = 4) and respective sham-joints. 
Significantly different results between OA and sham-joints are represented by * P ˂ 0.05 and *** P ˂ 0.001. 
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Figure 7: Radiographic views at week 10, the first row (A and B) are 45-degree dorsolateral-palmaromedial 
oblique views of metacarpo-phalangeal joint from an individual of group A (ASCs-γ) and the second row (C and D) 
are from an individual of group B (vehicle). The first column (A and C) are the OA-joints and the second column 
(B and D) are the sham-joints. The arrows show osteophyte formation (grade 2) and the asterisk show the 
synovial effusion (grade 2) on the OA-joint of the individual of group B. 
 
3.4. Synovial fluid 
Mean results from TP analysis are presented (Figure 8A). There were significantly higher TP 
values in OA-joints compared to sham-joints of group B at week 1 and at week 2. Significantly higher 
values in SF of OA-joints compared to sham-joints of group A appeared one week after ASCs-γ 
treatment. There were no differences between OA-joints of group A and B. 
Mean results from PGE2 are presented (Figure 8B). There were significantly lower values in SF of 
ASCs-γ treated OA-joints (group A) compared to sham-joints at week 1 and week 10. There were no 
differences between OA-joints of group A and B. 
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Figure 8: Synovial fluid. (A) Mean (± SD) Total Proteins and (B) Mean (± SD) Prostaglandin E2 values in synovial 
fluid of the ASCs-γ treated group (Group A, n = 6) and the vehicle treated group (Group B, n = 4) compared to 
respective sham-joints (interrupted line). Significantly different results are represented by * P ˂ 0.05, ** P ˂ 0.01 
and *** P ˂ 0.001 (black asterisks: Group A; grey asterisks:  Group B). 
 
3.5. Macroscopic and microscopic evaluation 
Median results from macroscopic evaluation are shown in Table 4. There were higher but not 
significantly different total median scores in both OA-joint groups compared to respective sham-joints. 
Also, there were no significant differences in scores between OA-joints of group A and B. 
Median results from microscopic evaluation of grooved areas are also shown in Table 4. There 
were significant higher values in both OA-joint groups compared to respective sham-joints for groove 
and for adjacent to groove cartilage scores. Differences between OA-joints of group A and group B 
were not significant. However, two intra-groove mesenchymal-like cell focus in loose matrix (Figure 
9A) and one intra-groove chondrocyte-like cell focus in fibrous matrix (Figure 9B) were observed in 
OA-joints of two different ASCs-γ treated horses.  
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Table 4: Median macroscopic and microscopic scores (± MAD) at week 10. 
 Sham-joint OA-joint 
Group A (n=6) Group B (n=4) 
  
Group A (n=6) Group B (n=4) 
Macroscopic scores 
MC3 (0-9) 2.0 (± 2.0) 2.5 (± 2.5)  5.0 (± 0.0) 5.0 (± 0.5) 
P1 (0-6) 1.5 (± 0.5) 2.0 (± 1.0) 2.5 (± 0.50) 2.5 (± 0.5) 
PSB (0-6) 1.5 (± 0.5) 1.5 (± 1.5) 1.5 (± 0.50) 1.0 (± 0.5) 
Total joint (0-21) 5.0 (± 4.0) 6.0 (± 5.0) 9.0 (± 1.50) 8.0 (± 1.5) 
Microscopic scores 
Grooved areas     
Grooves (0-4) 0.0 (± 0.00) a* 0.0 (± 0.0) a* 3.0 (± 0.3) b 3.3 (± 0.3) b 
Adjacent Cartilage (0-32) 0.0 (± 0.00) a* 0.0 (± 0.0) a* 16.3 (± 1.0) b 17.5 (± 0.8) b 
Non-grooved areas 
Articular Cartilage    
DorsalMC3 (0-44) 2.0 (± 1.5) 2.3 (± 2.0) 2.0 (± 1.3) 3.0 (± 1.5) 
PalmarMC3 (0-44) 4.5 (± 2.8) 4.5 (± 4.5) 3.8 (± 2.3) 1.8 (± 1.3) 
P1(0-44) 3.0 (± 3.0) 2.3 (± 2.3) 4.3 (± 2.8) 1.8 (± 0.3) 
PSB (0-44) 3.0 (± 2.5) 5.5 (± 5.5) 4.5 (± 3.0) 0.0 (± 0.0) 
Total cartilage 
(0-176) 
12.0 (± 10.0) 15.8 (± 15.5) 19.8 (± 7.3) 9.0 (± 3.8) 
Subchondral Bone  
Dorsal MC3 (0-20) 0.0 (± 0.0) a** 0.0 (± 0.0) a* 2.3 (± 0.8) b 2.5 (± 0.5) b 
Palmar MC3 (0-20) 0.0 (± 0.0) 0.0 (± 0.0) 1.5 (± 0.5) 0.8 (± 0.5) 
P1(0-20) 0.0 (± 0.0) 0.0 (± 0.0) 0.0 (± 0.0) 0.0 (± 0.0) 
PSB (0-20) 0.0 (± 0.0) 0.80 (± 0.8) 0.0 (± 0.0) 0.0 (± 0.0) 
Total SCB (0-80) 0.3 (± 0.3) a* 1.0 (± 1.0) 4.3 (± 0.5) b 3.8 (± 2.0)  
Synovial Membrane  
Dorsal MC3 (0-20) 0.8 (± 0.3) 1.0 (± 0.5) 1.5 (± 0.5) 1.3 (± 0.8) 
Palmar MC3 (0-20) 0.5 (± 0.5) 0.0 (± 0.0) 0.3 (± 0.3) 0.5 (± 0.3) 
P1(0-20) 1.5 (± 1.0) 1.5 (± 0.5) 1.0 (± 0.5) 1.8 (± 1.0) 
PSB (0-20) 1.5 (± 1.0)  1.3 (± 1.0) 2.5 (± 0.5) 0.8 (± 0.5) 
Total synovial membrane 
(0-80) 
4.3 (± 2.0) 3.3 (± 1.3) 4.8 (± 0.8) 4.8 (± 0.5) 
Total non grooved joint 
(0-336) 
17.8 (± 12.3) 22.8 (± 18.5) 28.8 (± 10.3) 16.5 (± 3.5) 
The potential score range for each region is listed parenthetically next to each category in the first column.  
Group A received ASCs-γ and Group B received the vehicle injection in OA-joints. 
Different letters represent significantly different results between sham and OA-joints within groups. * P ˂ 0.05 and ** P ˂ 0.01. 
There were no significant differences between OA-joints of the two groups. 
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Figure 9: Light micrographs of grooved areas of the dorsal MC3 condylar cartilage (hematoxylin and eosin 
stained). (A) ASCs-γ treated horse with microscopic lesions adjacent to groove and intra-groove mesenchymal-
like cell focus found in loose matrix. (B) ASCs-γ treated horse with microscopic lesions adjacent to groove and 
intra-groove chondrocyte-like cell focus in fibrous matrix. 
 
Total median microscopic results of non-grooved areas are shown in Table 4. We have found 
significant differences between dorsal MC3 SCB scores in group A and group B and total SCB score 
in group A between OA and sham-joints. Most important features found in non-grooved cartilage of 
both OA and sham-joints were swelled/depressed areas (Figure 10A) and superficial/deep fissuring 
(Figure 10B). There was an absence of SCB edema and congestion besides absence of intimal 
inflammation and subintimal fibrosis of synovial membrane. 
 
CHAPTER III 
49 
 
 
 
Figure 10: Light micrographs of non-grooved areas of the dorsal MC3 condylar cartilage (hematoxylin and eosin 
stained). (A) Sham-joint of ASCs-γ treated horse showing a swollen (raised) area of non-calcified cartilage of the 
palmar MC3. (B) Sham-joint of ASCs-γ treated horse showing a superficial/deep fissuring in non-calcified cartilage 
of the palmar MC3. 
 
4. Discussion 
 
To the best of the authors’ knowledge this is the first study applying allogeneic ASCs pre-activated 
with INF-γ in horses. The role of IFN-γ in the immunosuppressive function of MSC has been reported 
(Krampera et al., 2006) but it was never studied in equine experimental OA. In the present study, 15 
million vehicled allogeneic ASCs-γ were injected into six MCP joints. The protocol treatment aplyed is 
according with a recent review on IA biologic therapies that describes several in vivo clinical and 
experimental studies in horses using 10-20 million cells per joint, suspended in 2 to 5 mL vehicle 
solutions (Monteiro et al., 2015). 
Evaluation of arthroscopic video records revealed pre-existing lesions in all groups, which might 
have influenced our results. Total score differences were not significant between OA and sham-joints 
of each treatment group, even if increased synovitis in sham-joints, which allowed comparison within 
groups. However, the significant higher pre-existent lesions in OA-joints from group A compared to 
group B may have attenuated a possible ASCs-γ effect. In fact, all the artroscopic scores except 
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synovitis, were higher in OA-joints of group A compared to group B. Exclusion was not considered 
before the biginning of the study because pre-evaluation of the overall status of the joint was 
performed by individual lameness and radiographic examination. In the future, magnetic resonance 
imaging or a diagnostic needle arthroscope could be used pre-operatively in order to assess both 
dorsal and palmar compartments in standing horses before OA-induction under general anesthesia 
(Frisbie et al., 2014). In the future, horses with pre-existent signs of OA should be excluded.  
At the day of treatment, one week after surgery, there was reduced inflammation in the OA-joints of 
both treated groups as showed by low TP and PGE2 values. This could be explained by the removal 
of debris with the lavage performed at the end of the surgery. Osteochondral equine OA model reports 
no flushing at the end of the surgery and so, apllying this model, TP and PGE2 are supposed to be 
significantly increased one week and until 7 weeks post-operatively, being associated with increased 
inflammation and pain (Frisbie et al., 2008). The authors have atttributed the high values of PGE2 at 
week 0, which were similar for all groups, to pre-existent lesions. However, significantly lower PGE2 
values at week 10 could support an anti-inflammatory role of ASCs-γ previously described by ter 
Huurne et al. (2012). Allogeneic source of MSCs is described to induce transient TP increase when 
compared to autologous source (Pigott et al., 2013). In the present study, there was increased TP in 
OA-joints of group A and B at week 2 compared to sham-joints but no significant differences between 
OA-joint groups were observed. This TP increase is probably due to the surgical model (Maninchedda 
et al., 2015) and the expected allogeneic effect was probably attenuated by IFN-γ pre-activation of 
ASCs by enhanced immunomodulation (Polchert et al., 2008).  
Objectively, forelimb asymmetry was more evident after 4 weeks of exercise and decreased at the 
end of the study, which was similar to the pilot study (Maninchedda et al., 2015). Maybe the 3-minute 
final lavage has removed the inflammatory debris, that are important for perpetuation of pain. In one 
study, chrondrogenic induced allogeneic stem cells preconditioned with PRP and injected intra-
articularly in horses with natural occurring OA, have shown 60% return to work compared to 45% with 
native MSCs at 6 weeks follow-up and 86% compared to 78% at 18 weeks (Broeckx et al., 2014). 
These authors reported 1.8% (3/165) flare reactions one week after treatment. Therefore, allogeneic 
treatments can induce flare reactions and IFN-γ doesn’t seem to preclude this risk, since this was also 
observed in our study. Interestingly, in spite of the flare reaction in one ASCs-γ treated joint, the 
median asymmetry value after flexion was much higher in group B compared to group A at week 6. 
Although it was not significantly different, this could reflect decreased pain in the ASCs-γ treated group 
at that time. 
Radiographic examination at week 6 and 10 revealed increased median scores in sham and OA-
joints of both groups. Interestingly, significant increased scores of OA-joints compared to sham-joints 
were present in group B but not in group A and could illustrate an ASCs-γ effect. In a caprine 
mechanical OA knee model, bone marrow tissue-derived MSCs have been described to reduce 
osteophyte remodeling compared to vehicle treated joints (Murphy et al., 2003). In a chemical OA 
carpal model, in donkeys, x-ray scores of OA were reduced several degrees after MSCs treatment 
(Mokbel et al., 2011). Considering the OA-joints, there was no significant difference between group A 
and B in the end of the study. 
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Macroscopic evaluation of the non-surgical damaged areas did not show differences between 
groups and suggest no influence or treatment effect on pre-existent or secondary cartilage lesions. 
Microscopically, there was significantly increased in lesion score, adjacent to groove lesions in OA-
joints compared to sham-joints in both groups, which reflects the effect of surgical model applied, but 
not a treatment effect. Significant higher SCB lesions found in dorsal MC3 of both groups were 
probably secondary to the surgical model and couldn’t depict a treatment effect. In the present study, 
microscopic slides were performed in a perpendicular direction to the ones performed in the previous 
pilot study (Maninchedda et al., 2015), latero-medial instead of dorso-palmar, to better detect wear 
lines. These macroscopic lesions probably correspond to “swelled and depressed areas” added to the 
microscopic classification system. The MCP groove model was chosen to be close to the natural 
disease in the horse (Maninchedda et al., 2015). However, as it presents more degenerative than 
inflammatory features, it is possible that ASCs-γ effect could be more evident in natural occurring 
disease. Horses had similar age and weight but had different sex and osteoarticular status despite no 
evident musculoskeletal abnormalities were found before including horses in the study. Moreover, the 
low number of individuals limited the statistical analysis.  
The chondrocyte-like cells found in fibrous matrix in one groove corresponded to the horse 
presenting a flare reaction and could represent an inefficient repair. On the other hand, the animal 
presenting mesenchymal-like cell focus in loose matrix, at the bottom of two grooves, could be 
interpreted as a sign of early healing. Interestingly, the latter horse didn't show OA-joint lameness at 
any evaluation, no osteophyte formation at radiographic examination and had normal TP throughout 
the study. The authors didn’t expect to find the injected cells at microscopic examination of SF, since 
systemic clearance of allogeneic cells has been reported to be around 40 days (Zangi et al., 2009). 
However, labelling injected cells would have been important in order to follow exogenous ASCs-γ in 
the joints, since whitout this we can not guarantee that mesenchymal-like cells found inside the 
grooves are from the horse itself and not remnants of the injected cells. 
In conclusion, the groove-model was validated by the vehicle treated horses (group B) results. We 
observed significantly increased TP at week 1 and 2, increased radiographic score at week 6 and 10 
as well as increased microscopic lesion score adjacent to groove microscopic score in OA-joints 
compared to sham-joints. Our hypothesis was partially confirmed by the results in group A. The IA 
allogeneic ASCs-γ treatment significantly decreased PGE2 values in OA-joints compared to sham 
joints at week 10. Moreover there were no significant differences in radiographic scores between OA-
joints and sham-joints at week 6 and 10, which suggest some OA disease-modifying effects. 
Therefore, the allogeneic ASCs-γ IA treatment is potentially interesting but should be further explored 
before being recommended for OA treatment in horses.  
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Abstract 
Cartilage degradation biomarkers are a potential tool for early diagnosis of osteoarticular disease. 
The aim of this research was to evaluate cartilage biomarkers changes in serum of a Lusitano horse 
population. Fibulin 3-2 has been reported to be higher in serum of humans with osteoarthritis (OA); in 
young horses, alpha-helical type II collagen peptide (Coll2-1) and is nitrated form (Coll2-1NO2) have 
been studied in serum and reported to be useful in the assessment of joint disease. In this study we 
have evaluated biomarkers’ changes with age, sex and exercise and studied the relationship with 
osteoarticular disease. Subjective and objective lameness evaluations as well as blood and 
radiographic examination were performed in 51 Lusitano horses. Females presented significantly 
higher concentrations of Coll2-1 (P = 0.015) and Coll2-1NO2 (P = 0.014) compared to males.  We 
have found significant influence of low level of work in higher concentration of Coll2-1 (P = 0.001) and 
significant influence of sex in concentration of Coll2-1NO2 (P = 0.030). There was no influence of sex, 
age and work on Fib3-2. All biomarkers were increased in the osteoarticular disease group (n = 35) 
compared to healthy controls (n = 16). This difference was significant for Coll2-1 (P = 0.015). When 
sorted by sex and age groups, significant difference in Coll2-1 between disease and healthy controls 
disappeared in old horses and females. In conclusion, Coll2-1 is a good marker of cartilage 
degradation in horses with osteoarticular disease, being more specific in young horses and males. 
Fib3-2 may be further explored to help identify disease in particular cases like female horses. 
 
1. Introduction 
 
OA is a debilitating disease that affects most commonly the metacarpo/tarso-phalangeal (fetlock), 
interphalangeal and intertarsal joints of old or sportive young adult horses (Baccarin et al., 2012). 
Radiological examination has a major impact on the animal’s commercial value and is useful if 
problems can be treated before horses start or continue training. However, bone radiographic changes 
are often seen in the latest stages of the disease. For early diagnosis of OA, human and veterinary 
research has been focused on an alternative tool: cartilage biomarkers analysis detection. Blood 
sample collection is better tolerated than synovial samples, and serum values have been described as 
having significant correlation with some molecules concentration in synovial fluid (SF) (Catteral et al., 
2010). This is probably due to gaps between synoviocytes, absence of a basal membrane and 
presence of subsynovial blood vessels allowing exchange of macromolecules between plasma and SF 
(Todhunter, 1996). 
Type II collagen is the most abundant protein in extra-cellular matrix from articular cartilage. Coll2-1 
is located in the collagen triple helix and Coll2-1NO2 is the nitrated form of Coll2-1, requiring oxidative 
stress to be expressed, possibly indicating the level of inflammation in the synovium (Henrotin et al., 
2004; Deberg et al. 2005). Coll2-1 fragment has been described as a valid biomarker for OA in mice 
(Ameye et al., 2007) and in human patients (Henrotin et al., 2004; Deberg et al., 2005; Deberg et al., 
2008).  
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In horses, these biomarkers were first monitored in serum of Ardenner horses with 1.25 to 2.33 
year-old (Lejeune et al., 2007). Coll2-1NO2 was significantly higher in females and in the group with 
degenerative digital osteoarthropathy. Interactions between sex, time and pathology were significant 
for Coll2-1NO2 and between time and pathology for Coll2-1. Subsequently, a mixed sex and breed 
population, with a mean age of 3.46 years-old, showing joint effusion and lameness had cartilage 
assessed by arthroscopy (Gangl et al., 2007). Coll2-1NO2 was significantly higher in the osteochondral 
lesion group, and no differences in sex and age were reported. In a different study, using warmblood 
stallions with a mean age of 2.56 years-old, Coll2-1 in serum was reported to be significantly higher in 
the degenerative joint disease group assessed by radiography (Verwilghen et al., 2009). There was a 
negative correlation between age and Coll2-1 and no correlation between age and Coll2-1NO2. More 
recently, a mixed sex and breed population with a mean age of 3.5 year-old was studied by 
arthroscopy (Verwilghen et al., 2011). There were significantly higher blood values of Coll2-1 in the 
higher degenerative class group. There were no differences in Coll2-1NO2 concentrations in serum 
between inflammatory and degenerative classes. These studies involved young horse populations and 
none evaluated the effect of exercise on the biomarkers' concentration. However, there are several 
studies in horses reporting higher concentrations of macromolecules in serum from horses submitted 
to exercise (Billinghurst et al., 2003; O’Kane et al., 2006; Frisbie et al., 2008).  
Fibulin 3, a member of a family of extracellular matrix proteins, has been described to be elevated 
in OA cartilage (Wu et al., 2007). It was lately shown that fibulin 3 fragments (Fib3-1 and Fib3-2 
peptides) were elevated in urine and serum of human OA patients and could discriminate between OA 
and normal populations (Henrotin et al., 2012). Fib3-2 in serum was not affected by the severity of the 
disease but presented the advantage of not being affected by sex or age. Therefore, this could be 
useful in detecting OA alone or in association with other biomarkers. To our knowledge, this is the first 
study reporting Fib3-2 concentrations in horses. Moreover, No data exists about osteoarticular disease 
and cartilage biomarkers’ concentration in serum of Lusitano horses.  
In the present study we evaluated differences in serum biomarkers’ concentration for sex, age and 
exercise level and tried to establish a relationship with joint disease. The first hypothesis was that all 
three serum biomarkers concentrations change with sex, age and exercise. Secondly, we expected 
that all three biomarkers would increase in horses affected by osteoarticular disease.  
 
2. Materials & Methods 
 
2.1. Examined horse population, age and exercise groups 
The studied population included Lusitano horses presented for lameness examination at three 
different veterinary clinics between July 2013 and February 2014. Owners signed an informed consent 
before horses were enrolled in the study. Owners or trainers answered a complete questionnaire and 
a total of fifty-one horses underwent a subjective and objective lameness evaluation, digital 
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radiographic examination and blood sample collection. Horses other than Lusitano or with weight 
bearing lameness were excluded from this study. 
There were 37 non-gelded males and 14 females (mean ± SEM age 10.39 ± 0.91 years, range 3-
25 years). Two different categories of age were established considering that mean age of horses 
presenting OA have been described to be 8.4 ± 3.9 year-old (Baccarin et al., 2012). Therefore, 26 
animals were included in the young horse category (less than 9 year-old) and 25 animals in the old 
horse category (9 year-old and more). Regarding exercise, there were 34 horses performing at low 
level (less than 5h per week) and 17 horses performing at high level (5h per week and more). There 
were young horses in training (n = 6), horses in competition (n = 22), field/breeding mares (n = 8) and 
stall/breeding stallions (n = 15).  
 
2.2. Lameness examination 
All animals underwent a general and orthopaedic examination. Lameness exams were always 
performed subjectively according to the American Association of Equine Practitioners (AAEP) grading 
system (Ross, 2003) and recorded by digital video. All horses had a second subjective evaluation 
through video records visualization. Furthermore, lameness was objectively assessed using an inertial 
sensor device (Lameness Locator® v2014.1.0, Equinosis). Objective reports from at least 25 strides in 
a straight-line over concrete surface were reviewed (Keegan et al., 2011; McCracken et al., 2012). 
Horses with “moderate to strong evidence” of lameness were considered positively lame for that limb.  
 
2.3. Radiographic examination and classification 
All radiographic examinations were performed according to a standardised procedure. Whenever 
needed horses were sedated, using 0.01 mg/kg detomidine IV (Domidine®, DFV) alone or combined 
with 0.02 mg/kg butorphanol IV (Dolorex®, Intervet). Radiographic evaluation was performed for all 
four distal limbs (metarcarpo/tarso-phalangeal joints; distal and proximal inter-phalangeal joints) and 
the two tarsal regions (tibio-tarsal, inter-tarsal and tarso-metatarsal joints). Four standard orthogonal  
projections were taken, including the latero-medial; dorso-palmar/plantar; dorso 45º latero-
palmar/plantar medial oblique and dorso 45º medial- palmar/plantar lateral oblique. These joints were 
chosen based on the most commonly affected OA sites in Lusitano horses (Baccarin et al., 2012) but 
in cases where clinical signs were observed elsewhere (e.g. joint remodelling, pain or effusion), 
supplementary joints were analysed. Radiographs were evaluated by 3 veterinarians and scored from 
absence (0) to severe (4) radiographic lesions (Figure 11).  
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Figure 11: Latero-medial radiographs of equine distal limb region (A, B) and tarsal region (C, D) illustrating grade 
0-normal (A, C) and grade 4-severe OA lesions (arrows) of the proximal inter-phalangeal joint (B) and distal inter-
tarsal and tarso-metatarsal joints (D). 
 
The OA scale was adapted from previously reported scales (Kellgren & Lawrence 1957; de Grauw 
et al., 2006), in order to obtain a mean grade per joint (0-4) and a mean total score per horse (0-72) 
(Table 5). 
 
Table 5: Radiographic scoring system (adapted from Kellgren and Lawrence, 1957 and de Grauw et al., 2006). 
Grade Severity of OA Description of radiographic lesions 
0 Normal Rounded joint margins, no subchondral bone sclerosis. 
1 Doubtful Pointed joint margins or minimal localised subchondral bone sclerosis. 
2 Minimal Small spur(s) on joint margins or mild localized subchondral bone 
sclerosis. 
3 Moderate Moderate spur(s) or moderate localised subchondral bone sclerosis. 
4 Severe Large spur(s), severe subchondral bone sclerosis or evidence of joint 
space narrowing. 
!1!
 
2.4. Osteoarticular disease 
The presence of OA was defined by the presence of a mean radiographic joint grade higher than 1 
associated with the presence of one objective lameness report in the same limb or with two positive 
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subjective lameness reports. Furthermore, osteochondritis dissecans (OCD) lesions were identified 
separatly, as being a source of OA but potentially leading to a more inflammatory than degenerative 
joint environment. Horses with presence of OA and OCD were included in the disease group and 
horses with absence of OA or OCD fragments were used as controls. 
 
2.5. Blood samples 
Venous blood samples were collected from the jugular veins in serum tubes (Serum-gel S-
Monovette® 4.9 mL, Sarstedt) for the Coll2-1, Coll2-1NO2 and Fib3-2 peptide measurments. Blood 
was centrifuged at 1500 rpm for 10 min at 4ºC. The serum was aliquoted and frozen at -20 ºC within 
60 min from sampling for three months and then kept at -80 ºC. Serum samples were thawed 
immediately prior to their use.  
 
2.6. Coll2-1, Coll2-1NO2 and Fib3-2 assays 
Degradation fragments derived from type II collagen and Fibulin-3 are released into horse serum 
and immunoassays can be used to measure Coll2-1, Coll2-1NO2, and Fib3-2 sequences. These 
assays are competitive immunoassays utilizing a synthetic peptide pre-coated onto the ELISA plate for 
the quantification of the corresponding antigen in serum samples. A binding competition between the 
immobilized peptide and the peptide contained in the serum samples takes place upon addition of the 
antibodies. After removal of the unbound peptide, a peroxidase-conjugated antibody is added into 
each well to detect and quantify the level of competitive binding. After washing the unbound detection 
antibody, the antibody-antigen complex is detected by a chromogenic reaction. The reaction is 
stopped and the colorimetric endpoint is determined spectrophotometrically (Verwilghen et al., 2011).  
The measurement of Fib3-2 was performed in triplicate and adapted from the F3F ELISA kit 
(Artialis SA), applying a 8-fold dilution of samples. Coll2-1 and Coll2-1NO2 were quantified in triplicate 
by competitive ELISA (Artialis SA), applying a 16-fold dilution of samples. Buffers were adapted from 
previous studies in horse blood (Verwilghen et al., 2009).  
 
2.7. Statistical analysis 
All data was analysed under SPSS commercial available software (v22). Data were represented by 
mean ± standard error of the mean (SEM) and significance was set at P ≤ 0.05. Normality of data was 
checked using Shapiro-Wilk test.  
Relationship between continuous variables was assessed using Pearson’s correlation coefficient. 
Mean values of biomarkers between groups of age, sex and exercise were compared using t-test 
procedure and disease proportions between groups were studied with Pearson Chi-square test.  
The effects of age, sex and exercise on biomarkers were measured using a Generalized Linear 
Model (GLM) procedure. Binary logistic regression models were applied to evaluate the effect of the 
biomarkers on the probability of presence/absence of osteoarticular disease and lameness and on the 
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probability of belonging to a high radiographic category. Finally, sensitivity and specificity of 
biomarkers’ concentration were analysed using the Area Under the Curve (AUC) of the Receiver 
Operating Characteristic Curve (ROC) analysis. 
 
3. Results 
 
3.1. Effects of sex, age and exercise on serum biomarkers 
Significantly higher concentrations of biomarkers were obtained in females compared to males for 
Coll2-1 (2068.61 ± 56.77 nM compared to 1861.43 ± 58.36 nM; P = 0.015) and for Coll2-1NO2 (10.51 
± 0.49 nM compared to 8.63 ± 0.41 nM; P = 0.014). Fib3-2 values were not significantly different but 
showed higher concentrations in females (605.86 ± 53.85 pM) compared to males (563.53 ± 26.05 
pM). Biomarkers presented no significant differences between the two age groups (Coll2-1 P = 
0.0881; Coll2-1NO2 P = 0.995; Fib3-2 P = 0.973). Moreover, we observed a negative, small and not 
significant correlation between age and type II collagen biomarkers, and a positive, small and not 
significant correlation for Fib3-2. There were significantly increased concentrations of biomarkers in 
horses working less than 5 hours compared to horses working more than 5 hours per week for Coll2-1 
(1993.09 ± 54.11 nM compared to 1768.71 ± 79.13 nM; P = 0.022) and for Fib3-2 (608.43 ± 32.34 pM 
compared to 508.58 ± 24.51pM; P = 0.047). There was higher percentage of females (32.35%) in the 
low-level compared to the high-level of exercise group (17.65%), this difference was not significant. 
Using the GLM procedure we observed that there was significant influence of exercise on Coll2-1 
(P = 0.001), increasing in the low level of exercise group, there was a significant influence of sex on 
Coll2-1NO2 (P = 0.030), increasing in females, and that Fib3-2 was not influenced by age, sex or 
exercise. 
 
3.2. Correlation between biomarkers 
There was significant correlation between Coll2-1 and Coll2-1NO2 (r = 0.650; P = 0.000) and 
between Coll2-1 and Fib3-2 (r = 0.329; P = 0.018). Coll2-1NO2 and Fib3-2 were not correlated (r= 
0.006; P = 0.966). 
 
3.3. Relationship between Coll2-1, Coll2-1NO2 and Fib3-2 and clinical findings 
 
Lameness and radiographic examination 
Considering subjective grades of lameness and the presence of lameness assessed objectively, 
there were no significant differences between biomarkers concentrations (Table 6). However, there 
was a significantly higher percentage of OA horses in the objectively lame group (P < 0.001). Binary 
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logistic regression (backward stepwise method) was used to study the probability of being objectively 
lame (r2 = 0.256 with P = 0.938 at the Hosmer-Lemeshow test). The log-odd probability of belonging to 
the positive objective lameness group compared to the negative lameness group increased by 1.238 
per year of age (P = 0.027). 
 
Table 6: Distribution of objective lameness, disease and mean (± SEM) serum biomarkers’ values n=51.  
! 1!
 
 OA % OA + 
OCD% 
OCD % Without 
disease 
Coll2-1 (nM) Coll2-1NO2 
(nM) 
Fib3-2 (pM) 
Sound  
(n=11) 
0.00a 
(0/11) 
0.00 
(0/11) 
9.09 
(1/11) 
90.91 
(10/11) 
1845.39 ± 
83.91 
8.72 ±  
0.64 
553.12 ± 
34.08 
Lame  
(n=40) 
60.00b *** 
(32/40) 
20.00 
(8/40) 
5.00 
(2/40) 
15.00 
(6/40) 
1938.35 ± 
54.95 
9.27 ±  
0.41 
581.20 ± 
29.03 
Different letters represent significantly different results between lame and sound groups. *** P < 0.001 
 
There was a positive correlation between total radiographic score per horse among the 3 
evaluators (P = 0.001). Total mean radiographic scores had positive, small and not significant 
correlation with the 3 biomarkers. However, there was a significant influence of more advanced age on 
the increased radiographic score (GLM procedure; P = 0.003). Moreover, binary logistic regression 
(backward stepwise method) was used to study the probability of having radiographic score above 14 
(r2 = 0.223 with P = 0.832 at the Hosmer-Lemeshow test). The log-odd probability of belonging to the 
higher radiographic class increased by 1.002 for each increased unit of Coll2-1 (P = 0.040) and by 
1.125 per year of age (P = 0.025) 
 
Osteoarticular disease 
Older horses had higher percentage of OA (84.00%) compared to young horses (42.30%) and this 
was significantly different (P = 0.002). There was higher percentage of OA (69.70%) in lower exercise 
category compared to horses working more than 5h per week (47.05%) but this difference was not 
significant (P = 0.101). Considering only males, there was significantly more OA within the lower  
compared to higher exercise class (P = 0.010). 
Biomarkers’ concentrations in different groups of age, sex and exercise sorted by presence or 
absence of disease are presented in Tables 7-9.  
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Table 7: Distribution of age classes and mean (± SEM) serum biomarkers’ values for horses with or without 
osteoarticular disease n = 51. 
 
Table 8: Distribution of sex classes and mean (± SEM) serum biomarkers’ values for horses with or without 
osteoarticular disease n = 51. 
 
Table 9: Distribution of exercise classes and mean (± SEM) serum biomarkers’ values for horses with or without 
osteoarticular disease n = 51. 
 
Coll2-1 biomarker values were significantly higher (P = 0.015) in horses with joint disease (OA or 
OCD) compared to control healthy horses (Table 10).  
 
Table 10: Distribution of osteoarticular disease and mean (± SEM) serum biomarkers’ values n = 51. 
 
 
! 1!
Disease    Controls    
 Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM)  Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM) 
Young (n = 14) 2049.22 ± 81.79a 9.80 ± 0.69 625.87 ± 71.78 Young (n = 12) 1750.47 ± 95.52b * 8.40 ± 0.55 517.69 ± 31.29 
Old (n = 21) 1956.79 ± 74.35 9.29 ± 0.61 574.83 ± 25.74 Old (n = 4) 1761.53 ± 94.75 8.38 ± 0.10 571.69 ± 49.13 
Different letters represent significantly different results between disease and control groups. * P < 0.05 1!
! 1!
Disease    Controls    
 Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM)  Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM) 
Male (n = 25) 1964.93 ± 71.22a ** 8.98 ± 0.56 578.96 ± 34.63 Male (n = 12) 1645.79 ± 71.10
b 
7.89 ± 0.46 531.38 ± 35.44 
Female (n = 10) 2075.55 ± 87.13 10.76 ± 0.58 635.95 ± 74.16  Female (n  = 4) 2065.84 ± 74.18
a **  9.89 ± 0.99 530.62 ± 9.40 
Different letters represent significantly different results between disease and control groups and between female and male groups. ** P < 0.01 1!
Disease    Controls    
 Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM)  Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM) 
Low level (n = 26) 2028.41  ± 64.08 9.61  ± 0.49 627.93  ± 41.00 Low level (n = 8) 1878.31 ± 92.43 8.72  ± 0.77 545.04  ± 26.18 
High level (n = 9) 1893.66  ± 106.77 9.14  ± 1.08 500.80  ± 22.63 High level (n = 8) 1628.15  ± 102.09 8.07  ± 0.56 517.33  ± 47.33 
!
! 1!
 OA% OA + OCD% OCD% Coll2-1 (nM) Coll2-1NO2 (nM) Fib3-2 (pM) 
Controls 
(n = 16) 
0 a 0 a 0  1753.23 ± 73.95 a 8.39 ± 0.47 531.19 ± 26.37 
Disease  
(n = 35) 
68.57 b ***  
(24/35) 
22.86 b * 
(8/35) 
08.57  
(3/35) 
1993.76 ± 55.09 b * 9.49 ± 2.67 595.24 ± 32.25 
Different letters represent significantly different results between disease and control groups. * P < 0.05 and *** P < 0.001. 1!
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Moreover, binary logistic regression (backward stepwise method) was used to study the probability 
of having osteoarticular disease (r2 = 0.169 with P = 0.677 at the Hosmer-Lemeshow test). The log-
odd probability of belonging to the osteoarticular disease group increased by 1.002 for each increased 
unit of Coll2-1 (P = 0.022). Using the area under the ROC curve analysis, the specificity and sensitivity 
of the 3 biomarkers were tested for osteoarticular disease. The AUC of Coll2-1 was 0.716 (95% 
confidence interval (CI): 0.570-0.862; p= 0.014). The optimal cut-off was determined as the value 
corresponding to the greatest sum of sensitivity and specificity of the test for discriminating disease 
from healthy subjects. At a cut-off point of 1859.73 nM the sensitivity was 71.4% and specificity was 
62.5%. Considering males alone, for the same cut-off point was achieved but obtained 68.0% of 
sensitivity and 83.3% of specificity. 
Considering horses with OA separately, there was higher Coll2-1 (P = 0.068) in positive OA 
(1951.61 ± 70.49 nM; n = 24) compared to negative OA horses (1753.23 ± 73.95 nM; n = 16) being 
significantly different if considering male horses alone (P = 0.025). There was no difference on OCD 
distribution between age, sex and exercise groups. Horses with OCD had significantly increased mean 
values of Coll2-1 (P = 0.007) compared to control horses (2085.73 ± 81.60 nM; n = 11 compared to 
1753.23 ± 73.95 nM; n = 16). Also, Fib3-2 presented higher values in horses with OCD (655.11 ± 
67.61 nM) compared to control horses (531.19 ± 26.37; P = 0.065).  
 
4. Discussion 
 
The Lusitano horse population presented in this study included different sex, level of work and a 
large age-range in order to study the influence of these factors on cartilage degradation biomarkers’ 
concentration allowing confirmation of the relationship with the presence of osteoarticular disease. The 
authors adapted a simple radiographic scale per joint, based on bone sclerosis, osteophyte and new 
bone formation (de Grauw et al., 2006). The distal limb and tarsal regions were chosen based on 
previous studies reporting these as the most frequent affected joints in horses (Baccarin et al., 2012). 
To our knowledge this is the first time radiographic findings were associated with an objective inertial 
sensor evaluation of lameness besides the classic subjective evaluation in a biomarkers investigation 
in horses. 
Orthopaedic examination revealed a high prevalence of horses presenting OA lesions (62.74%), 
which is higher than the 31.75% previously reported by Verwilghen et al. (2009) and probably due to 
the advanced mean age of the studied horses. There were 21.57% of horses presenting OCD lesions, 
which is lower than the 36.51% in the young horse population described by Verlwilghen et al. 2009. In 
accordance to clinical signs of joint disease in horses (Cantley et al., 1999), 80% of lame horses had 
OA and 25% of lame horses had OCD.  
Globally, we have found significantly higher concentrations of Coll2-1 and Coll2-1NO2 in females 
compared to males. In particular, Coll2-1 was significantly higher in healthy females compared to 
healthy males, whereas the difference between the disease groups being only significant in males. 
Although the number of healthy females was very small, this finding is in disagreement with previously 
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reported studies in horses from Lejeune et al. (2007) and humans from Deberg et al. (2005), both 
authors describing no influence of sex for this specific biomarker. We could hypothesised that the 
healthy group of females had osteoarticular problems elsewhere. Using a nuclear scintigraphy would 
be interesting to better differentiate disease from healthy control horses. However, radiographic exam 
was performed in the most frequent affected joints and the lame limb was objectively identified through 
an inertial sensor device.  
Not surprisingly, age was the most important factor influencing higher radiographic scores and the 
presence of OA. We have found a negative correlation of age with Coll2-1 that was much lower (r = - 
0.053) compared to the previously reported (r = - 0.38) by Verwilghen et al. (2009). Interestingly, the 
difference between the disease groups was only significant for horses less than 9 years-old and could 
be explained by most of the cartilage breakdown have been completed in chronic stages (Gangl et al., 
2007).   
Exercise alone has been reported to significantly increase collagen metabolism biomarkers in 
serum (Billinghurst et al., 2003). O’Kane et al. (2006) also found increased levels of cartilage 
degradation biomarkers (C2C – carboxy-terminal telopeptide of Type II collagen and CTXII – carboxy-
terminal cross-linked telopeptide fragment of type-II collagen) in serum of heavily exercised versus 
non-exercised horses. Surprisingly, exercise had a negative and significant influence in Coll2-1 in the 
present study. Higher number of females and horses presenting OA at the low-level of exercise could 
explain higher concentrations of Coll2-1 in this group. 
Similarly to Verwilghen et al. (2009) Coll2-1 biomarker value was significantly elevated in horses 
with osteoarticular disease compared to control horses. There were only eight horses presenting OCD 
associated to OA and only 3 had OCD alone. In these eleven horses, Coll2-1 was significantly higher 
compared to healthy controls. This agrees with the significantly higher values in blood described by 
Verwilghen et al. (2011) in higher degenerative classes of horses with OCD evaluated by arthroscopy. 
Horses presenting OA alone had higher concentrations of Coll2-1 but this was only significant 
considering males.  
Coll2-1NO2 was significantly higher in females supporting the results of Lejeune et al. (2007) and 
this could be explained by estradiol pro-oxidant action on neutrophil degranulation (Chiang et al., 
2004). However, difference between OA negative and positive groups was not significant, which 
differs from the same author results. Coll2-1NO2 was higher in horses presenting OCD, which is 
similar to Gangl et al. (2007) results.  Significance might not have been reached because the small 
sample size of horses with OCD fragments (n = 11). 
Fib3-2 peptide was higher but not significantly different in horses presenting osteoarticular disease, 
horses with OCD presenting the highest values. Although less significantly than Coll2-1, there was 
higher Fib3-2 in the low-level of exercise group but significance disappeared when sorting horses by 
disease. This biomarker presented no significant differences between sex and age groups, which 
agrees with Henrotin et al. (2012) that describes no influence of sex in this biomarker even though 
oestrogens up regulate Fibulin-3 expression (Chiang et al., 2004). These findings, together with 
significant correlation between Coll2-1 and Fib3-2 concentrations could justify Fib3-2 use to better 
identify disease in particular cases like in female horses.   
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The first hypothesis was partially validated. Coll2-1 and Coll2-1NO2 concentrations were 
significantly increased in females. Coll2-1 concentrations were significantly correlated with exercise, 
being significantly increased in the low-level group. There was a tendency for collagen type II 
biomarkers to decrease with age. Fib3-2 was not different between sex and age but also had a 
tendency to increase with low-level of exercise. Finally, we have confirmed the second hypothesis. 
The 3 biomarkers were increased in the osteoarticular disease group. Only Coll2-1 was significantly 
higher in horses presenting disease, maybe because horses presented a more degenerative than 
inflammatory process, being more specific in young horses and males. No effect of combined 
biomarkers was found to predict disease. However, in females presenting higher values of collagen 
type II biomarkers, disease could be identified by an associated increase in Fib3-2 and should be 
further explored. 
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Abstract 
The aim of the present study was to compare subjective and objective evaluation after flexion test 
of distal limb and correlate these responses to the presence of different grades of radiographic lesions 
in Lusitano horses. Fifty-one Lusitano horses were assessed for distal limb flexion test response 
(positive or negative) and had radiographic evaluation of the 4 distal limbs. Objective evaluation was 
performed using an inertial sensor device. Forelimbs were objectively assessed for total asymmetry of 
the head change (ΔVS). Hind limbs were assessed for change in pelvic maximum movement 
difference (ΔPDmax) and change in pelvic minimum movement difference (ΔPDmin) between left and 
right proportions of the stride, before and after flexion. Regarding straight-line lameness there was a 
moderate agreement between subjective and objective classification (κ = 0.49). Despite low 
agreement in flexion response, positive correlation was observed between subjective and objective 
evaluation in hind limbs flexion for ΔPDmax (P = 0.017). Also for hind limbs, there was a significant 
correlation between radiographic scores of the metacarpo-phalangeal (fetlock) joint and subjective 
response to flexion (P = 0.048). Objective (ΔPDmin) evaluation correlated to fetlock joint (P = 0.004) 
and mean distal limb radiographic score (P = 0.012). In conclusion, positive response to distal hind 
limb flexion test is significantly correlated to fetlock joint lesions and asymmetry is better detected 
objectively and as an impact lameness.  
 
1. Introduction 
 
Lameness examination including flexion test and radiographic examination has become an integral 
part of the locomotor and pre-purchase evaluation of the horse. Flexion tests are performed to 
exacerbate the baseline lameness and identify the source of pain, and can be performed in specific 
regions of one or all four limbs. Most veterinarians perform flexion tests, but they are time consuming 
and usually subjectively assessed. In a study comparing flexion test response and radiographic 
findings, using fifty non-lame horses, it was found that response to distal flexion of forelimbs did not 
correlate with the presence of distal limb radiographic abnormalities (Ramey, 1997).  
In the last decades the validity of subjective lameness evaluations have been studied (Keegan et 
al., 1998). Agreement between different observers for identification of mild lameness and detection of 
the most lame limb is generally low, and therefore it is not reccomended to have more than one 
experienced observer during clinical trial or when comparing to other lameness evaluation methods 
(Keegan et al., 2010). Evaluation of proximal hind limb flexion test was also reported by Armentrout et 
al. (2012) to have great variability between practitioners. Wireless, inertial sensor-based systems have 
been described as an objective method of continuous lameness quantification that could be used in 
the field (Keegan et al., 2004). Repeatability was confirmed (Keegan et al., 2011), compared to a 
stationary force plate (Keegan et al., 2012) and sensitivity when compared to subjective evaluations 
(McCracken et al., 2012). In the latter study the inertial sensors detected lameness in the straight line 
sooner than the consensus of 3 experienced evaluators, regardless of the induced foot pain was 
located on  fore/hind limb. Furthermore, inertial sensor devices have been evaluated for proximal hind 
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limb response to flexion (Marshall et al., 2012; Starke et al., 2012). Using the same device of the 
present study, it was found that observers’ positive response to flexion was associated with significant 
changes in maximum pelvic height differences between the right and left hind limbs (PDmax) resulting 
from pushing off less (Marshall et al., 2012). However, this response was never studied for distal limb 
flexion in forelimbs and hind limbs. 
Osteoarticular problems like osteoarthritis (OA) are frequently the cause of lameness. Flexion tests 
are expected to help localise the affected region (Kidd, 2001) and the fetlock joint is the most common 
source of pain in equine distal limb (Cantley et al., 1999). Although there is poor correlation between 
the presence of radiographic changes and clinical signs of OA, radiography is the most used method 
of diagnosis (Widmer & Blevins, 1994) because it is non-invasive, portable and cost effective. 
The aims of the present study were: 1) to measure agreement between subjective and objective 
evaluations, 2) to determine the association between objective and subjective response to flexion, and 
3) to determine the association between distal limb flexion test response with presence of 
osteoarticular abnormalities, both in fore and hindlimbs. We hypothesised that there would be a 
significantly stronger positive association between the presence of radiographic signs of OA with 
objective evaluation than with subjective evaluation of a positive response to flexion.   
 
2. Materials & Methods 
 
2.1. Sample population 
The studied population included Lusitano horses presented for lameness examination at three 
different veterinary clinics between July 2013 and February 2014. Owners signed an informed consent 
before horses were renrolled in the study and a total of fifty-one horses underwent subjective and 
objective lameness evaluation and digital radiographic examination. There were 37 non-gelded males 
and 14 females (mean ± SEM age 10.39 ± 0.91 years, range 3-25 years). Horses other than Lusitano 
or with weight bearing lameness were excluded from this study.  
 
2.2. Lameness examination 
All animals underwent a general and orthopaedic examination (Ross, 2003), which was recorded at 
the same time by digital video. Horses were trotted away and towards the camera, two times, on a 
concrete surface (straight line). Before flexion-tests, the horse was trotted towards the camera for the 
forelimbs and away from the camera for the hind limbs, one time, on a concrete surface. Flexion test 
of the distal limb was then performed during 60 seconds and after flexion the horse was trotted again. 
The foot was supported in the air by the toe without pressure applied to the back of the fetlock joint or 
the tendinous structures and with minimum flexion of the proximal region (Ramey, 1997). The same 
sequence was always used: left and right forelimb followed by left and right hind limb flexion. A single 
observer subjectively and blindly evaluated all video records, including straight line, before flexion and 
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after distal limb flexion. This was performed through visualization video records (with sound) at normal 
speed and at slow motion. Response was given for all limbs during straight line (lame or not lame) and 
for the flexed limb (positive or negative).  
Simultaneously, lameness was objectively assessed using an inertial sensor device (Lameness 
locator® v2014.1.0, Equinosis) as previously described in other studies (Keegan et al., 2011; Marshall 
et al., 2012; McCracken et al., 2012; Rettig et al., 2015). Briefly, horses were instrumented with 3 
inertial sensors: one uni-axial accelerometer between the ears attached to a head bumper, a second 
uni-axial accelerometer placed between the tubera sacrale on the midline of the most dorsal aspect of 
the pelvis with tape, and a third uni-axial gyroscope wrapped to the dorsal aspect of the right forelimb 
pastern. Data were obtained wirelessly from the inertial sensors for at least 25 strides in straight line 
and for at least 10 strides before flexion and after distal limb flexion over concrete surface. The same 
person handled the horse before and after flexion and the same person flexed both forelimbs and both 
hind limbs.  
 
2.3. Objective lameness measures 
The body-mounted inertial sensors provided objective measure of forelimb and hind limb lameness 
by measuring head and pelvic vertical movement asymmetry. There were 2 situations where at least 
moderate evidence of asymmetry is reported. 1) when the lameness measure is above threshold and 
the standard deviation of the lameness measure over all analyzed strides is < 1.2 times the absolute 
value of the mean over all strides, and 2) when the standard deviation of the lameness measure over 
all analyzed strides is < 0.5 times the absolute value of the mean of over all strides. 
Vertical head movement asymmetry is reported as the vector sum (VS) of maximum (Hmax) and 
minimum (Hmin) head height difference in millimetres (mm) between the right and left components of 
each forelimb stride. Lameness side is determined by: sign of Hmin, with positive values indicating 
right forelimb lameness and negative values indicating left forelimb lameness (Marshall et al., 2012; 
Rettig et al., 2015). In the present study, VS change (ΔVS) before and after flexion was used to 
determine positive (more asymmetry) or negative (less asymmetry) response to forelimb flexion, 
considering that Hmax and Hmin are conceptually related.  
Vertical pelvic movement asymmetry is reported as the maximum (Pmax) and minimum (Pmin) 
pelvis height difference in millimetres (mm) between right and left halves of the stride. Pmin is 
associated with decreased downward movement (impact lameness) in the first half of the stance and 
Pmax associated with decreased upward movement (push-off lameness) during the second half of the 
stance. Positive values of Pmax and Pmin indicate asymmetric pelvic movement due to right hindlimb 
lameness and negative values indicate asymmetric pelvic movement due to left hindlimb lameness. 
Pmax and Pmin are conceptually un-related and therefore separately evaluated as dependent 
variables for hindlimb lameness. For positive and negative response to flexion, left sided pelvic 
asymmetry values were first standardised my multiplying by -1 to convert to right-sided values 
(Marshal et al., 2012; Rettig et al., 2015). In the present study, before and after flexion change for 
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Pmax difference (ΔPDmax) and Pmin difference (ΔPDmin) was used to determine positive (more 
asymmetry) or negative (less asymmetry) response for each component.  
 
2.4. Radiographic examination and classification 
All radiographic examinations were performed following a standardised procedure. Whenever 
needed, horses were sedated, using 0.01 mg/kg IV of detomidine (Domidine®, DFV) alone or 
combined with 0.02 mg/kg IV of butorphanol (Dolorex®, Intervet). Radiographic evaluation was 
performed in the four distal limbs (metarcarpo/tarso-phalangeal joints; distal and proximal inter-
phalangeal joints). Four classical projections were taken, including the latero-medial; dorso-
palmar/plantar; dorso 45º latero-palmar/plantar medial oblique and dorso 45º medio-palmar/plantar 
lateral oblique. Radiographs were evaluated by 3 veterinarians using a digital software system 
(Examion® CR-360 system) and scored from absence (0) to severe (4) OA lesions. The OA scale was 
adapted from previously reported scale (de Grauw et al., 2006), in order to obtain a mean grade per 
joint (0-4) and mean distal limb score per horse (0-12).  
 
2.5. Statistical Analysis 
All statistical analyses were performed using commercially available software (SPSS® v22, IBM 
corporation).  Significance was set at P ≤ 0.05. Normality of data was checked using Shapiro-Wilk’s 
test. Agreement was estimated by calculation of κ (kappa) between subjective and objective 
evaluations performed for straight line (lame or not lame) and response to flexion (positive or 
negative). In the present study, agreement (κ) was considered to be poor if less than 0.2; fair if 
between 0.21 and 0.4; moderate if between 0.41 and 0.6; good if between 0.61 and 0.8 and very good 
if between 0.81 and 1 (Altman, 1991).  Spearman test was used to correlate objective variables (ΔVS, 
ΔPmax and ΔPmin) and radiographic scores with response to flexion. Differences between groups 
were analysed using Mann-Whitney rank sum test.  
 
3. Results 
 
A total of 51 horses were assessed for lameness on a straight line. A total of 102 distal limb flexion 
tests were performed on 51 left and 51 right forelimbs. One young horse did not allow the hind limb 
distal flexion; therefore, 100 distal hind limb flexion tests were performed on 50 left and 50 right limbs. 
Objective parameters (ΔVS, ΔPmax and ΔPmin) and radiographic scores were not normally distributed 
among different flexion responses, therefore non-parametric tests were used. Data are represented by 
median and interquartile range (IQR). 
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3.1. Relationship between subjective and objective evaluations  
Regarding straight-line lameness (n = 204), 82.53% of subjectively classified lame limbs agreed 
with objective classification, whereas 66.19% of subjectively classified non-lame agreed with objective 
classification (κ = 0.49 – moderate agreement, CI: 0.37-0.61). There was low agreement between 
subjective response to flexion and objective results for ΔVS (κ = 0.011) ΔDPmax (κ = 0.132) and 
ΔDPmin (κ = 0.116). 
There were lower ΔVS for subjective negative (n =74, median 2.2, IQR -1.93, 8.77) compared to 
subjective positive (n = 28, median 2.7, IQR -2.22, 9.37) response to flexion but this was not 
significantly different (P = 0.970). 
Spearman correlation test between objective parameters and subjective response to flexion 
(negative or positive) was significant for ΔPDmax (P = 0.017). There was a significant difference (P = 
0.018) of ΔPDmax values between negative response (n = 54, median 0.79, IQR -0.83, 3.51) and 
positive response (n = 46, median 2.74, IQR 0.66, 6.19). Using the area under the ROC curve 
analysis, the specificity and sensitivity of ΔPDmax was tested for negative or positive response to 
flexion. The AUC was 0.638 (95% confidence interval (CI): 0.528-0.747; P = 0.018). The optimal cut-
off was determined as the value corresponding to the greatest sum of sensitivity and specificity of the 
test. At a cut-off point of 1.0415 of ΔPDmax the sensitivity was 71.0% and the specificity was 58.4%.  
 
3.2. Correlation between flexion response and radiographic scores 
Spearman correlation test between radiographic scores and the forelimb response to flexion was 
not significant. Regarding the hind limbs, Spearman correlation test between radiographic scores and 
subjective response to flexion was positive and significant for fetlock joint (P = 0.048) but not for the 
distal mean radiographic score (P = 0.077). Correlation between radiographic scores and ΔPDmin 
response to flexion was significant for fetlock joint (P = 0.004) and distal mean radiographic score  (P 
= 0.012).  
 
3.3. Forelimb radiographic scores and responses to flexion 
In what concerns the forelimbs there were no differences between the mean of the three 
evaluators’ radiographic scores for horses classified with a negative distal flexion test (n= 74, median 
score 2.5, IQR 1.7, 4.0) or a positive distal flexion test (n = 28, median score 2.5, IQR 1.5, 4.2) (Figure 
12A, P = 0.799).  
Concerning objective evaluation of flexion tests in the forelimbs, radiographic scores of distal limb 
of horses categorised as presenting a negative flexion test (ΔVS negative; n= 34, median score 2.2, 
IQR 1.7, 4.1) were not significantly different from horses with a positive flexion test (ΔVS positive= 68, 
median score 2.6, IQR 1.6, 3.9) (Figure 12B, P = 0.616). Radiographic scores were not significantly 
different (P = 0.258) in fetlock joints between horses with negative (n = 34, median score 1.3 , IQR 
0.7, 2.0) and positive response to flexion (n = 68, median score 1.0, IQR 0.7, 1.7).  
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Figure 12: Box plot of distal limb radiographic mean score for positive and negative flexion tests assessed (A) 
subjectively and (B) objectively, head asymmetry change (ΔVS). There is no significant difference in radiographic 
scores for positive and negative subjective or objective flexion-test. 
 
3.4. Hind limb radiographic scores and responses to flexion 
Concerning subjective evaluation of the hind limbs, mean radiographic scores of the distal limb 
between horses classified with a negative flexion (n = 54, median score 1.9, IQR 1.0, 3.0) were not 
significantly lower when compared to a positive flexion test (n= 46, median score 2.6, IQR 1.3, 3.7) 
(Figure 13A, P = 0.077). However, when comparing mean radiographic scores of fetlock joints the 
differences were significant (P = 0.048) between horses with a negative flexion test (n = 54, median 
score 0.7, IQR 0.3, 1,0) and a positive response (n = 46, median score 0.85, IQR 0.3, 1.7). 
Distal limb radiographic scores in the hind limbs showed no significant differences between horses 
with an objective negative (ΔPDmax, n= 27, median score 2.2, IQR 1.15, 2.95) or positive (ΔPDmax 
positive, n = 73, median score 2.3, IQR 1.0, 3.7) flexion test (Figure 13B, P = 0.484). However, when 
using the objective parameter defined as ΔPDmin, significant differences were observed in horses with 
a negative flexion test (n = 39, median score 1.7, IQR 1.0, 2,8) and a positive flexion test (n = 61, 
median score 2.4, IQR 1.6, 4.1) concerning radiographic score of distal limb (Figure 13C, P = 0.013). 
These differences concerning radiographic scores of the distal limb were associated to significantly 
different (P = 0.005) fetlock radiographic scores between horses with negative (n = 39, median score 
0.3, IQR 0.3, 1.0) and positive response to flexion (n = 61, median score 0.7, IQR 0.3, 1.7). 
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Figure 13: Box plot of distal limb radiographic mean score for positive and negative flexion tests assessed A: 
subjectively and objectively for B: maximum pelvic height change (ΔPDMax) and for C: minimum pelvic height 
change (ΔPDMin). There was significant difference in radiographic scores between negative and positive 
response for ΔPDmin (* P = 0.013). 
 
4. Discussion 
 
In this study the authors have focused on the agreement between subjective and objective 
evaluation of lameness and flexion test response and their relation with severity of distal limb 
radiographic lesions. First, subjective and objective agreement was assessed and objective 
parameters correlated with the subjective response. Secondly, a response to flexion-test was 
compared to distal limb radiographic scores. It has been described that distal limb flexion of 30 
seconds does not always reveal a positive response; while flexion of 2 min could yield a false positive 
result, optimal duration being between 60 and 90 seconds (Keg et al., 1997). We have decided to 
perform distal limb flexion for 60 seconds because it is our routine and in order to allow the 
comparison with previous studies (Ramey, 1997, Marshall et al., 2012). Several aspects have not 
been addressed in this study, such as the exact source of pain, force of flexion and the probability of a 
specific limb being called positive.  
Previous reports have described an agreement of 76.6% between subjective evaluations (lame or 
not lame limb) in straight line (κ = 0.44) (Keegan et al., 2010). Similarly, in the present study, 82.5% 
agreement was achieved for the lame limb between the video observations in straight line and the 
machine (κ = 0.49). Maybe this was due to the repeated visualisations (with sound) and the use of 
slow motion mode. Subjective and objective response to flexion had poor agreement as depicted by 
low κ values. The agreement values are arbitrary but useful as long as limitations are take into 
consideration. There should be statistical independence of observations and low trait prevalence. 
Because the orthopaedic and objective exams were performed simultaneously, the subjective 
classification of lameness was completed through blinded film observation to guarantee 
independence. Besides, there were horses from different ages and not all the animals were presented 
with a pain related problem, reducing lameness prevalence (trait prevalence). 
We have first compared subjective response to flexion to objective parameters. There was less 
head asymmetry change for subjective negative response compared to positive response to flexion 
but these differences were not significant. This could be explained by the fact that on subjective 
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evaluation, observers classified the flexion as negative, despite increased assymetry within the first 
steps, which led to increased objective measurements. Moreover, the authors suspect this could be 
justified by contralateral lameness, which was taken into account by VS but not in the subjective 
evaluation. In the future, a distinction between flexed or contralateral limb positive responses should 
be performed for a better analysis of the origin of the pain in the forelimbs. 
Regarding pelvic asymmetry, an increase in PDmin difference in response to flexion-test would 
indicate a decrease in the fall of the pelvis during the stance phase of the flexed limb (impact 
lameness) and it is surprising that this was not significantly different between negative and positive 
subjective response. However, the positive subjective response presented significantly increase in 
PDmax difference. This response to flexion-test would indicate a decrease in the pelvis elevation 
during the swing phase (propulsion) of the flexed limb (push-off lameness). Similar results have been 
found previously for proximal hind limb flexion subjective response assessed by the same inertial 
sensor device in 17 healthy horses (Marshall et al., 2012). These authors suggested that the 
decreased push-off could be observed as an increase in ‘hip drop’. In fact, hind limb lameness causes 
a slight different vertical movement of the pelvis between left and right hind limb strides and a big 
different vertical movement of the left and right tubera coxae, the pelvis moving less up during and 
after the last half of stance of the lame limb (Keegan, 2007) and would correspond to the  ‘hip drop’. 
Tubera coxae increased amplitude has been recently measured during hind limb lameness evaluation 
(Starke et al., 2015). Our findings show that after a positive flexion-test the observer depicted lower 
elevation of the pelvis (hip drop) during propulsion of the lame limb. Considering this, we have 
determined whether PDmax would be useful to differentiate negative from positive flexion test. Using a 
1.0415 change of ΔPDmax the sensitivity was 71.0% and the specificity was 58.4%. In this study there 
was a lower difference of maximum pelvic height for the same sensitivity of a positive response when 
compared to the previous report on proximal limb flexion (Marshall et al., 2012).  
In our study there was no significant difference in radiographic scores between horses with 
negative and positive response to fore limb distal flexion. This agrees with a previous report (Ramey et 
al., 1997) that found that normal horses responding positively to forelimb distal flexion-test had 50:50 
chance of having a radiographic abnormality. However, inertial sensor device were associated to 
lower radiographic scores for negative response and higher radiographic scores for positive response, 
compared to subjective evaluations. This confirms the utility of the inertial sensor device and suggests 
higher sensibility to detect asymmetry due to radiographic changes. Regarding the hind limbs, there is 
significant higher radiographic scores in presence of decreased pelvic downward movement 
(ΔPDmin), which was mainly due to fetlock changes. This is an interesting finding and confirms 
assumed osteoarticular problems in association with impact lameness. 
In conclusion, agreement between subjective and objective evaluation was moderate for straight-
line but low for flexion-test response. This justifies the interest on novel technology for objective 
assessment of flexion response. Hind limb subjective positive response to flexion-test resulted from 
significantly less upward movement of the pelvis (push-off lameness). Subjective response to a distal 
flexion test can be negative in presence of radiographic changes and positive in the absence of 
lesions. However, objective evaluation was more likely to detect radiographic osteoarticular lesions. 
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Increased change on minimum pelvic height (impact lameness) was highly correlated to fetlock joint 
abnormalities. These findings support the inertial sensor system in distal limb flexion-test response 
evaluation. Objective response in the forelimbs should be further explored to better distinguish a 
negative from a positive response. 
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Abstract 
The aim of this study was to objectively evaluate the effects of a single intra-articular (IA) injection 
of high concentrated (88mg/4mL) and high molecular weight (HMW) hyaluronic acid (HA). Lameness 
examination was performed subjectively and asymmetry measured objectively using an inertial sensor 
device at week 1, 2, 4 and 8 after treatment. Serum biomarkers’ concentration (Coll2-1, Coll2-1NO2 
and Fib3-2) and synovial fluid (SF) analysis (subjective viscosity asessement, total proteins (TP), and 
cytological examination) were evaluated before treatment and at the end of the study. Eight horses 
with clinical osteoarthritis (OA), diagnosed with lameness examination, perineural anaesthetic block 
and digital radiographic examination, were included. One week after treatment six horses (75%) 
subjectively improved, being significantly less lame (P = 0.020), but only 25% (2/8) remained clinically 
better after two months. Subjective flexion test response improved in 50% (4/8) of the horses at the 
end of the study. Objectively, there was decreased asymmetry at straight line one week after 
treatment and decreased change in asymmetry after flexion in forelimbs (week 1 and 2) and hind 
limbs at 2 months (P = 0.016). SF showed significant reduction in TP at the end of the study (P = 
0.042). Finally, all serum biomarkers decreased 2 months after treatment, in particular Fib3-2. In 
conclusion, a single 88mg HMW-HA IA injection has shown to reduce cartilage degradation and 
inflammation, based on serum biomarkers assessment, besides producing modest subjective and 
objective improvement in lameness. A randomized, double blind and controlled study should be 
performed in order to confirm the clinical interest of this therapy. 
 
1. Introduction 
 
OA is a disabling joint disease mainly responsible for premature retirement in sport horses with 
consequent economic losses. Various medical treatments are available for systemic or IA injection. 
They include HA reported to have anti-inflammatory (Takahashi et al., 1999) and disease-modifying 
effects on OA joints (Marshall et al., 2000). HA is a nonsulfated, unbranched polysaccharide of 
alternating disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid (Richardson & Loinaz  
et al., 2007). The molecular weight is determined by polymerization and the number of repeating 
disaccharide units. Commercially molecular weight is usually referred as low (< 5 x 105 Da), 
intermediate (5-10 x105 Da) and high (>1 x 106 Da) (Williams, 2007). It has been suggested that HA 
preparations of HMW have better chondroprotective effects and better clinical results in horses 
(Philips, 1989). In vitro, high HMW-HA (4,000 kd) supplementation restored lubricant function in SF 
sampled from acute OA joints (Antonacci et al., 2012) to normal equine SF values.  
A study on experimental OA revealed that 3 injections of 22mg HA together with 125mg amikacin 
did not improve lameness but reduced cartilage fibrillation (Frisbie et al., 2009). More recently, the 
same authors compared HA together with sodium chondroitin sulphate and N-acetyl-D-glucosamine 
with IA saline and amikacin alone. In this study, there was 16% improvement in lameness scores, 
slight improvement on radiographic bone proliferation and less cartilage erosion when compared to 
placebo treated joints (Frisbie et al., 2013). Different concentrations have been studied and better 
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lameness results, measured by a force plate, were obtained with a single injection of 20mg and 40mg 
when compared to lower HA concentrations (Richardson & Loinaz, 2007). In a Portuguese equine 
veterinarian survey we have found that, in field practice, HA (20mg) is most often injected in high 
motion joints alone or simultaneously with IA corticosteroids in a single injection protocol. Moreover, a 
recent study compared the clinical efficacy of a single IA injection of 12mg triamcinolone acetonide 
(TA) alone or together with 20mg HMW-HA and it found lower short-term clinical success with the HA 
combination but the same outcome 3 months after treatment (de Grauw et al., 2014). Therefore, the 
single injection of 20mg HA is a commonly used protocol but it usually leads to a modest clinical 
improvement. That is the reason why we decided to investigate a recent product using high 
concentration (88mg/4mL) of HMW-HA for a single IA injection that has been approved for humans 
(Goldenberg, 2014). This protocol was never objectively tested in horses, but, if effective, it would 
present a clear advantage since a single injection of high concentrated HA would be less time 
consuming and safer. 
In order to objectively assess this therapy we have used a body mounted inertial sensor device 
technology that measures head and pelvic asymmetry in horses (Keegan et al., 2004). Its repeatability 
was confirmed (Keegan et al., 2011) when compared to a stationary force plate (Keegan et al., 2012) 
and its sensitivity when compared to subjective evaluations was higher in mild cases of lameness 
(McCracken et al., 2012). Furthermore, as this device would be blind to a drug injection, it will be 
interesting on objective lameness assessment after treatment.  
Several evaluation tests can be used to assess articular status. SF analysis reflects the joint health 
and can be performed by description of gross appearance, determination of TP, total nucleated cell 
count but most importantly by cytologic examination (Steel, 2008). Biomarkers are biochemical 
measures that are indicative of a biologic process or the response to an intervention. Biomarkers of 
cartilage can be found in SF but also in serum. Type II collagen and Fibulin-3 are abundant in the 
extra-cellular matrix from articular cartilage. In serum, collagen type II degradation fragments (Coll2-1 
and Coll2-1NO2) (Henrotin et al., 2004) and Fibulin-3 fragment (Fib3-2) have been shown to identify 
joint disease in humans (Henrontin et al., 2012). Moreover, Coll2-1 in serum has recently been 
reported to decrease after OA treatment in humans (Henrontin et al., 2014). In horses, type II collagen 
fragments have been correlated with OA (Lejeune et al., 2007; Verwilghen et al., 2009) but, as Fib3-2, 
they have never been used to assess therapy response.  
The aim of this study was to objectively test the effect of a single IA injection of high concentrated 
HMW-HA in horses with clinical signs of OA. The authors hypothesized that lameness, SF parameters 
and serum cartilage biomarkers would decrease after treatment. 
 
2. Materials & Methods 
 
The care and handling of the animals were in accordance with the provisions of the European 
Economic Community Council Directive 86/609. Horse owners signed an informed consent for IA 
treatment and agreed to respect protocol recommendations. 
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2.1. Animals 
 Client-owned horses, presenting lameness, with no distinction in sex, age or breed were 
selected from three different veterinarian practices from February to April 2014. Animals presenting a 
positive response to anaesthetic block (abaxial sesamoid or distal low palmar/plantar nerve block and 
DIP or fetlock joint IA anaesthesia) together with radiographic signs of distal limb OA were included in 
this study. Exclusion criteria consisted of animals receiving any type of systemic or IA treatment 2 
weeks before the study, horses presenting osteochondritis dissecans (OCD) lesions in the affected 
joint or horses with non-weight bearing lameness or signs of systemic disease.  
 
2.2. Lameness evaluation  
Lameness examinations were performed routinely and horses subjectively classified according to 
the pain level from 0 to 5 (Ross, 2003) and according to digital flexion test response: negative or 
positive, from 1 to 3 (Broecks et al., 2014). Simultaneously, objective assessment was performed 
using a body-mounted inertial sensor system at week 0 (before treatment) and 1, 2, 4 and 8 weeks 
after treatment. Horses were instrumented with 3 inertial sensors: one uni-axial accelerometer in a 
head bumper or the crown piece of the head halter, a second uni-axial accelerometer placed between 
the tubera sacrale on the midline of the most dorsal aspect of the pelvis with tape and a third uni-axial 
gyroscope in a pastern wrap placed on the right forelimb. Data were obtained wirelessly from horses 
trotted in straight line (at least 25 strides), before and after flexion (at least 10 strides) (Marshall et al., 
2012; Rettig et al., 2015).   
Vertical head movement asymmetry is reported as the vector sum (VS) of maximum (Hmax) and 
minimum (Hmin) head height difference in millimetres (mm) between the right and left components of 
each forelimb stride. The side of lameness is determined by sign of Hmin during right forelimb stance 
minus Hmin during left forelimb stance, with positive values indicating right forelimb, and negative 
values indicating left forelimb lameness (Marshall et al., 2012; Rettig et al., 2015; Maliye et al., 2015). 
In the present study, VS at different time points was used to compare straight-line asymmetry. VS 
change (ΔVS) before and after flexion, at different time points was used to determine response to 
forelimb flexion, considering that Hmax and Hmin are conceptually related.  
Vertical pelvic movement asymmetry is reported as the maximum (Pmax) and minimum (Pmin) 
pelvis height difference in millimetres (mm) between right and left halves of the stride. Pmin is 
associated with decreased downward movement (impact lameness) in the first half of the stance and 
Pmax associated with decreased upward movement (push-off lameness) during the second half of the 
stance. Positive values of Pmax and Pmin indicate asymmetric pelvic movement due to right hindlimb 
lameness and negative values indicate asymmetric pelvic movement due to left hindlimb lameness. 
Pmax and Pmin are conceptually un-related and therefore separately evaluated as dependent 
variables for hindlimb lameness. Left sided pelvic asymmetry values were first standardised my 
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multiplying by -1 to convert to right-sided values (Marshall et al., 2012; Rettig et al., 2015). In the 
present study, Pmax difference (PDmax) and Pmin difference (PDmin) at different time points were 
used to study straight-line asymmetry. Before and after flexion change for PDmax (ΔPDmax) and 
PDmin (ΔPDmin) between the right and left part of the stride was used to determine flexion response 
in hind limbs. 
 
2.3. Synovial fluid analysis 
SF analyses were performed before and 2 months after treatment. Affected joints were clipped and 
aseptically prepared. Sedation was performed using detomidine hydrochloride (0.01 mg/kg) and 
butorphanol tartrate (0.02 mg/kg). SF sample collection was performed using an 18-21 G needle. TP 
concentration was measured using a portable refractometer (ref: 50303020), concentrations less than 
20 g/L were considered normal. Viscosity was assessed as decreased (SF string less than 2.5 cm) or 
normal (SF string between 2.5 -5 cm) as a gross measure of HA content. Subsequently, SF was 
stored in EDTA tubes and centrifuged at 1500 rpm for 10 min. The sediment was resuspended after 
which the smear was performed and air-dried for cytological examination. Smears were stained with 
May-Grunwald (MGG) and microscopically examined for cellularity (normal or increased), percentage 
of neutrophils (less than 10% was considered normal) and for mucin pink material on the background 
of smears (decreased or normal) (Steel, 2008). 
 
2.4. Treatment protocol 
Product contained 88 mg of lightly cross-linked HMW-HA in 4 mL of phosphate buffered saline. 
Horses were restricted to box rest for 48h after injection. Exercise protocol consisted of 10 min hand 
walking exercise for one week followed by lounge exercise with increased trot periods during the 
second week. Owners were told that no other medications should be given for 2 months. 
 
2.5. Serum biomarkers analysis 
Biological assays using specific ELISA kits were performed according to manufacturer’s 
recommendations. Coll2-1 (nM), Coll2-1NO2 (nM) and Fib3-2 (pM) were measured in the serum of OA 
patients before and 2 months after treatment (Henrotin et al., 2012; Henrotin et al., 2014). 
 
2.6. Statistical analysis 
The effect of treatment on subjective and objective lameness, SF parameters and serum 
biomarkers were determined using Wilcoxon signed rank test or t-test related samples. Statistical 
significance was set at P ≤ 0.05 and data were presented by median and interquartile range (IQR). 
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3. Results 
 
3.1. Animals 
Included horses consisted of 3 Lusitano, 3 Portuguese Crossbreed and 2 Hanoverian horses, from 
6 to 18 years of age (median 9.50 years). There were 2 females, 1 gelding and 5 males (n = 8).  
One horse had two affected joints and the others had a single affected joint. Therefore, there were 
7 fetlock joints (2 forelimbs and 5 hind limbs) and 2 distal inter-phalangeal joints (2 forelimbs) treated 
with HA (n = 9). Six horses presented acute signs of the disease (less than 1 month with mild to 
moderate radiographic lesions) and two horses presented chronic signs (more than 1 month with 
severe radiographic lesions). No severe adverse reactions were noted after treatment. 
 
3.2. Lameness examination 
On a straight line, horses presented median grade 3 subjective lameness at all times except at 
week 1 (median grade 2) and this was significantly different compared to what was found before 
treatment (P = 0.020). Six horses were clinically improved one week after treatment and 2 horses 
remained less lame at the end of the study. In what concerns the flexion test, horses presenting 
median grade 1 positive response to subjective flexion at all times. At the end of the study 4 horses 
treated for fetlock OA had flexion response improvement, but this was not significantly different. One 
horse from the forelimb group improved from grade 1 to grade 0, from the hind limb group one horse 
improved from grade 2 to 0 and two horses improved from grade 3 to 1. 
Objective lameness evaluation was performed in 4 the forelimbs and 4 the hind limbs, one horse 
(hind limb fetlock) being excluded due to high outlier values. Examinations had at least 2 animal 
evaluations at each time point for forelimb and hind limbs. Results were presented as head asymmetry 
(VS) and pelvic asymmetry (PDmax and PDmin). Straight-line evaluations presented lower VS at 
week 1 (median 7.15 IQR: 6.22, 15.80) but there were no significant differences compared to week 0 
(median 15.98 IQR: 7.24, 21.63) (Figure 14A). Regarding hind limbs (Figure 15A and Figure 16A), 
straight-line evaluations presented lower values at week 1 (PDmax median 6.27 IQR: 1.86, 10.54; 
PDmin median 4.43 IQR: 1.76, 8.78). Differences between week 0 (PDmax median 9.72 IQR 4.72, 
13.53; PDmin median 11.61 IQR: 5.29,14.06) and week 1 were not significant for PDmax or PDmin. 
Asymmetry before and after flexion-test was presented as change on head asymmetry (ΔVS) and 
on pelvic asymmetry (ΔPDmax and ΔPDmin). Forelimbs presented negative median ΔVS values at 
week 1 (median -2.96 IQR: -6.53,1.21) and at week 2 (median -0.31 IQR: -7.33, 1.78), but there were 
no significant differences compared to week 0 (median 0.59 IQR: -0.28, 22.53) (Figure 14B). Hind 
limbs, presented positive ΔPDmax values at the first four time points but decreased from week 2 to 
negative values at week 4 (median -5.60 IQR: -8.71, -2.48). Furthermore differences between week 0 
(median 4.56 IQR: 0.99, 16.16) and week 8 (median -5.60 IQR: -8.71, -2.48) were significant (P = 
0.016) (Figure 15B). Change in PDmin was positive at all time points, decreasing from week 1 
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(median 6.37 IQR: 2.51, 10.60) to week 8 (median 1.97 IQR: -3.64, 7.58), but differences were not 
significant (Figure 16B). 
 
 
Figure 14: Box plot of objective lameness evaluations in fore limbs (A): head asymmetry (VS) at straight line and 
(B): head asymmetry difference before and after flexion (ΔVS). There were no significant differences. 
 
 
Figure 15: Box plot of objective lameness evaluations in hind limbs (A): maximum pelvic asymmetry (PDmax) at 
straight line and (B): difference between before and after flexion asymmetry (ΔPDmax). Significant differences 
between ΔPDmax at week 0 and at week 8 are represented by * P < 0.05. 
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Figure 16: Box plot of objective lameness evaluations (A): minimum pelvic asymmetry (PDmin) at straight line 
and (B): difference between before and after flexion asymmetry (ΔPDmin). There were no significant differences. 
 
3.3. Synovial fluid analysis 
It was possible to retrieve SF samples from all joints before the IA injection (n = 9). However, 2 
months after treatment 2 owners were not available to allow for the sample collection procedure (n = 
7). 
TP concentration was higher before treatment (median 22 g/L, IQR: 10, 29) than after treatment 
(median 8 g/L, IQR: 6, 30) and related samples analysis were significantly different (P = 0.042). Five 
horses presented abnormal elevated concentrations before treatment. The two horses presenting 
persisting elevated values at the end of the study were associated with iatrogenic haemorrhage at 
collection time. Subjective macroscopic viscosity and cytological mucin assessment did not differ 
before and after treatment. Cytological examination showed increased cellularity in 5 horses with no 
significant differences 2 months after treatment injection. Percentage of neutrophils was elevated in a 
single horse and decreased to normal values after treatment.   
 
3.4. Biomarkers analysis 
Biomarkers concentrations in serum of treated horses (n = 8) are presented graphically for Coll2-1, 
Coll2-1NO2 and Fib3-2 in Figure 17A-C, respectively.  
There were higher median concentrations of all biomarkers before treatment compared to 2 months 
after treatment: Coll2-1 presented median 1752.2 nM (IQR: 1650.9, 1862.0) compared to median 
1696.9 nM (IQR: 1559.9, 2013.2); Coll2-1NO2 presented median 3.63 nmol/L (IQR: 3.26, 5.03) 
compared to median 3.39 nM (IQR: 3.08, 4.09); Fib3-2 presented median 523.1 pM (IQR: 402.7, 
567.3) compared to median 484.6 pM (IQR: 459.7, 558.9). However, related samples analysis showed 
no significant differences. 
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Figure 17: Box plot of serum biomarkers’ concentration (A): Coll2-1 (B): Coll2-1NO2 and (C): Fib3-2 before (week 
0) and 2months after HA treatment (week 8). There were no significant differences. 
   
4. Discussion 
 
HA is a ubiquitous component of extracellular matrices, and performs important functions in 
cartilage. By binding and immobilising aggrecan, HA mediates the formation of massive aggregates of 
fixed negative charge, that retain water, it is a critical extracellular matrix component and assures 
cartilage mechanical properties. This molecule is produced by synoviocytes and chondrocytes and is 
responsible for SF viscoelasticity, playing an important role in cartilage lubrification (Todhunter, 1996).  
The aim of this study was to test a high concentrated single HMW-HA injection on distal limb OA 
joint treatment. Besides subjective methods an objective assessment was used at the short-term 
outcome and 2 months after treatment. Body mounted inertial sensor device was used for lameness 
evaluation. Serum biomarkers’ concentration was measured in order to assess cartilage degradation 
and joint inflammation. As far as we know, these methodologies have never been used to evaluate 
therapeutic response in horses. Eight horses presenting clinical signs of the disease were injected 
intra-articularly. One horse had two treated joints making a total of nine distal limb high-motion joints 
assessed. The treatment was well tolerated and there were no adverse reaction reported.   
Median grade of subjective lameness on a straight line was significantly reduced one week after 
treatment regardless acute or chronic OA. The objective evaluation proved asymmetry reduction but it 
didn’t confirm the significant difference. However objective evaluation of impact lameness (PDmin) 
showed a clear reduction almost aproaching significance. 
We did not include a placebo-treated group as it was considered practically unfeasible to get 
owners to consent to withholding treatment of their lame horses. We can not exclude that clinical 
improvement during the first week in 75% of horses could be associated to the restricted walking 
protocol that was recommended. However, a recent cohort double-blinded study reported only 10% 
(1/10) improvement in acute and chronic OA groups after IA placebo (Spadari et al., 2015). In the 
present study there were 50% of the horses with decreased response to subjective flexion test at the 
end of the study in particular for hind limbs. This could be explained by the presence of two DIP joints 
in the forelimb group, that showed no improvement in our study. In fact another study associated DIP 
joint OA to a worst outcome (Brommer et al., 2012). Objective improvement of flexion response was 
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only evident during the first two weeks after treatment in forelimbs. Gradual improvement was 
observed in hind limbs, presenting significantly difference between week 0 and week 8 for PDmax, 
and meaning less push-off lameness or pain during the swing phase of the stride. Surprisingly, the 
asymmetry improvement in hind limbs flexion response had different evolution from straight-line, 
where asymmetry increased from week 1 until the end of the study. One horse was excluded from the 
objective analysis due to extremely high asymmetry values in spite of bearing weight on the OA limb. 
This probably reflects the disappointing results often encountered in chronic cases. However, the 
second chronic clinical case also had important asymmetry reduction at week 1.  
Viscosity of SF is directly related to the quantity and degree of polymerization of HA (Pearson, 
1971). The authors expected significant improvement of viscosity after treatment but this was only 
seen in one horse both macroscopic and histologically. Maybe differences existed sooner after 
treatment but samples were performed only once, 2 months after HA injection. It would also have 
been interesting to biochemically analyse the concentration of HA using an ELISA-kit assay 
(Antonacci et al., 2012). Beside increased lubricant function in SF from acute cases after HMW-HA 
supplementation, these authors reported that SF from acutely inflamed joints presented significantly 
lower HA concentration compared to controls but difference did not exist in chronic cases. The other 
parameter tested before cytology was TP concentration. TP increase in case of joint trauma and 
inflammation due to protein leakage from damaged vessels (Steel, 2008). Our results before treatment 
confirm the presence of joint injury and showed significant reduction at the end of the study. There 
were no significant changes in cellularity and neutrophils percentage. The mild increase of TP is not 
always present in OA joints but TP significant reduction confirmed decreased inflammation after this 
specific HA treatment.  
To our knowledge this is the first time that serum type II collagen and a Fibulin-3 fragment are used 
to assess IA therapy in OA horses. We found that Fib3-2 presented the highest reduction after 
treatment, which is different from Henrotin et al. (2014) reporting Coll2-1 to be more significantly 
decreased. Another study reported both type II collagen biomarkers’ reduction early after IA HA 
treatment in humans (Henrotin et al., 2013). Biomarkers serum concentration can be affected by the 
presence of OA elsewhere, even in unassessed joints. That was the reason for treating two joints in 
one horse. Moreover, we have recently found Coll2-1 and Fib3-2 to be increased in the serum in the 
presence of OCD. In our study, horses were only excluded if presenting OCD in the treated joint. If 
OCD was present elsewhere, this could have increased serum biomarkers’ values and explain 
absence of statistical significance. Instead, low number of horses may have precluded significant 
difference. It was our intention to test the same biomarkers in treated joints but there was not enough 
SF for all horses before and after treatment. Verwilghen et al. (2011) reported a significant correlation 
between the degenerative score and the synovial levels of Coll2-1. In the future, it would be interesting 
to study these biomarkers in SF together with serum at additional time points closer to the injection 
treatment.  
In conclusion, our results suggest that high concentration of HMW-HA is safe, induces transient 
lameness reduction on a straight line but progressive improvement in response to flexion-test either in 
acute or chronic OA cases.  HMW-HA reduces joint inflammation by significant reduction of TP in SF. 
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A tendency for cartilage biomarker decreased concentrations in serum also reflects improved cartilage 
breakdown. These results suggest that pain reduction is modest but joint inflammation is reduced in a 
protracted way. This could represent an alternative for pain relief while preserving joint metabolism to 
drugs that are banned from competition. A randomized, double blind and controlled study, with a large 
number of horses should be performed in order to confirm the clinical interest of this therapy.  
 
5. References 
 
Antonacci JM, Schmidt TA, Serventi LA, Cai MZ, Shu Y, Schumacher BL, Mcllwraith CW, Sah RL. 
Effects of equine joint injury on boundary lubrication of articular cartilage by synovial fluid: role of 
hyaluronan. Arthritis & Rheumatism 2012; 64 (9):2917-2926. 
 
Broecks S, Zimmerman M, Crocetti S, Suls M, Marien T, Ferguson SJ, Chiers K, Duchateau L, 
Franco-Obregón A, Wuertz K, Spaas JH. Regenerative therapies for equine degenerative joint 
disease: a preliminary study. PloS one 2014; 9, e85917. 
 
Brommer H, Schipper P, Barneveld A, van Weeren PR. Systemic or intrasynovial medication as 
singular or combination treatment in horses with (peri-) synovial pain. Veterinary Record 2012; 
171(21):527. doi:10.1136/vr.100811. 
 
de Grauw JC, Visser-Meijer MC, Lashley F, Meeus P, van Weeren PR. Intra-articular treatment with 
triamcinolone compared with triamcinolone with hyaluronate: A randomised open-label multicentre 
clinical trial in 80 lame horses. Equine veterinary journal 2014; 6: doi: 10.1111/evj.12383. 
 
Frisbie DD, Kawcak CE, Mcllwraith CW, Werpy NM. Evaluation of polysulfated glycosaminoglycan or 
sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced 
osteoarthritis. American journal of veterinary research 2009; 70(2):203-209. 
 
Frisbie DD, Mcllwraith CW, Kawcak CE, Werpy NM. Evaluation of intra-articular hyaluronan, sodium 
chondroitin sulphate and N-acetyl-D-glucosamine combination versus saline (0.9% NaCl) for 
osteoarthritis using equine model. The Veterinary Journal 2013; 197(3):824-829. 
 
Goldenberg MM. Pharmaceutical Approval Update. P T 2014;39:337-338. 
 
Henrotin Y, Chevalier X, Deberg M, Balblanc JC, Richette P, Mulleman D, Maillet B, Rannou F, Piroth 
C, Mathieu P, Conrozier T. Early decrease of serum biomarkers of type II collagen degradation (Coll2-
1) and joint inflammation (Coll2-1NO2) by hyaluronic acid intra-articular injections in patients with knee 
osteoarthritis: a research study part of the biovisco study. Journal of Orthopedic Research 2013; 
31(6):901-907. 
CHAPTER VI 
92 
 
Henrotin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. Type II collagen peptides for 
measuring cartilage degradation. Biorheology 2004; 41:543-547. 
 
Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E, Bonnet V, 
Castermans C. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by 
treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complementary 
and Alternative Medicine 2014;14(1):159. doi:10.1186/1472-6882-14-159. 
 
Henrontin Y, Gharbi M, Mazzucchelli G, Dubuc JE, De Pauw E, Deberq M. Fibulin 3 peptides Fib3-1 
and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis & Rheumatism 2012; 64(7):2260-2267. 
 
Keegan KG, Kramer J, Yonezawa Y, Maki H, Pai PF, Dent EV, Kellerman TE, Wilson DA, Reed SK.  
Assessment of repeatability of wireless, inertial sensor-based lameness evaluation system for horses. 
American journal of veterinary research 2011; 72(9):1156-1163.  
 
Keegan KG, Yonezawa Y, Pai PF, Wilson DA, Kramer J. Evaluation of a sensor-based system of 
motion analysis for detection and quantification of forelimb and hind limb lameness in horses. 
American journal of veterinary research 2004; 65(5):665-670. 
 
Lejeune JP, Serteyn D, Gangl M, Schneider N, Deby-Dupont G, Deberg M, Henrotin Y. Plasma 
concentrations of a type II collagen-derived peptide and its nitrated form in growing ardenner sound 
horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Veterinary 
research communications 2007; 31(5):591-601. 
 
Maliye S, Voute LC, Marshall JF. Naturally occurring forelimb lameness in the horse results in 
significant compensatory load redistribution during trotting. The Veterinary Journal 2015; 204(2): 208-
213. 
 
Marshall JF, Lund DG, Voute LC. Use of a wireless, inertial sensor-based system to objectively 
evaluate flexion tests in the horse. Equine veterinary journal 2012; 44(S43):8-11. 
 
Marshall KW, Manolopoulos V, Mancer K, Staples J, Damyanovich A. Amelioration of disease severity 
by intraarticular Hylan therapy in bilateral canine osteoarhtirits. Journal of Orthopedic Research 2000; 
18(3):416-425. 
 
McCracken MJ, Kramer J, Keegan KG, Lopes M, Wilson DA, Reed SK, Lacarrubba A, Rasch M. 
Comparison of an inertial sensory system of lameness quantification with subjective lameness 
evaluation. Equine veterinary journal 2012; 44(6):652-656.  
 
 CHAPTER VI 
93 
Mcllwraith CW, Howard RD. Hyaluronan and its use in the treatment of equine joint disease. In: 
Mcllwraith CW, Trotter GW, editors. Joint disease in the horse. Philadelphia: WB Saunders 1996; 
pp.270-280. 
 
Pearson L. On the synovia in horses. Acta veterinaria Scandinavica. Supplementum, 1971; 35:1-77. 
 
Philips MW. Clinical trial comparison of intra-articular sodium hyaluronate products in the horse. 
Journal of Equine Veterinary Science 1989; 9(1):39-40. 
 
Rettig MJ, Leelamankong P, Rungsri P, Lischer CJ. Effect of sedation on fore- and hinlimb lameness 
evaluation using body-mounted inertial sensors. Equine veterinary journal 2015; 1: 
doi:10.1111/evj.12463. 
 
Richardson DW, Loinaz RL. An evidence-based approach to select joint therapies in horses. 
Veterinary Clinics of North Amercia: Equine Practice 2007; 23(2):443-460. 
 
Ross MW. Movement. In: Ross MW and Dyson SJ, editors. Diagnosis and Management of Lameness 
in the Horse. WB Saunders; 2003; pp.66-67. 
 
Spadari A, Rinnovati R, Babbini S, Romagnoli N. Clinical evaluation of intra-articular administration of 
stanozolol to manage lameness associated with acute and chronic osteoarthritis in horses. Journal of 
Equine Veterinary Science 2015; 35(2):105-110. 
 
Steel CM, Equine Synovial Fluid Analysis. Veterinary Clinics of North America: Equine Practice 2008; 
24(2), 437-454.  
 
Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effects of hyaluronan on 
matrix metalloproteinases-3 (MMP-3, interleukin-1beta (IL-1beta), and tissue inhibitor of 
metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis 
and Cartilage 1999; 7(2):182-190. 
 
Todhunter RJ, General principles of joint pathobiology. In: Mcllwraith CW, Trotter CW, editors. Joint 
disease in the horse. Philadelphia: WB Saunders 1996; pp.1-28. 
 
Verwilghen D, Busoni V, Gangl M, Franck T, Lejeune JP, Vanderheyden L, Detilleux J, Grulke S, 
Deberg M, Henrotin T, Serteyn D. Relationship between biochemical markers and radiographic scores 
in the evaluation of the osteoarticular status of warmblood stallions. Research in veterinary science 
2009; 87(2):319-328. 
 
CHAPTER VI 
94 
Williams VS. Intraarticular hyaluronic acid supplementation in the horse: the role of molecular weight. 
Journal of Equine Veterinary Science 2007; 27(7):298-303. 
 
 
 
 
 
 
 
 
 
CONCLUSION 
95 
GENERAL CONCLUSION 
 
Early recognition of OA is of major importance in both human and in equine medicine, in particular 
in young athletes. Nevertheless we need to be able to stop and revert the disease progression at any 
stage. While advances in human and veterinary medicine will progressively increase the longevity of 
species if we do nothing OA will become one of the most disabling, frequent and important disorders 
in the future.  
Currently, we are still looking for the gold standard therapy for joint disease, which would be able to 
achieve pain relief and return to function with maximal safety and at the lowest price possible. In this 
quest, researchers and manufacturers have made available a large arsenal of drugs but ambiguous 
information is frequently encountered. Therefore, objective evaluation of the effect of various therapies 
is mandatory, representing the main issue at the origin of our work.  
Both in human and equine medicine joint, therapy is difficult due to the limited healing capacity of 
cartilage and progressive degeneration along side with age and work. As equine surgeons with 
particular interest on equine orthopaedics we have to deal with challenging cases where cartilage loss 
is important and diffuse in joints of the distal limb. When we first designed this project we were 
convinced that objective methodologies were the only way to achieve early recognition of a disease 
process and would help assessing the effectiveness of a proposed therapy. For the equine species, as 
for human athletes, effective treatment means returning to the intended function. As veterinarians, it is 
our responsibility to use the available technology to achieve a specific and correct diagnosis and to 
recommend the best therapeutical option. 
Our goal being to find a medication that could stop the progression of the disease, we have paid 
attention to the biologic therapies and their promise of true regeneration. We first looked to the human 
and equine literature on this subject and made a survey amongst equine field practitioners about OA 
diagnosis and treatment in Portugal. The review article shows that blood and cell derived products 
induce mild clinical improvement and some cell-therapies are associated with better outcomes in 
horses, with higher rates of return to work and better histologic repair compared to controls, being 
described. In spite of the large amount of therapies described, there is still a lack of significant clinical 
response, which, together whith the high price and associated risk of flare reaction, make 
veterinarians and owners reluctant to the application of these therapies. Therefore, it was not suprising 
to find that equine veterinarians, including pratitioners working with sport horses, are still rarely using 
biologic products on OA patients.  
In order to standardize protocols, while achieving good safety and a less expensive therapy, we 
decided to investigate an allogeneic cell-derived treatment. The adipose tissue stem cells (ASCs) 
allows a good yield of cells while being easy to obtain from the patient itself or another animal. The 
novelty of our therapy was the preactivation with IFN-γ. The in vitro work allowed testing the effects of 
the ASCs in equine cartilage explants before their application in vivo. Cartilage degradation molecules 
and GAG release measurements were increased after OA induction and values were reverted by high 
dose of ASCs. Interestingly, GAG release achieved the lower values after preactivation of ASCs with 
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IFN-γ, for an extended period of time and, more importantly, when using the lowest dose of cells. The 
hypothesis that inflammatory conditions further enhance ASCs protective effects were confirmed and 
then tested in equine experimental disease in vivo. The same research group had previously 
developed the metacarpo-phalangeal groove model of OA in horses specially designed to be closer to 
the natural occurring disease and allowing to test the efficacy of therapies. Our in vivo study confirmed 
the induction of predictable lameness, radiographic and histological lesions with the groove model. 
Secondly, the study shows that the ASCs-γ treated joints have significantly reduced PGE2 
concentration and radiographic changes 9 weeks after IA treatment. This therapy should be further 
explored in clinical cases and for an extended period of time before being recommended in practice. 
The experimental study performed at the beginning of the research work allowed the PhD student 
to learn a new methodology for objective lameness detection and has allowed its application on the 
subsequent clinical part of the work. We performed lameness and radiographic examinations in 51 
Lusitano horses in order to correlate objective pain and radiographic signs of OA with cartilage 
degradation and inflammation biomakers in the blood. Using a heterogenous population, our study 
confirmed the utility of Coll2-1 as a biomarker of cartilage degradation being more specific in young 
horses and males. Increased concentration of Fib3-2 was found in the joint-disease group with the 
advantage of not being influenced by sex or age, which could potentially help to predict disease in 
certain cases. The Coll2-1NO2 biomarker was not significantly increased but should probably be part 
of a biochemical panel to detect more inflammatory than degenerative cases. Instead of an extensive 
but certainly incomplete radiographic screen, horses can have blood analysis performed in order to 
assess their osteoarticular status or a response to an OA therapy. With this study we concluded that a 
biochemical osteoarticular scan both in young males and females is a possibility for early detection of 
joint disease. 
Using the same 51 Lusitano horses we further analysed the relationship between subjective and 
objective detection of lameness. Straight-line evaluation and flexion-test responses were assessed 
and correlated with distal limb radiographic findings. Moderate agreement between subjective and 
objective evaluation for straight-line and low agreement for flexion-test response are described. We  
confirmed that a subjective assessement of a distal flexion test can be negative in the presence of 
radiographic changes and positive in the absence of lesions. However, objective lameness evaluation 
was more likely to detect increased asymmetry when radiographic osteoarticular lesions were present, 
in particular in hind limbs. These findings support the use of inertial sensor system to objectively 
assess distal limb flexion-test response evaluation but further analyses are important to better 
understand these correlations and other inertial sensors’ potential. In the future, we would like to 
explore the inertial sensor data by analysing response of the distal limb flexion not only in the flexed 
limb but also in the other limbs, in particular the contralateral limb.  
In order to use the studied methodologies (inertial sensor device and cartilage biomarkers) in 
natural occurring OA we have assessed response to HMW-HA therapy. Despite being more accurate 
to detect radiographic changes in the hind limbs we used the inertial sensors in clinical cases of both 
the forelimbs and the hind limbs OA. Flexion-test response was significantly decreased using the 
objective lameness detection in the hind limbs 8 weeks after treatment. Moreover, TP were 
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significantly decreased and all biomarkers were reduced by the end of the study. Although there were 
not significant changes, serum Fib3-2 was the biomarker that showed the more pronounced reduction 
and could be an important tool for therapy response assessment in the future. 
We believe that the purpose of our work has been fulfilled. We have explored two objective 
diagnostic methodologies for equine OA diagnosis and we have used these technologies to assess IA 
therapies in horses with experimental and naturally occurring disease.  
The strategy of our work was to perform all studies in close relationship between human and 
veterinary medicine, the private industry and field practitioners. Additionally, our association with 
VetAgro Sup, University of Lyon (France) has allowed us to integrate state of the art technologies to 
our local resources. 
Finally, this doctoral thesis provides a contribution to different aspects of the equine orthopaedic 
field and has allowed advancing in the student personal skills as well as developing knowledge about  
specific aspects of distal limb OA diagnosis and treatment in horses. As the objective methodology 
and therapies were inspired and performed in colaboration with different human and veterinary 
research centers and laboratories we hope to have contributed to a global medical progress.
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Introduction:
Mesenchymal stem cells (MSCs) have reparative 
effects due to paracrine actions and need to be activated 
by inflammatory mediators. Therefore, pre-activation of 
MSCs could lead to a more efficient therapeutic activity 
than unstimulated MSCs. Our objective was to study the 
effects of interferon-y (INF-y) pre-activated or “primed” 
allogeneic MSC in experimental osteoarthritis models, in 
vitro and in vivo, in horses.
Materials and Methods:
Equine adipose derived mesenchymal stem cells 
(ASC) were characterized and activated with IFN-y. ASC 
were tested on equine cartilage explants subjected 
to interleukin-1 (IL-1) and oncostatine-M (n=8). The 
experimental in vivo model of OA was induced by 
arthroscopy, using an adapted “groove” technique in one 
distal metacarpal condyle. Group A (n=6) did not receive any 
treatment; Group B (n=6) received intra-articular injection of 
15 million INF-y activated ASC in a vehicle (3 ml) and Group 
C (n=4) received the vehicle alone (3ml), 7 days post-surgery. 
After 15 days stall-rest horses respected a standardized 
exercise protocol. They were clinically evaluated before 
surgery (d0), in the middle (d45) and in the end of the study 
(d75), using an inertial sensor device for objective lameness 
examinations, synovial fluid analysis and radiography. All 
articular surfaces were evaluated macroscopically and 
histologically.
Results:
In the experimental study in vitro, IL-1 and oncostatine-M 
treatment induced a significant (p<0.001) increase in 
glycosaminoglycans (GAG) release to the culture medium. 
Cartilage explants treated with ASC showed less GAG 
degradation and IFN-y pre-activation enhanced the 
protective effect (p=0.019). In vivo, there was no significant 
difference in mean head movement asymmetry and 
radiographic scores between groups throughout the study 
(p>0.05). Estimated proportions of lame horses at the end of 
the study was 83%, 33% and 50% and mean radiographic 
score was 11.8, 7.7 and 9 in group A, B and C, respectively. 
There was no significant difference in synovial fluid TP and 
PGE2 mean values, nor in macroscopic and histologic mean 
scores between groups (p>0.05).
Discussion / Conclusion:
IFN-y primed allogeneic ASC treatment had benefic 
effects observed in vitro by significant reduced GAG 
production but these effects were less evident clinically. 
Perhaps there was not enough inflammation by the time 
of the treatment (d7) or maybe the number of stem cells 
was not adequate. This could be explained by insufficient 
number of cells for this type of joint or accelerated 
clearance of the cells from the joint environment. Using 
INF-y primed allogeneic ASC treatment has protective 
effect in vitro and should be further explored clinically 
before it can be recommended in acute osteoarthritis in 
horses.
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a b s t r a c t
Primary cartilage disease such as osteoarthritis (OA) or secondary degenerative disease to a
localized cartilage defect or a soft tissue injury is difﬁcult to treat. Osteoarthritis is asso-
ciated to important morbidity in human patients and is self-limiting for equine sport ac-
tivities. Many surgical and medical treatments are described with the common goal of
improving joint function and stop the disease progression. Biologic therapeutic strategies
are under evaluation and may be promising because they are based on the organism
natural capacity to heal and are supposed to have a regenerative potential. In the last
decades, these treatments have gained popularity in human and veterinary orthopedics
but there is still few clinical prove of efﬁcacy. This review of literature summarizes research
and clinical evidence of the so-called blood- and cell-derived therapies, providing scientiﬁc
evidence and understanding about their mechanisms.
! 2015 Elsevier Inc. All rights reserved.
1. Introduction
Compared with other tissues, cartilage composition is
quite simple, having only one cell type and no vasculari-
zation or innervation, which causes limited healing ca-
pacity [1,2]. Osteoarthritis (OA) is a slow progressive and
disabling joint disease that most commonly affects old or
high-level sportive young people [3]. Cartilage damage can
result from joint-level factors such as acute trauma, chronic
joint instability, or other joint-tissue diseases. Besides
these, individual-level factors contribute to disease pro-
gression, and both levels interact in a complex manner
making OA treatment difﬁcult [4]. These features are
similar both for human and equine patients.
There are two main approaches to cartilage treatment:
surgical and medical. The surgical approach is usually used
in case of focal cartilage lesions such as osteochondral de-
fects and subchondral bone cysts. The medical approach is
used in generalized cartilage disease such as OA [5]. The
main goal for both approaches is to alleviate clinical signs of
pain allowing humans and horses to continue to work and
compete. Moreover, in human medicine, a distinction is
made between symptom-modifying drugs and disease-
modifying drugs for OA. Drugs of the latter group are
expected to improve patient’s symptoms and to alter the
course of disease however; increased understanding of
inﬂammatory pathways is still needed [6]. In the last de-
cades, a different category of therapies have gained popu-
larity both in human and equine medicine. These are based
on biologic and natural organism ability to repair and try to
amplify their effects, the so-called regenerative or biologic
therapies. These therapies may be classiﬁed in two main
groups: the blood- and the cell-derived therapies.
There are obvious beneﬁts in the close collaboration
with humanmedicine and on testing advanced therapies in
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horses, but veterinarians and owners should keep a critical
mind when extrapolating human treatments for equine
patients without further investigation. In this review, we
look at several studies that support or bring into question
most common biologic therapies for cartilage repair, look-
ing in detail to their clinical ﬁndings in horse’s joints.
2. Blood-Derived Therapies
Blood-derived therapies are widely available because
there are no restrictions and few legislation regulating their
use. They are based on autologous products so readily
available from the patient and supposed to be safe for the
same reason. There are two main products being used in
equine patients, autologous-conditioned serum (ACS) and
platelet-rich plasma (PRP). The main interest is based on
their anticatabolic and anabolic effects. As performance
enhancement has not been demonstrated, these therapies
are not included in the prohibited list of doping controls,
and, consequently, competing horses can beneﬁt from their
effects. They have been adapted from human medicine
with little investigation but are being widely applied to
equine patients. One-step processed products such as bone
marrow concentrates and vascular stromal fraction of fat
tissue are brieﬂy discussed in the Section 3.1dcell-derived
therapies.
2.1. Autologous-Conditioned Serum
Autologous-conditioned serum was one of the ﬁrst
biologic products to be tested in horses. Autologous-
conditioned serum is produced from patient’s blood and
contains, among other biologic products, interleukin (IL)-1
receptor antagonist (IL-1ra) protein [7]. Interleukin 1ra is a
natural antagonist of IL-1 cytokine, which is known for its
central role in inﬂammatory responses, binding to the same
cell membrane receptor and reducing inﬂammation [8].
Therefore, ACS would be expected to have an effect on
cartilage metabolism and great potential for OA patients.
2.1.1. ACS Technique
Autologous-conditioned serum is a cell-free therapy
ﬁrst collected from patient peripheral blood into syringes
containing CrSO4-coated glass spheres followed by whole-
blood 24-hour incubation at 37!C, centrifugation, and
ﬁltration before serum being injected into joints [9]. Until
recently, there was only a commercial available method of
producing ACS, Orthokine (Orthogen; Düsseldorf, Ger-
many). There was little research on this product composi-
tion except one report from the manufacturer together
with an equine research team [10]. Authors report that
exposure of blood leukocytes to pyrogen-free surfaces,
glass spheres, causes an accumulation of anti-inﬂammatory
cytokines in human blood after 6 hours of incubation
compared with baseline. This included 8.5" higher IL-1ra
and 4" higher IL-10 for the anti-inﬂammatory cytokine
group compared with 2" higher IL-1b, 2.3" higher IL-6,
and 1.5" less tumor necrosis factor a (TNF-a) for the
proinﬂammatory cytokine group. In addition, increased
concentration of several growth factors (GFs), modest 1.4"
increase in insulinlike growth factor 1 (IGF-1), substantial
increase of 190" in platelet-derived growth factor (PDGF),
and 84" in transforming growth factor-b1 (TGF-b) were
achieved. Analyses were performed in the serum using
commercial human enzyme-linked immunosorbent assay
kits, but the number of patients was different for each
cytokine, from n ¼ 80 for TGF-b to n ¼ 224 for IL-1ra. Au-
thors assume that clinical effects are probably attributed to
the synergistic action of all factors and not to IL-1ra by it-
self. This list of cytokines is probably more extensive, and
the high standard deviations indicate great variability be-
tween individuals [9].
2.1.2. In VitrodLaboratory Findings
A recent study [11] reported ACS effects in vitro on
cartilage proteoglycan metabolism of autologous-
conditioned serum (n ¼ 24) compared with non-
conditioned serum (n ¼ 24) as well as cytokine levels in
synovial ﬂuid before and after treatment on 14 human
patients. They used ACS (Orthokine) with 6 hours of incu-
bation time. In line with other studies, increased levels of
anti-inﬂammatory cytokines IL-1ra, TGF-b, and IL-10 were
shown in ACS. However, proinﬂammatory cytokines IL-1b,
IL-6, and TNF-a were also upregulated. There was no
apparent in vitro effect of ACS on OA cartilage explants
from the six different donors during a 16-day culture.
Another interesting ﬁnding was that even after six intra-
articular in vivo injections of ACS during 21 days, there
were no signiﬁcant changes in cytokines levels. Authors
hypothesize that limited effects of this therapy in vivo can
be because of fast intra-articular clearance shown in this
study.
A newer generation of ACS is now available, and labo-
ratory results published by Hraha et al [12] helped to un-
derstand the major differences between the two equine
products. Most important conclusion is that the more
recent ACS system, IRAP II (Arthrex Inc, Naples, FL) yielded
signiﬁcant increase in IL-1ra compared with the other ACS
product, IRAP (Orthokine; Orthogen), and nonconditioned
serum. However, IRAPwould not cause an increase of IL-1ra
signiﬁcantly higher than 24 hours of nonconditioned
serum, which consisted in whole blood incubated 24 hours
in borosilicate glass tubes, centrifuged, and ﬁltered before
storage. In contrast to the previous study [10], which re-
ported less TNF-a after 6-hour incubation, in this study, this
proinﬂammatory cytokine was signiﬁcantly increased in
IRAP compared with 24-hour controls. Finally, the authors
remind that cytokines list present in ACS can be more
extensive than tested so far and conﬁrmed great variability
in cytokine production among individuals. In conclusion,
other factors besides IL-1ra could be involved in the re-
ported clinical effects.
More recently, another research group [13] compared
the effects of autologous equine serum (AES) to ACS (IRAPII)
on glycosaminoglycan (GAG) synthesis and metabolism of
postmortem equine chondrocyte pellets. Treatment with
recombinant human IL-1b and 10% of AES decreased the
amount of synthesized GAG. Instead, when associated with
20% of AES and 20% of ACS, results showed minimal
beneﬁcial effects of ACS treatment. Although both treat-
ments have increased IGF-1 concentrations and 20% of ACS
has increased IL-1ra in culture medium, this did not lead to
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a different direct effect on in vitro proteoglycan cartilage
metabolism compared with AES at same concentrations.
Once more, even if in a different study design, results
suggest that ACS is not so different in cartilage metabolism
in horses than autologous-unconditioned serum.
Gene therapy is beyond the scope of this review, but one
study using an osteoarthritic culture model reported re-
sults of a combination of proteins IGF-1 and IL-1ra. Trans-
duction with IGF-1 alone promoted cartilage production of
proteoglycan and type II collagen, suggesting a beneﬁcial
role for healing injured cartilage. Transduction with IL-1ra
alone decreased synovial expression of IL-1a, IL-1b, and
matrix metalloproteinase (MMP), indicating a mechanism
for prevention of matrix degradation. The combination of
the two resulted in improved preservation of proteoglycan
content of cartilage explants exposed to depleting effects of
IL-1. This study sustains a potential beneﬁt of combining
anabolic GFs and catabolic blockers [14].
2.1.3. In VivodClinical Studies
In humans, a randomized controlled trial in 376 knees of
OA-conﬁrmed patients was performed during 26 weeks
and reported for 345 patients at double-blind 6-month
follow-up [15]. Three parallel groups were formed and
received at least one treatment of ACS (Orthokine), hyal-
uronic acid (HA), or saline injection. The number and per-
centage of patients with 50% improvement of symptoms on
the Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) scores compared with baseline
weremarkedly highest in the ACS group comparedwith HA
and saline patients. There was the same frequency of local
adverse reactions in the ACS and placebo groups but
signiﬁcantly more in the HA group. Infection was not re-
ported in any case. An observer-blinded 2-year follow-up in
310 patients still showed improvements for all three
groups, and therewas still a signiﬁcant statistical difference
between ACS compared with control groups (WOMAC
scores). Autologous-conditioned serum reduces pain and
increases function and mobility, but authors believe that
although ACS can be recommended in low- to medium-
grade patients with painful knee OA, this cannot neces-
sarily be generalized to all patients.
Another study [16] reported function and symptoms
improvement after six intra-articular injections of ACS
(Orthokine) compared with placebo physiological saline.
There were 160 patients included in this double-blinded,
placebo-controlled, randomized, multicenter, prospective,
clinical trial at 3, 6, 9, and 12 months of follow-up. Results
showed similar improvements on the WOMAC score be-
tween groups but signiﬁcantly more improvement for Knee
injury and Osteoarthritis Outcome Score for ACS group.
Orthopedic surgeon and patient evaluations had better but
not signiﬁcantly different results for the ACS group
comparedwith placebo group. The reported adverse effects
on ACS group consisted in one case of severe inﬂammatory
reaction and one patient with septic arthritis. In contrast to
the previous study, improvement in symptomatology
seemed not clinically signiﬁcant. Additionally, placebo
group patients were reluctant to undergo further ACS
treatment, and thosewho accepted it (n¼ 20) did not show
clinical improvement [17].
Besides this contradictory results, IL-1ra is considered to
be “more than minimally manipulated” by Food and Drug
Administration and is therefore subjected to different reg-
ulatory laws than PRP and is generally not available for
human use in the United States [18].
In horses, ACS is now widely used in equine hospitals
and requested by many horse owners, but only anecdotal
personal communications report some results and sustain
good outcome for mild-to-moderate OA unresponsive to
conventional therapies. There are two experimental clinical
studies, one testing IL-1ra gene and the other ACS with
signiﬁcant lameness improvement in horses [19,20]. Clini-
cally, a new product, autologous protein solution, seems to
be effective in mild cases of OA and safe for intra-articular
administration in equine joints. It is a 2-step process, using
double centrifugation and ﬁltration through poly-
acrylamide beads that achieves high concentrations of Il-
1ra [21].
In the future, ACS complete cytokine proﬁle and differ-
ences from incubated patient’s blood alone need further
investigation. The potential for cartilage regeneration also
need to be proven in vitro, and large prospective blinded
clinical studies are required in natural occurring equine OA.
2.2. Platelet-Rich Plasma
Platelet-rich plasma is another autologous product
derived from patient’s blood known for its anabolic effects.
By deﬁnition, PRP is a volume of plasma fraction of autol-
ogous blood having platelet concentration above baseline
[22,23]. To expect clinical efﬁcacy, concentrations should
reach 1,000 " 103 cells/mL of nonactivated platelets in
plasma. This usually corresponds to twofold or more above
whole-blood baseline for humans, and in horses, this is also
considered the gold standard [24]. The concept that PRP
would improve joint disease is based on the physiological
role of platelets. Indeed, PRP interest is based on the ability
of platelets to release GFs from their a-granules on their
activation. Growth factors are cytokine proteins that regu-
late other cells function and play a role on modulation of
the inﬂammatory response, promoting angiogenesis,
attraction of ﬁbroblasts, and local stem cells to the site of
injury and induction of autocrine GF production [25].
Platelet-rich plasma has been applied since the 70 sec-
onds in bone, ligament, and tendon injuries and has
recently gained special interest for use in improving carti-
lage repair. Effects of IA PRP injection in injured or degen-
erated cartilage are promising and interesting results that
are being published every year. Ideally, the same PRP
product would be consistently used or at least consistently
characterized, but many times, this is not the case and that
is of major importance when assessing studies results.
2.2.1. PRP Preparation Techniques
Different techniques of processing the blood to separate
and concentrate platelets exist (Table 1). Major systems
consist in the automated apheresis, only available in human
hospitals, and automated centrifugation or “buffy coat”,
available for any human doctor or veterinarian. Several
companies sell the “buffy coat” technique, which involves
a centrifuge machine investment with its own PRP
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production protocol and separated individual kits. Care
should be made to guarantee that protocols for equine
patients are available before buying or using these systems.
Other options are manual centrifugation or “tube method”
and ﬁltration or “gravity method.” This last method can be
used by equine veterinarians in the ﬁeld, with no special
centrifuge requirements, besides room temperature con-
ditions and the kit cost.
Manual tube centrifugation has the advantage of being
economic but requires a centrifuge machine and sterile
technique while manipulating samples. Our double
centrifugation technique is similar to the one described by
Textor [9], which uses a ﬁrst centrifugation at 200g for
15 minutes and second centrifugation at 400g for 15 mi-
nutes and is described in Fig. 1. Using four acid-citrate-
dextrose (ACD) tubes will usually provide 4 mL of PRP at
Table 1
Equine platelet-rich plasma (PRP) preparation techniques [9].
Technique Preparation Advantages Disadvantages
Automated centrifugation:
buffy coat method
Single centrifugation; commercial kits Ease of use; rapid production; good
sterility; 10 minutes procedure
Kits price; human PRP protocols;
leukocytes and erythrocytes
contamination
Manual centrifugation:
tube method
Double centrifugation; pure PRP or
Leukocyte-poor PRP
Economic; less erythrocytes or
WBC contamination
Time consuming; sterility
breaking risk
Double centrifugation; leukocyte
PRP or leukocyte-rich PRP
Economic; bigger platelet
concentration potential
Less platelet concentration; time
consuming; sterility breaking
risk; leukocyte and erythrocytes
contamination
Filtration: gravity method Blood collected into a bag and ﬁltered
by gravity. Filter retains platelets
No centrifuge needed; good sterility;
10 minutes procedure
Kits price; some erythrocyte
contamination
Abbreviation: WBC, white blood cell.
Fig. 1. Platelet-rich plasma preparation using H-19F Regen Centrigel Centrifuge (RegenLab, Mollens, Switzerland)ddouble centrifugation technique: (A) taking
patient’s blood into four tubes of 8.5 mL acid-citrate-dextrose (yellow top); (B) centrifuge at 1,000 rpm during 15 minutes (soft spin); (C) three layers: plasma on
the top, thin white buffy coat in the middle, and the red blood cells on the bottom; (D) maximum amount of plasma should be collected without disturbing the
buffy coat; (E) transferred to 5 mL dry tubes (red top); (F) and centrifuged at 2,000 rpm during 15 minutes (hard spin); (G) a platelet pellet will be created on the
bottom of the dry tube; (H) the top plasma (3–4 mL) can be discarded, and the remaining plasma resuspended and mixed with other tubes before treatment.
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least threefold above baseline. As described by Alvarez et al
[26], if a sterile technique is used from collection until in-
jection, this PRP product should be safe for intrasynovial
injection. Some authors call this technique ﬁnal product
pure PRP or leukocyte-poor PRP because the buffy coat is
not disturbed, and slow centrifugation speeds are used. The
leukocyte PRP or leukocyte-rich PRP, when the entire buffy
coat and some red cells are aspirated, usually results in
higher concentrations of platelets and requires faster
centrifugation speeds [18,27]. Each clinician should test his
technique and centrifuge machine for platelet concentra-
tion and sterility before injecting it into patients.
Other platelet products have been used in the clinical
setting (Table 2). Platelet-rich plasma can be induced to clot
or be injected without activation. To clarify literature
terminology, the clot product should be termed of platelet-
rich ﬁbrin clot or matrix but is also known as “platelet gel”
(Fig. 2). A third product, rich in GFs, refers to the superna-
tant formed after clotting without the cellular portion and
is called platelet-rich clot releasate. The platelet concen-
trate has an extremely high concentration of platelets in
the smallest amount of plasma as possible. Textor et al [28]
showed that the liquid clot releasate provided 80% of total
available GF after calcium chloride (CaCl2) activation and
should be considered a valid method for percutaneous
treatment. This activation method takes time to clot (30–
60 minutes at 37!C) but has the advantages of being a
simple process, safe, and economic. Other studies have
studied the PRP releasate (PRPr) potential in vitro and also
sustain its use [29,30]. An alternative and optimized way of
producing PRP is described by Araki et al [31]. By collecting
whole blood into ethylene diamine tetra-acetic acid diso-
dium tubes, these authors show that there is greater
platelet aggregation inhibition, obtaining higher PDGF-BB
content compared with ACD. Moreover, if plasma of
platelet concentrate is replaced by saline, they obtain
higher PDGF-BB concentrations after activation but no
ﬁbrin gel formation (noncoagulating platelet-derived factor
concentrate), which is interesting for injectable purposes
such as in OA.
Few reports describe cellular and cytokine proﬁle
present in PRP. Major observations are that red blood cells
are not completely eliminated, and white blood cells
(WBCs) can even be concentrated depending on the
technique being used. One study reported concentrations
of cytokines in 11 human patient’s blood using two PRP
commercial systems. First, ACP (Arthrex Inc), a plasma-
based system, concentrated almost twofold more plate-
lets and decreased leukocytes compared with whole
blood. Second, GPSIII (Biomet Biologics Inc, Warsaw, IN), a
buffy coat–based system, concentrated more than fourfold
both platelets and leukocytes [32]. Hessel et al [33]
recently reported the same results in horses (n ¼ 6),
comparing the Equine Platelet Enhancement Therapy
(E-PET) (Pall Corporation, Port Washington, NY), an
equine-speciﬁc ﬁltration system, and four different
centrifugation techniques, including the manual double-
centrifugation method as described by Mos et al [34]. All
systems were able to concentrate platelets, but only two,
GPSIII and E-PET, had signiﬁcantly different results
compared with whole-blood baseline. E-PET had lower
platelet (3.8-fold) and WBC (1.8-fold) concentrations
compared with GPSIII (5.4-fold and 6.7-fold, respectively),
but the highest PDGF-BB and TGF-b1 values of all. Only
ACP system reduced the total leukocyte counts but was
associated to the lowest platelet enrichment. The manual
method showed acceptable cytokine concentrations but
high standard deviations. Based on these ﬁndings, the E-
PET system seems to be an acceptable choice for equine
veterinarians in the ﬁeld.
Table 2
Platelet-rich plasma (PRP)-derived products used in different clinical settings [9,28,31].
Product Preparation Advantages Disadvantages
PRP
Pure PRP Centrifugation Ready after centrifugation Cannot be adapted to wounds
or cyst cavitiesLeukocyte PRP
Platelet-rich gel Platelet activation after centrifugation Works like a scaffold; possible
to apply in wounds and cysts
Time consuming; cannot be used
in tendons, ligaments
Platelet-rich clot releasate Liquid portion retrieved after clotting No white or red blood cells;
good GF content
Time consuming
Platelet concentrate Small volumes High concentrations of platelets Very small volumes
Noncoagulating platelet
concentrate
Small volume of plasma replaced by
saline
Injectable without clotting Very small volumes
Abbreviation: GF, growth factor.
Fig. 2. Platelet-rich gel after injecting 50 IU of human thrombin and 1 mL of
10% CaCl2 into 2 mL of platelet-rich plasma tube and waiting for 30 minutes
at room temperature [39].
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The ideal ratio between platelets and WBC has not been
established yet, but it seems that a positive correlation
exists between WBCs, especially neutrophils, and both IL-1
and TNF-a concentrations in PRP [7]. Therefore, it is
accepted to favorless WBC concentrations, even if this
means less platelet numbers.
2.2.2. PRP Activation Methods
Clinicians should be aware of controversial results
depending on platelet and GF concentrations. In horses, GF
concentrations appear to depend on breed, gender, and age
of the patient [35]. Speciﬁcally, about GFs, McCarrel and
Fortier [36] sustain that GF measurements are the reﬂex of
platelet concentrations in PRP. Controversially, other au-
thors state that GF concentrations in the ﬁnal product do
not always correlate with total platelet number and can be
very different between individuals [37,38]. A simple reason
for this could be the activation of platelets during PRP
production with premature release of GFs into whole
plasma fraction (platelet-poor plasma [PPP]), not used in
the patient treatment. There are different chemical and
physical factors able to activate resting platelets. This can
be performed during or before administration, and in
equine practice, it has been described the use of thrombin,
CaCl2, or both [28,39]. However, because solid scientiﬁc
facts are lacking, most clinicians use PRP in the resting
form. It is believed that platelets would be activated after
injection by a collagen-rich lesion environment, but this
would vary based on site, type, and duration of the lesion
[40]. Resting platelets would have positive clinical effects
[36], and in vitro PRP is associated with sustained release of
GFs over aminimumof 4 days when relying on endogenous
activation only [41]. These ﬁndings were conﬁrmed
comparing resting and activated PRP injections into normal
joints showing no signiﬁcant difference on both GF con-
tents in synovial ﬂuid [42]. Exogenous activation would
only be recommended to ensure a maximal release of GFs
or in cases where clot formation is needed. Table 3 allows
further elucidation in respect to the use of these activators.
Other implications of the activation method are the
possible secondary effects on the tissue to be treated. As
reported by Han et al [45], thrombin activation method
eliminates the chondroinductive and osteoinductive
potential of PRP. In conclusion, if using PRP for cartilage
purposes, resting PRP or CaCl2-activated PRP should be
considered.
2.2.3. In VitrodLaboratory Findings
Interest on PRP effects in cartilage environment is
increasing, and some studies report surprising and prom-
ising results. On healthy cartilage, there are two studies
supporting its use. One study showed PRPr effects on
stimulation of porcine articular-chondrocyte proliferation
and matrix biosynthesis [46]. Treatment with 10% PRP
resulted in increased DNA content, proteoglycan, and
collagen synthesis compared with 10% PPP and fetal bovine
serum (FBS). The effects of PRP were more pronounced on
collagen synthesis than on proteoglycan synthesis, espe-
cially compared with the FBS group. A more recent work
reported biochemical evidences that PRPr supplementation
to human chondrocytes could support their chondrogenic
properties [47]. At 48 hours of 5% PRPr treatment, therewas
a 96% increased proliferation of chondrocytes in compari-
son with 5% PPP releasate treatment.
In fact, anabolic effects of PRP on healthy chondrocytes
are well documented, but there is also one study that re-
ports its effects on chondrocytes in the presence of IL-1 to
mimic an osteoarthritic environment. Platelet-rich plasma
releasate has diminished multiple-inﬂammatory IL-1b–
mediated effects on human osteoarthritic chondrocytes,
including inhibition of nuclear factor kappa B activation, a
major pathway involved in the pathogenesis of OA [48].
Other interesting feature of PRP potential was reported in a
study where synovial cells were isolated from 10 osteoar-
thritic patients [49]. Synoviocytes cultured in PRP
demonstrated increased angiogenesis, cell proliferation,
and HA production and secretion, suggesting chon-
droprotection and joint lubrication after intra-articular
application. Biologic effects of PRP-derived preparations
on chondrocyte proliferation have been repeatedly
demonstrated. These reports suggest that PRP action
mainly depends on proliferation andmigration, rather than
differentiation. Nevertheless, there is one study showing
that PRP enhances mesenchymal stem cell (MSC) prolifer-
ation, suggesting that PRP could induce chondrogenic dif-
ferentiation [50].
Table 3
Described platelet’s exogenous activation methods.
Activation Methods Advantages Disadvantages Reference
Freeze-thaw cycles Inexpensive and safe Additional step and time consuming if not
using liquid nitrogen
[28]
10% Calcium chloride (CaCl2) 23 mM comparable with 10 U/mL thrombin
and freeze-thaw cycles GF release in vitro
Potentially expensive [28,29]
Autologous equine thrombin Not effective in GF release [28]
Bovine thrombin Big dose-dependent GF release;
fast-inducing clot formation
Reported clinical reactions [28]
10% Calcium gluconate (CG) 9.3 mg/mL incubated at 37!C for 6 hr.
Complete release of GF
Time consuming [35]
CaCl2 þ thrombin At low concentrations: more protracted
GF release (until 6 d)
Potentially expensive [43]
Shear forces Do not affect GF release [44]
Collagen Inexpensive and safe Modest dose-dependent increase in GF; not
signiﬁcantly different GF’s concentrations
in synovial ﬂuid
[44]
Abbreviation: GF, growth factor.
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Another feature that has been proposed is that clinical
effects of PRP could also be explained by pain control
mechanisms. End-stage arthritic human cartilage was
treated in vitro with low WBCs and twofold to threefold
platelets PRP. There were decreased markers associated
with pain (TNF-a, substance P, and IL-1) which represents
possible antinociceptive effects [7]. Martin et al [51] also
reports thrombin receptor, possibly triggered after PRP
treatments, as an endogenous inhibitor of inﬂammatory
pain by activating opioid pathways.
2.2.4. In VivodClinical Studies
In laboratory animals, three experimental studies were
performed in rabbits and support PRP use. In collagenase-
induced OA, PRP-treated stiﬂes showed clear macroscopic
and histologic improvement compared with controls [52].
In an osteochondral defect experimental study, PRP-treated
group demonstrated cartilage regeneration and increased
production of GAGs in the extracellular matrix compared
with controls [53]. Finally, PRP microspheres injection into
OA knees in rabbits stimulated chondrocyte GAG synthesis
in vitro. Proteoglycan core protein messenger RNA in the
articular cartilage was increased after administration of
PRP. Treatment also suppressed progression of OA
morphologically and histologically [54].
In humans, there are several clinical studies testing
PRP’s effects on arthropathy. Autologous platelet gel has
been studied on 98 unilateral total knee arthroplasties, 61
had intraoperative platelet gel (PG) treatment, and 37 were
used as controls. Patients receiving PG during surgery had
less postoperative blood loss and less narcotic medication
requirement. PG group also achieved higher range of mo-
tion before discharge, which was in average a day earlier
than controls [55]. A retrospective cohort study evaluated
the effectiveness of intra-articular injections of an autolo-
gous preparation rich in growth factors (PRGF) compared
with a control group receiving HA injections, each group
including 30 human patients with knee OA. Treatments
were performed three times, 1 week apart, and WOMAC
questionnaires were ﬁlled before and 5 weeks after treat-
ment. Pain subscale reached 33.4% in PRGF group compared
with only 10% in the HA group but provided useful infor-
mation about PRGF safety [56].
A group of authors did a series of clinical trials on PRP
effect using a double-centrifugation method. This repre-
sented a mean increase of ﬁvefold platelet and 1.2-fold
WBC concentration compared with whole blood. Platelet-
rich plasma was stored at !30"C and given as one injection
per week for 3 weeks. The ﬁrst study analyzed 100
consecutive patients (115 knees) affected by chronic
degenerative condition. Evaluations were done before, at
the end of treatment, at 6- and 12-month follow-up,
through human pain scales. There was signiﬁcant
improvement of all clinical scores at the end of treatment
and at 6-month follow-up but became signiﬁcantly worse
at the 12 months. Authors concluded that PRP treatment
was safe and had the potential to reduce pain and improve
knee function and quality of life in younger patients with
low degree of articular degeneration; nevertheless, there
was no control group [57]. Ninety-one patients were
available for a 24 months of follow-up (114 knees), using
International Knee Documentation Committee (IKDC) and
Euroqol Visual Analogue Scale (EQ-VAS) scores. Further
analysis showed better results in younger patients and
lower degrees of cartilage degeneration. The median
duration of clinical improvement was 9 months [58]. The
same authors also compared a group treated with three
injections of PRP (n ¼ 50) with two HA treatment groups:
high (n ¼ 50) and low molecular weight (n ¼ 50), again
using IKDC and EQ-VAS scores at 2- and 6-month follow-up
interval. At the ﬁrst evaluation, PRP and low-molecular HA
had similar and better results than high-molecular HA. In
the 6-month follow-up, better results were observed in the
PRP-treated group. Moreover, both PRP and low-molecular
HA had similar results in patients more than 50 years, and
PRP showed better performance in younger patients
affected by cartilage lesions or early OA [59]. These clinical
results have not been conﬁrmed by a randomized
controlled clinical trial. Once more, PRP-treated group (n ¼
55) was compared with a HA control group (n ¼ 54) and
patients were evaluated by OA human pain scales at 2, 6,
and 12 months after a three-dose injection treatment.
There were some cases of mild pain and effusion after in-
jections, in particular in PRP group. Both groups presented
a clinical improvement, but there was no statistical differ-
ence. A trend favorable to PRP group was only found in
low-grade articular degeneration [60]. On contrary, a pro-
spective cohort study with a control group analyzed 120
patients with grade 1, 2, or 3 OA using the Kellgren and
Lawrence radiographic grading scale. One group was
treated with three PRP and the other three HA injections.
There was a fourfold to ﬁvefold platelet concentration in
PRP, and no adverse effects were observed. Three-month
and 6-month follow-up had signiﬁcantly better results in
the WOMAC and pain numeric rating scale in the PRP-
treated group [61]. More recently, Patel et al [62]
compared one high-concentrated PRP, 10-fold above base-
line, injection to one saline injection, and two low-
concentrated PRP, fourfold above baseline, injections in
humans (n ¼ 150). Patients had signiﬁcant improvement
of all subscales of the WOMAC scores, especially at the
3-month follow-up and decreased slightly after 6 months.
The saline group worsened over the 6 months.
In conclusion, in humans, PRP have beneﬁcial clinical
effects on pain reduction and function improvement on a
short-term period and especially in young and low-grade
severity OA cases. Compared with other therapies, PRP
can have the additional advantage of being economic.
Further consensus is still lacking on preparation, activation
methods, and treatment protocols. However, a single in-
jection of high-concentrated PRP, prepared using centrifu-
gation techniques and activation by CaCl2 or freeze-thaw
cycles, seems to be valid for cartilage treatment at this
time point.
In horses, the ﬁrst studies in cartilage focused on IGF-1,
and they have proven that this GF had anabolic effect on
chondrocytes. An experimental studywith extensive loss of
cartilage showed, 8 months after treatment, that IGF-1
group had enhanced incorporation into surrounding
cartilage, improved gross ﬁlling and higher proportion of
cells producing type II collagen [63]. Using the samemodel,
chondrocytes genetically modiﬁed encoding IGF-1 also
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showed beneﬁcial effect on cartilage healing [64]. On
equine natural occurring OA, there are few communica-
tions reporting clinical outcome after intra-articular PRP
treatment. The ﬁrst clinical report describes a decrease of
lameness and synovial effusion scores after three treat-
ments, 2-week apart, but only evident from 2 to 8 months
after the last injection, over a 1-year period [65]. This is in
agreement with clinical human studies. The second
communication reports no side effects in any of the 30
patients after intra-articular PRP treatment; however, there
is the evident bias of a retrospective study such as big
differences in number and clinical presentation of OA be-
tween groups [66]. Both studies were performed using
double-centrifugation technique and 50 mL of CaCl2 per mL
of PRP for activation [26]. This is not sufﬁcient to support
PRP treatment but clearly suggests that this is a safe, eco-
nomic, and beneﬁcial treatment in acute cases of OA in
horses. More recently, intra-articular platelet concentrate
has been applied to chronic cases of refractory OAwith 80%
of the horses returning to work, and no adverse reactions
reported [67].
Platelet-rich plasma injection into normal joints was
performed with the PRP gravity ﬁltration system (E-PET).
Authors obtained 3.2-fold and 1.9-fold increases in platelets
and WBCs, respectively, which are similar to the concen-
trations described in vitro before. Thrombin-activated PRP
increased proinﬂammatory cytokines (IL-6 and TNF-a) and
caused periarticular heat and swelling, effusion, and
increased ﬂexion scores. These clinical ﬁndings were not
observed in the resting or CaCl2-activated PRP groups.
Growth factors were globally low, so they have suggested
that PRP beneﬁts are not coming from PDGF or TGF-b1
concentrations [68].
The platelet gel has gained surgeons interest for local
cartilage lesions, used alone or combined with other ther-
apies such as stem cells, as a GF scaffold as discussed in
Section 3.1. A recent review was done in different species
about PRP application on abnormal cartilage. Eight studies
in vivo showed PRP can be used as adjunct in microfracture
surgery and implants scaffold and graft insertion besides
intra-articular injection, but not all studies concluded that
PRP has a positive effect on cartilage repair [69]. Some
authors state negative effects of PRP could only be excee-
ded by using speciﬁc anti-GF antibodies [70].
In conclusion, platelet-derived products seem prom-
ising as an intra-articular therapy, but consistent nomen-
clature and standardized protocols would be highly
beneﬁcial for future randomized controlled trials applica-
tion. Moreover, negative effects of some of its GFs should be
further investigated and modulated in the future.
3. Cell-Derived Therapies
Stem cells are unspecialized cells, which have the ability
to renew themselves indeﬁnitely, and under appropriate
conditions give rise to a variety of mature cell types [71].
They have gained increased interest in human and veteri-
nary medicine because of their therapeutic potential in
many ﬁelds. Intensive research has been performed to
achieve true regeneration, but in an equine clinical
perspective, functional recoverywould be the primary goal.
There are different sources of mesenchymal stem cells
(MSCs), and a hierarchy in stem cell plasticity exists such
that totipotent cells can differentiate into all cell types and
are available from the 1- to 3-day oocyte (morula) [72].
Pluripotent cells are able to differentiate into tissues from
the three germ layers but not to placenta and are available
from later embryonic stages or can be reprogrammed from
an adult differentiated tissuedinduced pluripotent stem
cells [72,73]. Multipotency means they can differentiate
into two or more cell lines, and unipotent cells can only
produce their own cell type [74].
In practice, autologous multipotent cells are normally
used because they have good differentiation capacity and
require simple procedures to be collected from the patient.
Mesenchymal line, containing undifferentiated cells from
bone marrow and adipose adult tissues are the two pop-
ulations most frequently used in cartilage repair [75]. Some
studies report a signiﬁcant higher chondrogenic potential
of bone marrow–derived stem cells, synovial membrane,
and intra-articular fat [76–78]. However, adipose subcu-
taneous tissue has gained popularity because it is more
readily available and allows obtaining a high number of
cells in the initial yield which means little need of expan-
sion and culture time [77,79].
Allogeneic administration of stem cells is also possible
because they are able to escape immune recognition [80].
Mesenchymal stromal cells are characterized by their
ability to adhere to plastic and by their capacity for multi-
potent differentiation, such as into osteogenic, chondro-
genic, and adipogenic lineages. Furthermore, they must
express a panel of mesenchymal stromal cell markers such
as CD29, CD44, CD73, CD90, and CD105 despite lacking
distinctive hematopoietic antigens such as CD34, CD45,
CD14, CD79a, and MHC [81]. In equine bone marrow and
adipose tissue MSCs, gene expression of membrane surface
markers has been reported by Ranera et al [82].
3.1. In VitrodLaboratory Findings
Ability of equinemultipotent adult MSCs to differentiate
into cells of chondrogenic lineage [83] have led to experi-
mental strategies to investigate whether they can be used
for regeneration. This includes research on cartilage im-
plants or vehicle solutions. Injecting MSC suspensions
would be responsible for initiating endogenous regenera-
tive activities in the OA joint by means of bioactive factors
production [84]. Some studies have shown the capacity of
MSCs to adhere to articular cartilage [85], but after intra-
articular injection, cell-labeling techniques demonstrated
that MSCs localized preferably in soft-tissue structures
with little or no retention within cartilage defects [86].
According to these studies, beneﬁcial effects of intra-
articular administered MSCs on articular cartilage are
likely mediated through soluble factors primarily on other
articular tissues and by changing tissue microenvironment.
When determining the optimal source of cells for
cartilage repair, two main criteria are considered: cells
performance and easy availability [87]. Intrinsic and clinical
superiority of puriﬁed MSCs populations over more het-
erogeneous cell isolates is questionable [88]. In fact, after
harvesting tissues, samples can be processed by simple
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techniques, such as centrifugation, or be cultured during
speciﬁc periods. The major differences are the total number
and purity of stem cells injected into the patient and the
processing time, which can take from several minutes for
centrifugation to several weeks if culture is performed [89].
Some authors defend that more heterogeneous products
can enhance MSCs proliferation and variably induced MSCs
migration, mediator secretion, and gene expression.
Recently, Kol et al [90] found that soluble factors from
adipose-derived stromal vascular fraction (ADSVF) induced
signiﬁcantly more MSCs proliferation and migration
in vitro compared with bone marrow mononuclear cells,
cord blood mononuclear cells, and platelet lysate. The use
of bone marrow aspirate concentrates (BMAC) has been
applied effectively to improve cartilage resurfacing in
horses [91].
Mesenchymal stem cells are commonly applied together
through vehicles and scaffolds containing other molecules.
It is assumed that for chondrogenic differentiation cells
need low oxygen environment and GFs [92]. A recent study
showed PRP to be a three-dimensional scaffold with a
mesh-likemicrostructurewith capability of endogenous GF
release and ready cell incorporation in vitro [93]. After
implantation in PRP, bone marrow MSCs had higher pro-
liferation rate and higher expression of cartilage-speciﬁc
genes and proteins than adipose-derived stem cells. Using
the same constructs in osteochondral defects in rabbits,
bone marrow also exhibited better gross appearance and
histologic and immunohistochemical characteristics,
higher cartilage-speciﬁc gene, and protein expression as
well as subchondral bone regeneration. However, when
associating GFs to MSCs’ suspensions, there are possible
secondary effects as induced osteophyte formation [94].
Surprisingly, in the same study, osteophytes were not
found when GFs were injected without the stem cells.
In inﬂammatory arthritic conditions, MSCs inhibit acti-
vation of T lymphocytes and secretion of inﬂammatory
cytokines while concurrently stimulating secretion of anti-
inﬂammatory ILs and reducing cartilage damage [95].
TheseMSC-mediated activities could be clinically beneﬁcial
in OA joints and support chondrocyte metabolism in the
face of arthritic disease. Lozito and Tuan [96] support that
MSCs are able to secrete active forms of MMPs, but their
activity is not detected probably because of tissue in-
hibitors of metalloproteinase (TIMPs) inhibition. These
authors showed that MSCs of the perivascular niche
inhibited high levels of exogenous MMP-2 and MMP-9
through TIMP-2 and TIMP-1, respectively. Stem cells
remained matrix protective when exposed to proin-
ﬂammatory cytokines and hypoxia, responding with
increased TIMP-1 expression and augmented MMP inhibi-
tion. In another study, using synovial explants subjected to
TNF-a and interferon gamma (IFN-g) to create short-term
osteoarthritic conditions, the group receiving MSCs had
decreased gene expression of IL-1b, MMP-1, MMP-13, and
increased cytokine signaling suppressor (SOCS) 1. In carti-
lage explants subjected to the same circumstances, IL-1ra
was upregulated, whereas disintegrin and metal-
loproteinase with thrombospondin motifs (ADAMTS) 5 and
collagen type II alpha 1 were downregulated. These ﬁnd-
ings are quite interesting and support that MSCs inhibit
inﬂammatory processes in short-term osteoarthritic syno-
vium [97]. Other in vitro study compared equine MSCs
derived from bone marrow, adipose tissue, and umbilical
cord blood and tissue. All tissue types decreased lympho-
cyte proliferation, increased prostaglandin (PGE2) and IL-6
secretion, and decreased production of TNF-a and IFN-g.
The only parameter by which MSCs differed was that bone
marrow and cord blood MSCs produced nitric oxide,
whereas adipose and cord tissue did not [98]. Despite these
ﬁndings, selecting the source of MSCs will depend on dif-
ferentiation potential but especially on the practicality of
obtaining, culturing, and banking each tissue.
3.2. In VivodClinical Studies
In laboratory animals, several experimental studies have
been developed using stem cell implants. Yan and Yu [99]
demonstrated that lesions in the femorotibial joint in rab-
bits treated with chondrocytes resulted in hyaline-cartilage
production. Comparatively, lesions treated with MSCs had
better cellular organization and integration into sur-
rounding cartilage. In another experimental osteochondral
study, defects were created on the patellar groove of the
right distal femur of 12 rabbits, divided into four groups (n
¼ 3) and managed by scaffold only, scaffold seeded with
adipose stem cells (ASCs), scaffold with TGF-b2 and bone
morphogeneic protein 7 (BMP-7), or scaffold with TGF-b2
and BMP-7 seeded with ASC. After 9 weeks, scaffolds were
ﬁlled with dense tissue and had distinct margins with
adjacent normal cartilage and GF groups had more foreign-
body giant cells and blood vessels. In practice, the use of
GF-immobilized scaffolds did not lead to better histologic
scores, because they were not signiﬁcantly different be-
tween groups, but increased International Cartilage Repair
Society macroscopic scores. This improvement was not
observed with ASC implants [100]. More recently, equine
meniscal sections were harvested from animals euthanized
for unrelated reasons, treated with ﬁbrin glue or ﬁbrin glue
and equine bone marrow MSCs, and then implanted sub-
cutaneously in nude mice. At 4 weeks of evaluation,
BMSCs-containing constructs had signiﬁcantly increased
vascularization, and histology showed subjectively
decreased thickness of repair tissue and increased total
bonding compared with ﬁbrin alone constructs [101].
Compared with cartilage implants, stem cell suspen-
sions are practical and increasingly studied. One report
used a caprine knee model of OA by complete excision of
the medial meniscus and resection of the anterior cruciate
ligament [102]. Adult stem cells were isolated from caprine
bone marrow, expanded in culture, and transduced to ex-
press green ﬂuorescent protein. After 6 weeks, a unique
dose of 10 million autologous cells suspended in a dilute
solution of sodium hyaluronan was injected by intra-
articular administration, whereas controls received so-
dium hyaluronan alone. There was a marked regeneration
of the medial meniscus, and implanted cells were detected
in the newly formed tissue. Degeneration of the articular
cartilage, osteophytic remodeling, and subchondral scle-
rosis were reduced in cell-treated joints compared with
joints treated with vehicle alone. There was no evidence of
repair of the ligament of the joints. Using a rabbit anterior
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cruciate ligament transection model, onemillion allogeneic
MSCs from infrapatellar fat pad were injected 12 weeks
after destabilization. There was reduced cartilage degen-
eration, osteophyte formation, and subchondral bone
sclerosis [103]. In contrast, in a monoiodoacetate model in
rats, MSCs reduced pain scores but not degenerative
changes [104]. In this study, bone marrow MSCs were
comparedwith bonemarrowmononuclear cells and saline.
There was signiﬁcantly pain reduction in MSC-treated
joints, compared with other groups, but no differences
were observed regarding cartilage damage, subchondral
bone alterations, and synovial inﬂammation.
There are limited human in vivo studies. Kuroda et al
[105] treated a large full thickness articular cartilage defect
in the femoral condyle of an athlete with autologous bone
marrow stromal cells, cultured and embedded within a
collagen gel, transferred to the articular cartilage defect,
and covered with an autologous periosteal ﬂap. Seven-
month arthroscopy showed the defect to have smooth
tissue, histologically being hyaline-like type cartilage, and
12-month follow-up showed clinical improvement and
returned to previous activity level. Another single human
case study also suggests that intra-articular administered
MSCs can restore articular cartilage volume, as assessed by
magnetic resonance imaging and improved clinical signs of
arthritic disease for several months [106]. Globally, bone
marrow stromal cell results have been similar to those
yielded using other cell-matrix systems; the repair tissue
formed being principally ﬁbrocartilaginous in nature, but
of variable quality and durability. Although many teams
have investigated stem cell use in orthopedic tissue
regeneration, limited evidence is currently available to
support its routine use; therefore, large-scale clinical trials
are lacking [107].
In horses, there is a study comparing single intra-
articular injection of autologous, related and nonrelated,
allogeneic placental-derived MSCs in 16 healthy horses
[108]. All groups had similar systemic and local response
with minimal joint swelling and lameness but marked
inﬂammation in synovial ﬂuid during the ﬁrst 72 hours
after injection. Despite the short period of evaluation, it is
important to clarify in vivo safety of allogeneic treatments,
although ﬂares can appear several days after injection or
after second treatment [109]. Most clinical studies are
experimental, and the main reason for this is the lack of
scientiﬁc support together with elevated price of stem cell
therapy. The ﬁrst experimental study in horses used bone
marrow MSCs–enriched ﬁbrin or ﬁbrin alone scaffolds.
Improvement in early cartilage healing was very variable
and not persistent at 8months [110]. Using ﬁbrin scaffold to
retain cells within cartilage defects requires cells to be
prepared before surgery which is not always possible in
clinical cases, or a two-step surgery is needed which is
expensive and time consuming. The other strategy involves
intra-articular injection of stem cell suspension, avoiding
collection and preparation before ascertaining the need of
the treatment [5]. However, treating extensive lesions is
more challenging than the repair of focal cartilage defects.
Two studies, using a carpal osteochondral fragment model
of OA and focused on clinical assessment of pain beside
radiographic, synovial ﬂuid and histologic evaluation, did
not found signiﬁcant improvement in pain score [111,112].
These studies in experimental OAmodels give little support
to the use of MSCs in the acute phase. However, a pro-
spective multicenter study was designed in naturally
occurring OA. Treated joints were mostly stiﬂes with
advanced ﬁbrillation and loss of soft-tissue structures and
received bone marrow MSCs and HA. In a mean of 21-
month follow-up, authors reported 76% return to work,
from which, 38% of horses returned to their intended use.
Authors also found a superior long-term outcome when
treatment was performed at least 1 month after diagnosis
[73,113]. More recently, this has been published in 33
clinical cases of stiﬂe lesions using autologous BMSCs and
allogeneic peripheral blood MSCs plus PRP in 91 clinical
cases of OA in different joints [114,115]. Both studies re-
ported high rates of returning to work, 75% at 24 months
[114] and 78% at 4.5 months of follow-up [115]. Based on
these reports, intra-articular administration of stem cells
seems an interesting and straightforward therapy, but it
would still be necessary to develop more clinically
controlled studies to support these ﬁndings.
Similar to other biologic treatments, there are still
practical questions about stem cell therapy that need to be
answered, for example, to know the optimal cell source for
each type of tissue or lesion, if there is a dose-dependent
response or if a high number of cells do not necessarily
improve clinical symptoms. Should cells be administered
locally or can be delivered systemically, and if so, can they
be injected alone or which type of scaffolds or vehicles
should be used? Furthermore, as for other biologic prod-
ucts, there is still no well-deﬁned window for treatment. It
is usually avoided to inject MSCs into acutely traumatized
inﬂamed tissues, but it is also possible that anti-
inﬂammatory and neoangiogenic activities of MSCs might
have positive effects in early phases of repair and affect
long-term results. Some authors believe MSCs would
beneﬁciate from an inﬂammatory joint environment for
their activation to occur. In practice, there is still the pos-
sibility to activate these cells and use them as allogeneic
products.
The sooner standardized protocols are available the
sooner will be possible to have more conclusive clinical
answers. It is also important to realize that positive or
negative results in experimental settings are not always
repeatable in other species or in the naturally occurring
disease. Moreover, equine veterinarians need to be aware of
each drug legislation and doping rules, if applicable.
4. Discussion
Different biologic strategies are available for treating
osteoarthritic joints, but until now, there is little evidence
of signiﬁcantly clinical improvements. Table 4 shows 11
in vivo studies using intra-articular biologic products in
horses: six experimental clinical studies and ﬁve studies in
naturally occurring OA. Not surprisingly, most therapies are
targeting a single intra-articular injection. This is mainly
because of the fact that there is a decreased risk of infection
and inﬂammatory reaction for the patient, fewer expenses
for the owner, and it is easier to standardize protocols for
equine veterinarians. In experimental clinical studies, most
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Table 4
Effects of intra-articular biologic therapies on equine joint disease.
Product Preparation Method Study Design Treatment Follow-up Findings
Autologous-conditioned
serum (ACS) versus
placebo [20]
- Autologous (Orthokine;
Orthogen)
Platelet:
WBC: NA
IL-1ra (mouse antibody):
5-, 2-fold increase
n ¼ 16
Experimental
Comparative mechanical
carpal fragment model
Strenuous exercise: 5 d/wk
14-d post-OA
4 ACS injections, 1 wk apart
(days 14, 21, 28, 35)
6 mL saline (n ¼ 8)
6 mL ACS (n ¼ 8)
- Every week: synovial
ﬂuid analysis (total
protein cytological
and biochemical analysis)
- Every 2 wk: clinical and
lameness evaluation
(AAEP scale)
- Before, after OA, and
in the end: X-rays
- After euthanasia (70 d):
gross and histologic
evaluation
Compared with placebo, ACS
group had:
- Signiﬁcant lameness degree
improvement on ACS group
on 70 d
- On OA joints, there was
signiﬁcantly decrease of synovial
membrane hyperplasia
- Signiﬁcant increased
IL1-ra after 35 d in
synovial ﬂuid
Autologous protein
solution (APS)
versus placebo [21]
Autologous
Double centrifugation
(Nstride; Biomet)
Platelet: 1-, 6-fold increase
WBC: 12-, 1-fold increase
Il-1ra: 5-, 8-fold increase
n ¼ 40
Clinical cases
- Predominantly 1
limb with
1 high motion OA joint
- Exercised 2" per week
on treadmill (#1, 4, 7,
10, and 13 d)
Single dose
5 mL saline (n ¼ 20)
5 mL APS (n ¼ 20)
- Before, 4, 7, 10, and 14 d:
assessment of joint pain
and swelling
- Before, 7, and 14 d: lameness
(AAEP scores and kinetic
gait analysis)
- Before and 14 d: synovial
ﬂuid, blood, X-rays
- Before, 12, and 52 wk:
client questionnaire
- APS signiﬁcantly improved
lameness by 14 d compared
with baseline and controls
- No adverse effects
- Clinical improvement at
12 and 52 wk by clients
- Better results if mild
lameness and X-ray scores
Platelet-rich plasma
(PRP) versus
corticosteroids [65,66]
Autologous
Manual double centrifugation
Reported concentrations
per mL of PRP [65]
WBC: 8.68 $ 3.78 " 106 cells
Platelet: 250 $ 71.8 " 106
cells
TGF-b1: 12,515 $ 2.443 pg
n ¼ 42
Clinical cases
Group 1 (n ¼ 12 chronic OA)
Group 2 (n ¼ 10 acute OA
and n ¼ 20 chronic OA)
Group 1: rest and IA
corticosteroids
Group 2: 1–3 PRP injections,
2 wk apart
Reported doses*: 10–20 mL
Evaluations before, 45 d, 2 m,
and 4 m after treatment:
- Lameness (AAEP scale)
- X-rays
- Joint effusionFollow-up
available from 1 to 3 y and 5 y:
- Owner’s questionnaire
Group 1d75% went back to
previous work with 33%
relapse
Group 2d70% went back to
previous work with 9.5% relapse
Worst prognosis if chronic
or more radiographic changes
Better outcome if more than
1 injection
Platelet concentrate
(PC) [67]
Autologous
Manual double
centrifugation
PC concentrations:
Platelet: 560 ($62) " 103
cells/mL
PDGF-BB: 1,280 ($70.9)
pg/mL
n ¼ 20
Clinical cases
Chronic OA refractory to
rest or corticosteroids
Not blinded nor
controlled study
- 3 PC injections; 2
wk apart
- PC activated with 3 mL
saline with 23 mM
CaCl2
1 hr before injection
15 d, 30 d, 1 y:
- Lameness examination
- Owner’s questionnaire using
modiﬁed Western Ontario and
McMaster Universities
Osteoarthritis index for
pain, stiffness, and physical
function
- 1-y follow-up examination
- Signiﬁcant lameness
degree and owner’s index
improvement between 1st,
2nd, and 3rd injections.
- Signiﬁcant correlation
between clinician’s and owner’s
index
- 80% of horses returning
to work after 1-y
follow-up.
- No adverse reactions
Bone marrow aspirate
(BMA) þ microfracture
versus microfracture
alone [91]
Autologous bone marrow
aspirated from sternum
(60 mL) and centrifugation
(SmartPreP2., Harvest
Technologies)
6 mL of BMA; 1 mL for
cytologic and ﬂow cytometry:
MCS: 13.4% in gate 5
n ¼ 12
Experimental
One-step surgery/treatment
15-mm cartilage defects on
both lateral trochlear ridge
- Microfracture þ5 mL
BMA (n ¼ 12)
- Microfracture alone
(n ¼ 12)
- 3 mo–2nd-look arthroscopy:
International Cartilage Repair
Society (ICRS) macroscopic
scoring system
- Signiﬁcant improvement
in BMA group in gross and
histologic evaluations
- Increased defect ﬁll and improved
integration of repair tissue at MRI
(continued on next page)
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Table 4 (continued )
Product Preparation Method Study Design Treatment Follow-up Findings
Platelets: 8-, 7-fold increase
WBC: 7-, 4-fold increase
! 2-wk stall rest
! 10-min walking
exercise/d increasing
each week until 3 mo
8 mo euthanasia: gross, histologic
(ICRS), and MRI evaluation
- Greater type II collagen
content and improved
orientation in BMA group
- More GAG in BMA group
- No adverse reactions
Bone marrow-derived
stem cells (BMSC)
versus autogenous
ﬁbrin [110]
" Sternum BMSC
" Self-polymerizing
autogenously ﬁbrin
vehicle (calcium-
activated
thrombin, 500 U)
n ¼ 6
Experimental
15-mm cartilage defects on
both lateral trochlear ridge
! 5-wk stall rest
! 7-wk 5-min walk
- Pasture exercise
Single implant
! 1 mL autogenous
ﬁbrin vehicle þ
12 % 106 MSCs
(n ¼ 6)
! 1 mL autogenous
ﬁbrin vehicle alone
(n ¼ 6)
! 0, 4, 7, 14, 21, 30 d: synovial
ﬂuid WBC and TP
! 1 mo–2nd-look arthroscopy:
macro and biopsy
! 8 mo euthanasia: gross,
histologic,
histochemical, and matrix
biochemical evaluation
- No signiﬁcant differences in
synovial ﬂuid between groups
- 1-m assessment:
MSC-implants treated defects
had signiﬁcantly improved
scores
- 8-m assessment
- No signiﬁcant difference
between groups
BMSC versus adipose-
derived stromal
vascular fraction
(AD-SVF) [111]
Autologous
BMSC from sternum
AD-SVF (Vet-Stem) from
tail head–nucleated cells
n ¼ 24
Experimental
Comparative mechanical
carpal fragment model
Strenuous exercise: 5 d/wk
Injection 14 d post-OA
BMSC (n ¼ 12): 10.5 % 106
cells per joint
AD-SVF (n ¼ 12): 16.3 % 106
cells per joint
- Every week: synovial ﬂuid
analysis (TP, cytologic, and
biochemical analysis)
- Every 2 wk: clinical and
lameness (AAEP scale)
- Before, after OA, and in
the before 70 d: X-rays
- After euthanasia (70 d):
gross, histologic, and
histochemical evaluation
- No lameness improvement
- AD-SVF increased ﬂexion
scores and synovial
ﬂuid TNF-a
- BMSC-reduced synovial
ﬂuid PGE2
BMSC þ hyaluronic acid
(HA) versus HA [112]
Autologous BMSC n ¼ 10
Experimental
10 % 10-mm cartilage
defects on both
medial femoral condyles þ
microfracture
- 2-wk rest
- 4-m hand walking
- Treadmill exercise
Single injection 1 mo
after surgery:
- 20 % 106 cells þ 22 mg
HA (n ¼ 10)
- 22 mg HA (n ¼ 10)
- Lameness evaluation
and X-rays every 2 mo
- 6 mo–2nd-look arthroscopy
- 12 mo–euthanasia: gross,
histologic, histomorphometric,
immunohistochemical, and
biochemical evaluations
- No signiﬁcant clinical
improvement in BMSC group
- Signiﬁcant increase in repair
ﬁrmness at arthroscopic and
gross evaluation
- Signiﬁcantly increased
aggrecan content in
repair tissue of BMSC group
Arthroscopy þ
BMSC & HA [114]
Autologous BMSC n ¼ 33
Clinical cases
Multicenter prospective
study: meniscal, cartilage,
and ligamentous stiﬂe
lesions treated by arthroscopy,
BMSC and HA
Single BMSC injection
3–4 wk after surgery
(n ¼ 30) or the day of
surgery (n ¼ 3): mean
13.2 % 106 & 5.6 cells
per stiﬂe & 20 mg HA
24 mo: clinic records,
evolution, and return to work
43% returned to previous level
of work
33% returned to work
24% failed return to work
- Meniscal injuries had signiﬁcant
higher return to some level of
work (75%) compared with
previous studies (60%–63%)
with arthroscopy alone.
- Postinjection ﬂare in 3
horses receiving BMSC
þ HA (9%)
PRP þ peripheral blood
native MSC (PBMSC)
versus PRP þ
chondrogenic-induced
PBMSCs [116]*
[115].
Allogeneic PBMSC and PRP
Reported technique*
Platelets: 200 % 106
cells/mL PRP
MSC: NA
n ¼ 165
Clinical cases
Number of OA joints:
stiﬂe, n ¼ 30; fetlock,
n ¼ 58; pastern, n ¼ 34;
cofﬁn, n ¼ 43
Single IA injection 24 hr
after local anesthesia
PRP with native PBMSC
or induced PBMSC
6 wk (n ¼ 165) and 18
wk (n ¼ 91):
0dfailure return to work
1drehabilitation
2dreturn to work
3dreturn to previous level
- Induced PBMSC had higher
average scores than native
PBMSC but not signiﬁcantly
different.
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authors decided to inject the treatments between 2 and
4 weeks after disease induction. However, despite some
authors [5] believe regeneration should be attempted after
inﬂammation resolution, others [6] state that inﬂammatory
mediators are the key of therapies success, and IA therapies
should be administered as soon as possible. Product
concentration and volume are variable. Authors using
blood-derived therapies try to concentrate GFs and anti-
inﬂammatory cytokines, such as IL-1ra, ﬁvefold above
baseline. Authors using cell-derived therapies injected be-
tween 10 and 20 million cells per joint. Frequently stem
cells are diluted in a 2- to 5-mL vehicle, saline, or HA, or in
association with a PRP product. Most often, biologic prod-
ucts have autologous origin, and as ADSVF has shown
increased ﬂexion scores and TNF-a concentration in syno-
vial ﬂuid, most of the equine research has been done with
bone marrow–derived stem cells. The exception is the
comparison of allogeneic PRP together with allogeneic
native or chondrogenic-induced peripheral blood-derived
stem cells. A large population of horses was used, but the
results have not shown signiﬁcant difference between
groups even if induced MSC group presented higher per-
centage of horses returning to work [115].
In Table 4 review, equine lameness improvement after
intra-articular biologic products injection was reported in
refractory chronic OA [67] but must often related to less
severe clinical OA cases [19,20,66,117]. However, therewere
studies where lameness improvement was not observed,
and in two stem cells studies, one associated to HA and the
other to PRP, there was postinjection ﬂare in 9% and 1.8% of
the cases, respectively [114,115]. This should always be
considered when doing intra-articular injections, despite
this could be solved as it usually responds to conservative
treatment.
Biochemical pathways are still only partially under-
stood, but histologic scores were always improved in the
ﬁve experimental studies using autologous bone marrow
stem cells and one using bone marrow aspirate. Cartilage
assessment time varied between 2.5 and 12 months and
showed better repair tissue quality and integration. One
study showed labeled MSCs are present in the newly
formed articular surface beside soft tissues. Soft tissue af-
ﬁnity can explain why stiﬂe meniscal injuries had higher
return to work compared with previously published re-
ports [117].
5. Conclusions
In the future, maybe therewill be no need for exogenous
MSCs administration by recruiting clinically effective
numbers of host MSCs to injury sites. The perivascular
location of most MSC niches facilitates their mobilization.
Delivery of key chemokine and/or GFs to sites of injury
could be used to attract and retain sufﬁcient MSCs for
effective repair. Ideally, readily available allogeneic biologic
products or inexpensive autologous products such as PRP,
ACS, BMAC, and ADSVF could preclude the need of stem cell
processing and be sufﬁcient to improve repair. With more
biochemical understanding and molecules combination,
biologic strategies could also be used in tissue engineering
to achieve true regeneration. Beside treatment products,
-
6-
w
k
fo
llo
w
-u
p:
45
%
of
na
ti
ve
an
d
60
%
of
in
du
ce
d
M
CS
ha
d
sc
or
e
2
or
3
-
18
-w
k
fo
llo
w
-u
p:
78
%
na
ti
ve
an
d
86
%
of
in
du
ce
d
M
CS
ha
d
sc
or
e
2
or
3
-
1-
w
k
po
st
in
je
ct
io
n
ﬂ
ar
e
in
3
ho
rs
es
(1
.8
%)
BM
SC
ve
rs
us
hy
al
ur
on
ic
ac
id
(H
A
)
[1
17
]
A
ut
ol
og
ou
s
Bo
ne
m
ar
ro
w
re
co
ve
re
d
fr
om
la
te
ra
ls
id
e
of
hu
m
er
us
bo
ne
BM
SC
gr
ee
n
ﬂ
uo
re
sc
en
t
pr
ot
ei
n
(G
FP
)
la
be
le
d
n
¼
27
do
nk
ey
s
Ex
pe
ri
m
en
ta
l
2
m
L
am
ph
ot
er
ic
in
-B
50
m
g
in
bo
th
ca
rp
al
jo
in
ts
Ex
er
ci
se
pr
ot
oc
ol
:
N
A
Si
ng
le
in
je
ct
io
n
at
3
w
k
(n
¼
9)
;
6
w
k
(n
¼
9)
;
or
9
w
k
(n
¼
9)
po
st
-O
A
Ri
gh
t
jo
in
t:
5.
4–
6.
9
"
10
6
ce
lls
su
sp
en
de
d
in
3
m
L
H
A
(1
.8
–
2.
3
"
10
6
ce
lls
/m
L)
Le
ft
jo
in
t:
3
m
L
H
A
D
iff
er
en
t
eu
th
an
as
ia
ti
m
es
fo
r
3
ho
rs
es
in
ea
ch
gr
ou
p
(1
,2
,a
nd
6
m
o)
:
la
m
en
es
s
(A
A
EP
sc
or
e)
;
X
-r
ay
s
(C
ra
w
fo
rd
sc
or
e)
-
G
FP
-l
ab
el
ed
M
SC
s
se
en
in
th
e
ne
w
ly
fo
rm
ed
ar
ti
cu
la
r
su
rf
ac
e
bu
t
al
so
so
ft
ti
ss
ue
s
-
Re
du
ce
d
X
-r
ay
an
d
hi
st
ol
og
ic
sc
or
es
fo
r
al
ld
iff
er
en
t
de
gr
ee
s
of
M
SC
s-
tr
ea
te
d
O
A
jo
in
ts
-
La
m
en
es
s
im
pr
ov
em
en
t
at
2
an
d
6
m
o
of
fo
llo
w
-u
p,
be
tt
er
fo
r
le
ss
se
ve
re
O
A
gr
ad
es
A
bb
re
vi
at
io
ns
:
A
A
EP
,A
m
er
ic
an
A
ss
oc
ia
ti
on
of
Eq
ui
ne
Pr
ac
ti
ti
on
er
s;
G
A
G
,g
ly
co
sa
m
in
og
ly
ca
n;
IA
,i
nt
ra
-a
rt
ic
ul
ar
;
IL
1-
ra
,i
nt
er
le
uk
in
1
re
ce
pt
or
an
ta
go
ni
st
;M
RI
,m
ag
ne
ti
c
re
so
na
nc
e
im
ag
in
g;
M
SC
s,
m
es
en
ch
ym
al
st
em
ce
lls
;
N
A
,n
ot
as
se
ss
ed
;
O
A
,o
st
eo
ar
th
ri
ti
s;
PD
G
F-
BB
,p
la
te
le
t-
de
ri
ve
d
gr
ow
th
fa
ct
or
-i
so
fo
rm
BB
;
PG
E2
,p
ro
st
ag
la
nd
in
;
TG
F-
b1
,t
ra
ns
fo
rm
in
g
gr
ow
th
fa
ct
or
b1
;
TP
,t
ot
al
pr
ot
ei
ns
;
W
BC
,w
hi
te
bl
oo
d
ce
lls
.
S.O. Monteiro et al. / Journal of Equine Veterinary Science 35 (2015) 175–190 187
researchers should control several factors such as differ-
entiation, cartilage matrix synthesis, and collagen type II
production.
More than standardized products and treatment pro-
tocols, it would be extremely important to deﬁne objective
methods to evaluate clinical outcomes. In cartilage assess-
mentandorthopedicpaindetection, itwouldbe important to
use advanced imaging modalities, biochemical analysis, and
objective lameness detection. Creating speciﬁc disease diag-
nostic scales would also help to standardize practitioner’s
evaluations. Finally, multicenter standardized protocols and
randomized controlled trials are probably the only way to
achieve sufﬁcient patient numbers for signiﬁcant answers
from ACS, PRP, and stem cell intra-articular therapies.
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Appendix C – Questionnaire  
Survey to Portuguese equine veterinarians
O estudo da osteoartrite em cavalos insere-se num programa de doutoramento em Ciências Veterinárias da Universidade de Évora.  Neste inquérito 
considera-se a osteoartrite (OA) como a doença primária na sua fase aguda ou crónica (osteoartrose).  Quando não souber ou não tiver a informação 
escolha a hipótese N/A (não se aplica). 
Qual é a percentagem da actividade  que exerce 
em clínica de equinos?
Há quantos anos exerce clínica de equinos?
Em que disciplina equestre diagnostica mais OA em cavalos?
Encontra sinais clínicos de OA sem presença de 
lesões radiográficas? Se sim, em que articulação/situação?
1 2
3
Nessa disciplina, a que nível de trabalho diagnostica mais OA?4
Baixo (0-5h/semana)
Moderado (6-10h/semana)
Elevado (11-15h/semana)
Não se aplica
Nessa disciplina, em que faixa etária diagnostica mais casos de OA?5
menos de 5 anos
5-9 anos
10-14 anos
mais de 19 anos
não se aplica
6 Encontra lesões radiográficos de OA sem presença de sinais 
clínicos? Se sim, em que articulação/situação?
7
Que opções recomenda para o tratamento de OA primária? 8
Ferração ortopédica
Adaptar maneio alimentar e de trabalho
Anti-inflamatórios não esteróides sistémicos
Ácido Hialurónico sistémico (endovenoso)
Polisulfato glicosaminoglicanos sistémicos (intra-muscular)
Suplementos alimentares
Tetraciclinas
Tratamento intra-articular
Ordene do mais ao menos frequente |  Marcar apenas uma oval por linha.
1º 2º 3º 4º 5º 6º 7º 8º N/A
Que tratamento intra-articular recomenda em articulações muito móveis (interfalângica distal, metacarpo/tarso falângicas e tíbio-társicas? 9
Ordene do mais ao menos frequente |  Marcar apenas uma oval por linha.
Acetato de triamcinolona
Acetato de metilprednisolona
Sulfato de betametasona
Ácido Hialurónico
Polisulfato-glicosaminoglicanos (PSGAG)
Antagonista do receptor da interleuquina I (IRAP)
Plasma Rico em Plaquetas (PRP)
Células estaminais
Antibiótico (ex: amikacina, gentamicina)
1º 2º 3º 4º 5º 6º 7º 8º 9º N/A
Osteoartrite em Cavalos 
Questionário
10 Que protocolo (ex: dose e n.º de tratamentos) utiliza na sua primeira opção de tratamento intra-articular?
15-19 anos
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